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Abstract 
 
Intensive Care Unit Acquired Paresis (ICUAP) is a major health concern facing today’s 
critical care patients. This syndrome of severe muscle wasting and weakness is associated with 
significant morbidity and mortality, resulting in a substantial clinical and financial burden. 
However as yet, other than early mobilisation and rehabilitation, there are no available 
treatments. The aim of this work was to identify molecular mechanisms in the aetiology of 
ICUAP with a view to finding novel therapeutic targets.  
 
In a prospective study of high-risk elective cardiothoracic patients, prolonged elevation 
of circulating GDF-15, a stress-induced cytokine and TGF-β family member, was associated 
with acute muscle wasting. Following on from this work, the hypothesis that GDF-15 might be 
a driver of muscle wasting in ICUAP was tested in an observational study of 20 ICUAP patients 
and 7 elective cardiothoracic controls. Both circulating GDF-15 and muscle GDF-15 mRNA 
expression were elevated in patients compared to controls. In addition microRNAs essential 
for muscle homeostasis and protection against TGF-β signalling were found to be down-
regulated. In vitro experiments demonstrated that GDF-15 could increase expression of muscle 
atrophy-related genes and supress these microRNAs. Increased sensitivity to TGF-β signalling 
secondary to down-regulation of muscle microRNAs driven by GDF-15 hypothesised as an 
aetiological mechanism of muscle wasting in critical illness. Supporting this hypothesis, 
transfection of miR-181a into C2C12 cells reduced the response to TGF-β1 and increased TGF-β 
signalling was found in the muscle of ICUAP patients. 
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An interventional study of neuromuscular electrical stimulation (NMES) in ICU 
demonstrated that although increased mobility in critical care patients can improve outcomes 
there is a risk that NMES may cause muscle damage.  Finally preliminary data, suggested that 
miR-181a is a potential biomarker for ICUAP.  
 
GDF-15 and microRNAs are potential therapeutic targets and this work supports the 
need for further investigation into these pathways in ICUAP.  
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Chapter 1 Introduction  
 
1.1 Why investigate molecular mechanisms in ICUAP? 
Intensive care unit acquired paresis (ICUAP) is one of the increasingly recognised 
complications of survival from critical illness. Advances in medical management have improved 
survival from acute severe illness and multi-organ failure and as a result the sequalae have 
become important clinical syndromes in their own right. ICUAP is associated with a significant 
morbidity and mortality independent of the severity of the primary illness (1) but, despite this, 
our understanding of the aetiology, pathology and potential management options of this 
disease is limited.  
ICUAP is characterised by significant skeletal muscle weakness and wasting  and results 
in a spectrum of physical disability ranging from mild loss of muscle function to complete 
paralysis and inability to wean from mechanical ventilation (2). The incidence of this condition 
is not fully described and depends on the cohort of patients examined. However, evidence 
suggested that more than 25% of patients admitted to ICU developed ICUAP (3, 4) and many 
more undocumented cases are likely to exist. Although many patients recovered their muscle 
function, neuromuscular dysfunction was still one of the major burdens affecting survivors of 
critical illness (5, 6). At discharge from hospital approximately 65% of patients had functional 
limitation (7) and 30% were left with permanent disability (7).  Rehabilitation and weaning of 
these patients is both lengthy and costly and as yet early mobilisation and rehabilitation are 
the only treatments available.  
ICUAP is likely to result from a complex interplay of many aetiological factors and as a 
result our understanding of the molecular mechanisms underlying the condition is limited. 
Patients and clinical circumstances are heterogeneous and much of our current understanding 
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is extrapolated from animal and in vitro studies with limited relevance. Clinical studies in ICU 
patients are both ethically and logistically challenging but, as highlighted by the NICE (National 
Institute for Health and Care Excellence) guidance on rehabilitation following critical illness (8), 
a better understanding of the clinical and molecular factors behind the disease is the key to 
identifying potential therapeutic targets from which future treatments and prevention can be 
devised.  Therefore, the work in this thesis aimed to investigate potential molecular 
mechanisms within the complex aetiology of ICUAP with a view to identifying future 
therapeutic targets.  
1.2 Intensive care unit acquired paresis (ICUAP) 
1.2.1 Background  
Muscle wasting has been a recognised complication of critical illness for more than a 
century; however, since patients rarely survived severe critical illness, it was not a significant 
problem. Therefore, it was not until early case studies describing muscle weakness following 
critical illness were first published in the 1950s (9) that the syndrome began to be formally 
recognised. Initially the clinical syndrome was attributed to an axonal neuropathy; however, in 
1977 a similar myopathic syndrome following treatment for acute severe asthma with 
corticosteroids and neuromuscular blocking agents was reported (10).  
In 1984 Bolton et al published a case series of 5 patients who developed a severe 
motor and sensory polyneuropathy during critical illness. Patients presented with difficulty 
weaning from mechanical ventilation despite the fact that their critical illness was resolving 
(11). The authors described the heterogeneous clinical features of the patients’ primary illness 
that all resulted in a common clinical syndrome: a severe bilateral flaccid paralysis affecting all 
skeletal muscle groups with some sensory involvement. The syndrome became known as 
Critical Illness Neuropathy (CIN), as an axonal neuropathy of both motor and sensory nerves 
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with reduced combined muscle and nerve action potentials was revealed by nerve conduction 
studies (NCS) and electromyography (EMG). Muscle biopsies were also taken from these early 
cases and demonstrated atrophy of both type 1 and 2 muscle fibres; this was explained as a 
secondary myopathy (11). Over time it was recognised that neuropathy alone could not 
account for the extent of muscle wasting and weakness, or the histological changes seen at 
muscle biopsy, and it was therefore proposed that a primary myopathic process, Critical Illness 
Myopathy (CIM), must also be present, (12, 13). Electrical in-excitability of muscle, even when 
stimulated by directly implanted intramuscular electrodes, confirmed that a primary 
myopathic process was also present (14).  Latronico et al published the first prospective series 
in 1996 in which 23 of 24 patients with muscle weakness following critical illness had 
myopathy on muscle biopsies. Furthermore in 15 of these patients there was no significant 
neuropathy and thus the paralysis could only be explained by myopathy (12). Latronico’s study 
also confirmed the co-existence of neuropathy and myopathy and the clinical overlap of the 2 
syndromes.  
The term ICUAP (or ICU-acquired weakness), developed in 2009 (15), is now widely 
accepted and used to reflect the fact that the separation of CIN and CIM is not only clinically 
difficult, but also that neither term would adequately describe what is probably a 
heterogeneous spectrum of disease, with significant overlap between the two pathological 
processes (15, 16). The heterogeneous nature of ICUAP in terms of its clinical aetiology, patient 
population and severity of clinical features as well as the complex pathological overlap is in 
part why the current understanding of the molecular pathology of the disease is limited. 
In the following sections we will review the current understanding of ICUAP from a 
clinical and molecular point of view.  
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1.2.2 ICUAP from a clinical perspective 
1.2.2.1 Definition and diagnosis  
ICUAP is defined as clinically detectable weakness in critically ill patients in whom 
there is no other plausible cause for the aetiology other than critical illness (15). In 2009 
Stevens at al set out the diagnostic criteria for ICUAP from a clinical and pragmatic 
perspective, these are now widely accepted and used in clinical practice (Table 1-1). 
Diagnostic criteria for ICUAP 
1) Generalised weakness which develops following critical illness. 
2) The weakness is diffuse, symmetrical and flaccid. Cranial nerves are usually spared. 
3) MRC-SS <48. 
4) Difficulty weaning from mechanical ventilation. 
5) Other causes for weakness have been excluded. 
For a diagnosis of ICUAP either 1,2 and 3, or 4 and 5 should be present.  
 
Table 1-1 Diagnostic criteria for Intensive care unit acquired paresis (ICUAP).  
Adapted from Stevens et a l  (15) (Crit Care Med. 2009 Oct;37(10 Suppl):S299 -308). MRC-
SS - medical research council strength score .   
ICUAP diffusely affects skeletal muscle so weakness presents in both proximal and 
distal limb muscles and as well as trunk and respiratory muscles. ICUAP often presents as a 
recovering critically ill patient who has difficulty weaning from mechanical ventilation, despite 
only requiring low airway pressures and inspired oxygen content (FiO2) and the fact that the 
primary cause for critical illness and cardiopulmonary function are improving (2, 17).  The 
cause for dependence on mechanical ventilation is suggested by signs of respiratory muscle 
weakness such as weak cough, paradoxical abdominal movement, difficulty clearing 
secretions, worsening respiratory function on lying flat and absence of inspiratory abdominal 
expansion (18). Alternatively ICUAP may be first suspected by evidence of reduced limb 
movements, for example in response to pain (18). Respiratory and peripheral limb muscle 
dysfunction have been shown to correlate with each other suggesting that, although the 
diaphragm is also affected by mechanical ventilation and the syndrome of Ventilator Induced 
Diaphragm Dysfunction (VIDD), the pathology of ICUAP affects the respiratory muscles in the 
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same way as other skeletal muscle (11, 19, 20).  On examination a symmetrical flaccid paresis 
of the limbs with loss or reduction of the deep tendon reflexes and marked muscle wasting is 
demonstrated; in severe disease quadriplegia may result leaving the patient completely 
immobile (2). Facial and ophthalmic muscle involvement is very rare and therefore facial 
grimacing in response to pain or eye movements on demand are a useful test of awakening 
and comprehension. However, a sensory component is described with the neuropathic 
component of the disease (21) and, therefore, the diagnosis should not be rejected in the 
absence of facial grimacing. If present, sensory involvement is a distal, symmetrical loss of 
pain, temperature and vibration sense and occurs alongside neuromuscular weakness. Pure 
sensory critical illness neuropathy is not documented in the literature although the sensory 
element is less well examined and researched (22). It is essential to exclude other causes of 
muscle weakness and central nervous and higher functioning should remain unaffected, 
although of course encephalopathy secondary to critical illness may often be a complicating 
factor.  
In practice the diagnosis of ICUAP is usually made clinically (23). Where possible this 
should include the accurate quantitative assessment of muscle strength (24). A Medical 
Research Council strength score  (MRC-SS) of less than 48 in the right clinical setting is 
sufficient to make the diagnosis of ICUAP (15); however the MRC-SS requires alertness, 
understanding and cooperation from the patient. The reliability and usefulness of the MRC-SS 
in the ICU setting is discussed further in the Methods Chapter of this thesis. Although the MRC-
SS has been shown to be sensitive in describing degrees of muscle weakness in those patients 
who are unable to lift their limbs against gravity, sensitivity is lost in stronger patients (24, 25). 
In these circumstances, hand-held dynamometry (for example of elbow flexion) (26, 27) and 
hand grip dynamometry (26, 28) have been used to detect muscle weakness in alert ICU 
patients and have been shown to correlate well with the MRC-SS (29). From a research 
perspective these techniques may be interesting; however, they require the patient to be alert 
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and cooperative, are not routinely used in clinical practice and clear normal ranges are not yet 
well established (24). Hand grip strength has probably been the best described (26) and, in 
combination with an MRC-SS of less than 48, a strength of less than 11kg in men or 7kg in 
women was useful in aiding diagnosis of ICUAP and was associated with increased in-hospital 
mortality (30). However, all techniques of hand-held dynamometry are not as sensitive or easy 
to interpret in patients who are very weak (31) and, although ICUAP affects all muscle groups, 
measurement of just one muscle does not necessarily truly reflect overall strength (32, 33). 
Furthermore, relatively large changes in strength are needed to accurately define progression 
or improvement as the variability is great (26).  
The ability to test non-volitional strength in ICU patients would obviously be useful, 
but again there is not, as yet, a standardised technique for doing this. The ulnar nerve supplies 
the adductor pollicis muscle of the thumb and is readily accessible and widely used in ICUs to 
assess the adequacy of neuromuscular blockade in the train-of-four technique. The twitch 
pressure generated following supra-maximal stimulation of the adductor pollicis has been 
studied in the ICU setting (34); however, again these techniques are not yet standardised and 
are also limited by drugs, the temperature of the patient and the presence of oedema and, 
therefore, cannot be routinely used or currently recommended (24, 31, 35).  
Muscle electrophysiology can be assessed by NCS and EMG. In clinical practice these 
tests are often time consuming and difficult to carry out (35): they require extensive expertise, 
the ICU is an “electrically unfriendly” setting, they are hampered by oedema, EMG requires 
patient cooperation and the tests are contraindicated in those with external pacemakers and 
require extra caution with the use of electrical charge in potentially wet areas (23, 35). The 
need for these investigations in the diagnosis of ICUAP is debated as, in both clinical practice 
and research, it is unclear how the results add to the diagnosis (36, 37) or change the 
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management (23, 37). However, where available and in the research setting they may provide 
useful insight into the relative contribution of myopathy and neuropathy present.  
Table 1-2 describes the changes that reported on NCS, EMG and with direct muscle 
stimulation with different underlying causes of ICUAP. In reality these often overlap and this 
further complicates their use (16).  
Investigation CIN CIM 
Nerve Conduction Studies   
CMAP (Motor) 
 
Reduced amplitude 
(may be the first sign) 
 
Normal 
(but may be reduced) 
SNAP (Sensory) Reduced amplitude Normal 
 (Nerve conduction velocity should 
be normal as CIN is an axonal 
neuropathy) 
 
EMG   
Step 1: No contraction Fibrillation (a late sign) 
 
Normal/none 
Step 2: Repeated slow contraction 
 
Large, polyphasic MUPs with early 
recruitment (secondary to axonal 
loss resulting in collateral 
recruitment) 
 
Small, polyphasic short duration 
MUPs (secondary to motor unit loss 
and dyssynchrony with in motor 
units) 
Step 3: Maximal voluntary 
contraction 
Reduced recruitment and lack of 
interference 
 
Low amplitude weak signal. 
Direct muscle stimulation   
 Reduced neuronal CMAP 
Normal muscle CMAP 
Reduced or absent CMAP 
 
 
Table 1-2 Summary of findings on nerve conduction studies (NCS), electromyography (EMG) and direct muscle 
stimulation in Critical Illness Neuropathy (CIN) and Myopathy (CIM).  
CMAP –  compound muscle action potential,  SNAP –  sensory nerve action potential,  MUP 
–  motor unit potential .  (Adapted from (2, 17,  38)).   
Although the use of electrophysiological tests in the diagnosis of ICUAP may be 
academically interesting and enable the detection of pathology early (39) and in unconscious 
patients (24, 34), the relevance of early electrophysiological changes in terms of the later 
development of clinically significant muscle weakness is unclear.  However, what is increasingly 
clear is that the insult that results in ICUAP occurs very early in the course of critical illness (40) 
and that changes in neuromuscular function can be detected long before clinical presentation 
of ICUAP (4, 41). This was illustrated by the study by Khan et al (39), where 31/48 of patients 
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(63%) had abnormal nerve conduction studies at day 2-5 of ICU admission but only 10/48 
(21%) developed a diagnosis of ICUAP (39). However, even at baseline assessment abnormal 
nerve conduction studies were associated with increased risk of mortality (39) and at day 7 
were predictive of a diagnosis of ICUAP (39).  
Although muscle wasting may not be clinically obvious to the observer until marked, it 
can be detected as early as day 3 on ICU as a downward trend in cross-sectional area of 
quadriceps muscle measured by ultrasound which becomes statistically significant by day 6 
(42). This is a non-invasive technique that is not technically challenging and does not require 
patient cooperation and quadriceps cross-sectional area has been shown to correlate with 
muscle strength (42). Therefore, in the future it may be a useful screening tool to identify 
those patients who are developing wasting and weakness.  
Assessment and quantification of respiratory muscle strength is also important but 
even more challenging and fraught with contentious issues than the testing of peripheral 
muscle strength. In clinical practice respiratory muscle strength can be estimated in ambulant 
patients by sniff or maximal voluntary static mouth pressures.  The equivalent for ventilated 
patients would be the maximal inspiratory pressure measured by the ventilator. More detailed 
tests of diaphragm function, such as the transdiaphragmatic pressure elicited by magnetic 
stimulation, diaphragm EMG and ultrasound are really only used for research purposes and by 
a few experienced investigators (38, 43, 44). Pragmatically, respiratory muscle weakness is 
generally assumed on the grounds of failure to wean associated with limb muscle weakness 
and wasting. 
As the need for accurate diagnosis and documentation of progression of the disease 
becomes better understood, these techniques may become more widely used and could 
potentially be useful in predicting outcomes and detecting response to treatment. However, at 
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present the diagnosis of ICUAP is more pragmatic and, although the MRC-SS is widely used, in 
non-alert patients the diagnosis relies entirely on the clinical picture. 
1.2.2.2 Incidence.   
The reported incidence of ICUAP ranges from about 25% to 100% depending on the 
definition and diagnostic techniques used and the case mix of patients (3, 4, 36, 45). The first 
large prospective study to examine the incidence of ICUAP found that 25% of unselected 
patients intubated for more than 7 days had clinically detectable weakness at awakening (3). 
However, by limiting the definition to those with clinically detectable weakness the study only 
included patients who were awake and could communicate, potentially missing significant 
weakness in those patients who were either transferred out of the unit pre-awakening or died 
prior to assessment (109 out of 206 identified patients) (3). In contrast, studies using EMG 
criteria identified muscle dysfunction in 49%-59% of unselected patients (46, 47). In a further 
study, at an average of 28 days on ICU, 70% of patients had electrophysiological evidence of 
muscle dysfunction, but in only 30% of these was the weakness clinically detectable (19). 46% 
of patients included in a review of studies including patients with sepsis, multi-organ failure or 
prolonged mechanical ventilation were diagnosed with ICUAP (by various methods) (48) and of 
patients with severe sepsis or multi-organ failure 70-100% had abnormal EMGs (4, 19).  
In the UK over 230,000 patients a year are admitted to critical care with over 30,000 
staying more than 1 week (UK Hospital Episode Statistics (UK HES) adult critical care data 2012-
13 (49)); at least 25% of these could be expected to develop ICUAP and at any one time 5% of 
critical care beds are occupied by weaning patients (50). When combined these data 
demonstrate that ICUAP is a huge clinical and financial burden.  
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1.2.2.3 Clinical risk factors 
In order to assess the clinical risk factors for the development of ICUAP, studies have 
typically adopted prospective observational or retrospective case-control designs. These vary 
further in terms of patient case-mix and sample size and for these reasons the evidence for 
even the most accepted risk factors is often inconclusive and studies have contradicted each 
other. It is impossible to design a randomised controlled trial (RCT) in humans to assess the 
causal effects of clinical exposures and in the case of pharmacological exposures where the use 
of any drug will be indicated in the management of the patients’ critical illness, it would 
therefore be unethical to do so. Management of hyperglycaemia is the exception and RCTs of 
intensive insulin therapy have led to the acceptance that hyperglycaemia is an important risk 
factor for the development of ICUAP (51).  
The most established and accepted risk factors for ICUAP are sepsis, systemic 
inflammatory response syndrome (SIRS) and multiorgan failure (3, 19, 20, 36, 41, 45, 48, 52). 
These factors have been reliably shown in prospective trials and systematic review to increase 
the risk of development of ICUAP (48). This is consistent with the finding that, on multivariate 
analysis, APACHE III score (a score reflective of illness severity and underlying co-morbidity in 
critically ill patients) was an independent risk factor for ICUAP and, when combined with the 
presence or absence of SIRS, could be used to predict the risk of ICUAP (36) Table 1-3.  
Stratified group Apache III Score Presence of SIRS 
Risk of ICUAP within 30 
days of mechanical 
ventilation 
Low risk < 70 No 8% 
Medium risk 
70-85 Yes 
28% Or  
>85 No 
High risk > 85 Yes 72% 
Table 1-3 APACHE III score and the presence of SIRS predict the chance of developing ICUAP within 30 days of 
mechanical ventilation  
Adapted from data from de Letter et al (36).  
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Hyperglycaemia is an important risk factor for ICUAP and the evidence supporting this 
is strong; 5 out 6 trials included in the 2007 systematic review found an association between 
the risk of developing ICUAP and hyperglycaemia (48); on multivariate analysis a 1mmol/l 
(20mg/dl) increase in blood glucose resulted in an increased odds ratio of 1.24 (95% CI 1.15-
1.56) for the development of ICUAP (46, 48). Furthermore, hyperglycaemia is modifiable and 
two large RCTs of tight glucose control achieved by intensive insulin therapy demonstrated 
that the incidence of ICUAP was reduced from 49% to 25% (46) and from 50% to 38.9% in 
surgical and medical ICUs, respectively (51). Intensive insulin therapy was also an independent 
protector against the need for prolonged mechanical ventilation in both studies.  
Other potential independent risk factors for the development of ICUAP that have been 
identified in prospective studies include renal failure and renal replacement therapy (3, 53), 
illness severity score (36, 54), duration of vasopressor or catecholamine support (46) and 
parenteral nutrition (46). One study also suggested an increased risk in women compared to 
men (3); however, this result has not been reproduced (48). Age also may be a risk factor 
although this was not demonstrated on multivariate analysis (48). Pharmaceutical exposures 
that have been implicated include glucocorticoids (GCS) (19) and neuromuscular blocking 
agents (NMBAs) (48). GCS were associated with an increased risk of ICUAP (3, 55), with an 
odds ratio of almost 15 (3), but this was not confirmed in other studies (36, 45, 56). A 
Cochrane review of the treatment options for ICUAP identified one RCT in which the 
development of ICUAP was assessed with respect to treatment with corticosteroids. The 
review retrospectively analysed data from the trial comparing three weeks treatment of 
patients with un-resolving ARDS with methylprednisolone or placebo and no difference in the 
development of ICUAP was found (57, 58). Furthermore in Hermams’ and Van den Berghe’s 
studies GCS were in fact found to be protective against ICUAP, potentially due to their anti-
inflammatory properties predominating once their hyperglycaemic effect had been suppressed 
33 
 
by insulin (46, 51).  Perhaps clinical studies that have not in the past controlled for insulin 
therapy, hyperglycaemia or insulin resistance are less relevant to current practice.  
Similarly systematic review has disputed the proposed role of NMBAs in the aetiology 
of ICUAP. This was initially suggested following the observation, in case studies and 
retrospective analyses, of prolonged neuromuscular dysfunction following long term NMBA 
use in the ICU (59, 60). Most prospective studies and systematic reviews have not been able to 
reproduce this association (3, 45, 48, 54, 56, 60, 61); however, some prospective studies do 
suggest a link (51, 53) and authors have postulated that a combined effect of corticosteroids 
and high dose prolonged NMBAs may lead to a necrotising myopathy as was described in 
asthmatic patients in the 1990s (53). A recent randomised controlled trial in ARDS patients 
demonstrated improved survival and no difference in ICUAP in those treated with NMBAs (in 
this case cisatricurium) compared to placebo (62). Aminoglycosides have minor effects at the 
neuromuscular junction (48) and these drugs are contraindicated in myasthenia gravis;  an 
aetiological role in ICUAP was suggested (3, 54) but the majority of studies demonstrated no 
association (48, 53). 
ICUAP develops in patients who are usually immobile as a result of their critical illness 
and often have impaired consciousness.  Although there is a well-recognised syndrome of 
disuse atrophy resulting in dramatic loss of muscle mass (63) and immobility is often used in 
animal models of ICUAP (64, 65), the evidence that immobility is a critical factor in ICUAP is 
indirect. Additionally, models comparing skeletal atrophy in disuse and sepsis show distinct 
differences (65). However, early mobilisation and attempts to reduce immobility are currently 
the main components of both prevention and treatment of ICUAP and, therefore, it is plausible 
that immobility is at least one of the contributing factors in its development (64). It is possible 
that immobility and inflammation/ systemic stress are synergistic in combination (66).   
34 
 
1.2.2.4 Outcome and prognosis 
ICUAP is an independent predictor of poor outcome and is associated with prolonged 
length of stay on ICU (1, 3) , delayed weaning (1, 3, 61, 67), and increased risk of death (1, 28, 
47, 53).  
The link between ICUAP and delayed weaning is now well established. Following 
observations that reduced diaphragmatic compound nerve potentials correlated with 
peripheral muscle weakness in ICU patients (19), prospective studies demonstrated that ICUAP 
was associated with prolonged duration of mechanical ventilation (3) and was an independent 
risk factor for delayed weaning. The first prospective study to demonstrate this was in the 
cohort of patients described by de Jonghe et al where ICUAP was associated on average with a 
two-fold increase in weaning time (67). Since then several other groups, controlling for other 
causes of respiratory failure, have continued to demonstrate the same association (1, 61). 
Respiratory muscle strength (as measured by maximal inspiratory and expiratory force, rather 
than diaphragm strength) was also predictive of delayed weaning (20) and correlated with 
peripheral muscle diagnosis of ICUAP.  When taken together this evidence suggests that 
ICUAP, and its involvement of the respiratory muscles, is causally associated with delayed 
weaning.  
Increased dependence on mechanical ventilation naturally leads to increased length of 
stay in critical care units (3, 61) as, although criteria for ICU admission and discharge vary 
worldwide, specialist weaning units are rare and the level of support required for a weaning 
patient is generally only available in the ICU/critical care setting. The increased time on ICU 
results in increased exposure to ICU-related complications (infection, thromboembolism, 
pressure areas) and this translates directly into increased costs of health provision. Even when 
controlled for length of stay, weak patients had increased health care costs compared to 
matched non-weak patients (1). UK national ICU data reveal that patients with delayed 
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weaning who are otherwise clinically stable occupy 5% of ICU beds; although the data did not 
delineate between the causes of difficulty weaning, it can be presumed that a significant 
percentage of these patients will have some degree of ICUAP (50).  
Historically, the association between ICUAP and mortality was debated because 
several studies did not conclusively demonstrate a link (3, 61) or the authors attributed it to 
confounding factors such as severity and duration of illness (47). Indeed ICUAP is more 
common in severe and prolonged illness so increased mortality would be expected and its 
aetiology difficult to attribute. Risk adjusted for severity of illness and other confounders, ICU 
mortality in ICUAP patients was not increased in several studies, but later in-hospital and 1 
year mortality was increased (1, 28, 61). The reasons for this are as yet unclear but mirror 
observations in other conditions, for example COPD that muscle weakness is associated with 
increased mortality (68).  
Recovery from critical illness is a lengthy and challenging process (23) although 
prognosis of recovery from ICUAP is generally reported as good and 70% of patients recovered 
“fully” (defined as being able to walk and breath independently) (7); follow-up of survivors 
from Acute Respiratory Distress Syndrome (ARDS) demonstrated that patients only recover to 
a median of 70% of their baseline performance at 5 years (as measured by 6 minute walk test) 
(69). 64% of survivors with ICUAP were left with weakness at discharge from hospital (6). 
Prognosis may be worse in those patients with pure CIN (rather than CIM) (6, 70), although 
data to support this are limited. At 5 years 30% of patients reported some degree of functional 
disability that impaired their ability to walk and breath independently (7) and EMG 
abnormalities were still demonstrated in 90% of individuals with a history of prolonged ICU 
admission (5). Even in those patients with the most severe forms of ICUAP (tetraparesis) a 
similar pattern was seen; the majority recovered fully, but 32% remained severely disabled at 
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2 years (71). Older patients and those with premorbid medical conditions consistently had 
poorer outcomes and recovery from ICUAP (55, 69, 72, 73).  
Thus the data suggest that, while the overall prognosis is good with most patients 
making a good recovery in the first few months and by 5 years even returning to work (69, 74), 
about one-third will be left with a severe disability. This has long-term implications not only for 
individuals but also from the point of view of resource provision for rehabilitation and long 
term care (1, 69).  
1.2.2.5 Prevention and treatment strategies 
Unfortunately despite the increased awareness of the impact of ICUAP there are still 
few rigorously evaluated interventions for either the prevention or treatment of the condition. 
Aggressive and early treatment of sepsis and multi-organ failure is generally accepted to 
improve outcomes and would be expected to reduce the risk of ICUAP, but it would be 
unethical to design a trial to test this hypothesis. As discussed above, some pharmacological 
exposures may be associated with increased risk of ICUAP; however, the evidence to support 
this is inconclusive and, therefore, guidelines do not go further than suggesting judicious use of 
drugs such as GCS and NMBAs and generally trying to limit exposure to potentially harmful 
medications. However, even this approach is controversial as GCS have been associated with 
improved outcomes in septic-shock and multi-organ failure (75) and are  widely used to treat 
several medical conditions (e.g. asthma). Indeed, in some studies (62, 75), but not others (76), 
as with NMBAs, GCS have been shown to improve outcomes in ARDS.  
Although it has been accepted since at least 2001 that hyperglycaemia is associated 
with increased morbidity and mortality in ICU patients (77) and specifically with increased risk 
of ICUAP (46, 48), tight glucose control with intensive insulin treatment is not without its own 
risks and controversies.  Robust evidence does exist that tight glucose control can reduce the 
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risk of ICUAP. For example, a Cochrane review of 2 large trials included an intention-to-treat 
analysis (of all 2748 randomised patients) as well as a combined analysis only including those 
patients still on ICU at 7 days (n=825) as previously published (51, 78, 79) . The risk of ICUAP 
was significantly reduced in those treated with intensive insulin therapy in both analyses (RR 
0.7 and 0.65 respectively) (46, 51, 57, 80); furthermore, duration of mechanical ventilation, ICU 
stay and 180-day mortality were also reduced.  Intensive insulin therapy aimed to maintain the 
patients’ blood sugar between 4.4 and 6.1mmols/dl (80-110mg/dl); the greatest benefit was 
seen in those patients who had the best control, but those treated with insulin in whom 
control was not so well achieved still received a benefit (81). It has therefore been postulated 
that insulin itself may have positive effects beyond blood glucose control, potentially including 
endothelial protection as well as anabolic, neuro-protective and anti-inflammatory properties 
(22). However, other studies in which increased insulin administration was associated with 
death have refuted this (82). Tight glucose control in the ICU setting has been widely adopted 
by the ICU medical community (77), but the level of control itself remains contentious because 
of the associated risks of hypoglycaemic episodes and recurrent hypoglycaemia (57, 77, 80). 
The risks of hypoglycaemia are thought not to be limited to the severe acute symptoms 
(reduced consciousness and seizures), but may also include more subtle long-term negative 
systemic effects (77). Furthermore, some studies have shown that even single episodes of 
hypoglycaemia were associated with increased risk of death (83-85). Perhaps a more moderate 
approach of aiming for a controlled level at less than 10mmols/l (180 mg/dl) would be safer, 
but still deliver a benefit (83, 86); however, the impact of this level of glucose control on ICUAP 
has not yet formally been assessed.  
Over recent years there has been a growing body of evidence to support the use of 
early rehabilitation and mobilization in the critical care population. This approach challenges 
the acceptance of the ICU patient as bed-bound and immobile and aims to achieve awakening 
and mobilisation much earlier than classically accepted. The approach is increasingly 
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recognised to be safe and feasible (64, 87-92) but, despite this, few ICU units have adopted it 
(89). Positive outcomes are difficult to assess as the studies have varying protocols and report 
on different outcome measures (80, 93). Systematic review suggested that studies generally 
reported improvements in terms of mobility milestones, time to achieve these and improved 
muscle strength (but only in the chronic/ recovery setting, not on the ICU), but that the 
evidence to support a reduction in duration of mechanical ventilation or hospital stay, 
mortality or improvement in quality of life was contradictory and hampered by the variability 
of patients and protocols (93, 94).  Among other things, barriers to early mobilisation include 
sedation, haemodynamic instability and practical considerations with respect to staffing 
expertise, time and equipment (64, 89). However, when these factors were addressed with the 
help of an experienced multidisciplinary team, not only were mobility milestones achieved 
more quickly (87, 91), but ICU and hospital lengths of stay were also reduced (90). One 
prospective randomised controlled study addresses the specific risk of developing ICUAP (68). 
This study combined early mobilisation and rehabilitation with daily interruption of sedation or 
just interruption of sedation alone (previously shown to be beneficial) (95). The intervention 
group initiated occupational and physiotherapy at a median of 1.5 days after intubation, 
compared to 7.4 days in the control group. The risk of ICUAP was significantly reduced (OR 
0.62, 95% CI 0.39-0.96) and the authors reported improved physical independence at 
discharge, reduced duration of mechanical ventilation and shorter duration of delirium. 
However, there was no effect on length of ICU or hospital stay, or mortality. These results are 
encouraging and have led researchers to explore further the use of passive exercise (for 
examples with neuromuscular electrical stimulation (96)) and other modalities such as cycle 
ergometry (97), some of which show promising results (89). However, overall the data are 
often contradictory and there is a need for further large, multicentre RCTs with clear and 
clinically relevant outcome measures before the critical care community will widely adopt this 
approach.  
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Other treatments that have been explored include antioxidant therapy, nutritional 
supplementation (e.g. glutathione and glutamine), hormonal therapy and intravenous 
immunoglobulins. Little data to date support these interventions and therefore it is difficult to 
comment further although there are theoretical benefits to these approaches and they 
warrant further exploration (80). 
1.2.3 ICUAP muscle dysfunction and molecular mechanisms 
The current understanding of the muscle dysfunction that occurs in ICUAP and the 
molecular mechanisms behind it are mainly inferred from in vitro and animal models of muscle 
wasting.  Predominantly rodent models are used and those commonly cited are denervation, 
cast immobilisation or hind-limb suspension and models of sepsis induced by endotoxin, pro-
inflammatory cytokines or caecal ligation and puncture (CLP). In combination with these, 
administration of high dose corticosteroids and NMBAs are also often used. Thus, these data 
should be extrapolated to humans with caution. The aetiology of ICUAP is probably multi-
factorial, the syndrome is a spectrum and both neuropathy and myopathy are involved. As a 
result, ICUAP is unlikely to be due to a single easily targetable molecular mechanism. It is also 
important to note that some of the data have also been derived from the diaphragm in 
ventilated animal models and, although ICUAP is thought to affect the diaphragm, the 
diaphragm is also exposed to the unique insult of mechanical ventilation and VIDD. The 
translation of data from the laboratory to the clinical condition is difficult and limited, but 
these models have helped to identify candidate pathways involved in ICUAP, which should be 
further validated in clinical studies. As discussed above and demonstrated by the variability of 
the clinical studies to date, well controlled and relevant clinical studies are difficult to carry out 
successfully and because of this there remains a lack of human data describing the molecular 
mechanisms of ICUAP.  
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A range of alterations occur in the muscle of patients with ICUAP and, as previously 
discussed, both neuropathy and myopathy play a role. It is widely accepted that in the majority 
of cases these 2 pathological processes overlap and exist simultaneously to a greater or lesser 
extent (15, 98). Furthermore motor nerve and muscle function are physiologically dependent 
on each other and, therefore, attributing any one pathological process or feature solely to 
either neuropathy or myopathy may be an oversimplification. Within these limits and the 
current understanding of muscle and nerve function, this section will review the data available 
and the major molecular pathways that are likely to be important in the pathophysiology of 
ICUAP. 
1.2.3.1 Alterations in muscle phenotype and function in ICUAP. 
The strength of a muscle depends on both the muscle mass and the force generating 
capacity of that muscle. ICUAP affects both of these components and clinically manifests 
initially as abnormal muscle electrophysiology followed by wasting. Disruption of the organised 
muscle architecture is a key component of the pathophysiology of ICUAP. There is marked loss 
of thick myosin filaments with disruption of both the actin:myosin ratio (13, 99-101) and 
myofilament organisation (17, 102) on which healthy force generation is dependant.  
Histologically, ICUAP muscle demonstrates atrophy of both type 1 and 2 fibres (103) and can 
be associated with an inflammatory infiltrate and myofibre necrosis (40). A shift towards fast 
fibres expressing type 2 myosin has been reported in models and early case studies of ICUAP 
(99, 104); however, unlike in muscle wasting associated with aging and other atrophic states, 
such as chronic inflammation, starvation or indeed disuse (104, 105), this has not been 
conclusively demonstrated even in animal models (106).  However, type 2 fibres demonstrate 
greater atrophic changes and are thought to waste more rapidly (99, 107), suggesting 
potentially increased sensitivity of type 2 fibres to the multifactorial insult of critical illness.  
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Neuropathy, electrical inexcitability, dysregulation of calcium handling and a reduction 
in energy generation by the muscle through insulin resistance and mitochondrial dysfunction 
also contribute to muscle dysfunction in ICUAP and will be considered individually in the 
coming sections.  
1.2.3.2 Muscle Mass in ICUAP 
In healthy skeletal muscle a balance exists between muscle atrophy (due to muscle 
protein breakdown, autophagy and apoptosis) and muscle hypertrophy (muscle protein 
synthesis).  Muscle homeostasis depends on the balance of these factors and in steady state 
the two processes balance equally with no overall net change in muscle mass/ protein 
although this can alter in response to changes in demand.  For example, in hypertrophic 
responses both protein synthesis and degradation pathways can be increased with a greater 
increase in the rate of protein synthesis; similarly during atrophic responses the reverse can be 
true. The aim of this flexible balance in healthy muscle is to allow for repair of muscle fibres 
and release of amino acids for gluconeogenesis. A disruption in this balance has been believed 
to be responsible for the loss of muscle mass in ICUAP since it was first demonstrated in 1968 
in response to denervation (108). However, only recently has this been conclusively 
demonstrated in human critical care patients. Using dynamic markers of muscle synthesis and 
breakdown, Puthucheary et al demonstrated reduced protein synthesis in the initial phase of 
critical illness followed by a sustained increased in rate of muscle protein breakdown resulting 
in maintained catabolism over the first week (40). Figure 1-1 summarises the basic   molecular 
mechanisms regulating muscle protein synthesis and breakdown.  
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 Figure 1-1 Schematic of the basic molecular pathways balancing muscle protein synthesis and breakdown.  
In ICUAP sepsis,  inf lammation and immobility result in muscle atrophy by shifting this  
balance in favour of muscle protein breakdown. IGF -1 - Insulin l ike growth factor, MAPK –  
Mitogen Activated Protein Kinase, mTor –  mammalian target of rapamycin,  FoxO –  Forkhead box 
protein, FoxO-P –  phosphorylated FoxO (inactive),  UP  –  ubiquitin proteosome, U –  ubiquitin.  
Published in Bloch et al   ERJ 2012 39 (4): 1000 -11 (109) copyright permission granted see 
appendix A1.  
 Up-regulation of muscle protein breakdown in ICUAP 1.2.3.2.1
The primary mechanism of proteolysis is thought to be the ubiquitin-protesome (UP) 
pathway, but caspase and calpain activity, as well as autophagy also play important roles (110). 
Briefly, the UP pathway involves the specific regulated degradation of proteins by tagging of 
the targeted proteins with ubiquitin moieties. The tag is recognised by the proteasome, which 
consists of a multi-protein complex that breaks down the targeted protein into its constituent 
amino acids. Proteins E1 and E2 activate and carry the ubiquitin molecule, thus preparing it for 
conjugation. E3, the ubiquitin ligase, then catalyses the ligation to the target protein (110). E3 
ligases target specific proteins, and their own expression can be restricted to specific tissues. 
Atrogin and muscle ring finger-1 (MuRF-1) are muscle-specific (110-112). MuRF-1 is of 
particular interest in ICUAP as it specifically targeted thick myosin filaments (113, 114), whose 
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loss is a key feature of ICUAP. However, these ligases not only target contractile and structural 
proteins, but also those involved in regulation of muscle proliferation and differentiation, such 
as myogenic differentiation factor D (MyoD) (115, 116). MuRF-1 and atrogin were identified in 
models of disuse atrophy (111, 112, 117) and knock-out rodents were resistant to denervation-
related atrophy (112) and MuRF-1 and atrogin mRNA expression were induced following CLP 
(118). In addition, inflammation also activated ubiquitination (110).  UP and MuRF-1 
expression were regulated by the transcription factor nuclear factor kappa-B (NF-кB) which 
itself was negatively regulated by the inhibitor of NF–кB (IкB) (119-121). Sepsis and 
inflammation also activated the UP pathway potentially by increased ubiquitination and 
degradation of IкB induced by Tumour Necrosis Factor (TNF)-α (119). GCS, which are elevated 
in stress responses including critical illness, were also found to up-regulate the UP pathway 
(122). Furthermore GCS disruption of the balance between protein synthesis and breakdown 
can be exacerbated by denervation (108).  The clinical relevance of GCS is unclear as there is 
only inconclusive evidence that GCS are a risk factor for ICUAP at all (48).  
In human patients with ICUAP increased protein ubiquitination was demonstrated 
alongside damage to myosin filament structure (123).  In the muscle of septic patients on ICU 
UP mRNA was increased (124) and increased activity of the proteosome (direct evidence for 
increased muscle proteolysis) was demonstrated in both respiratory (30% higher than controls) 
and limb (45-55% higher than controls) muscles (125). 
 Autophagy 1.2.3.2.2
Autophagy is a major catabolic process by which the cell breaks down its own 
components within special lysosomes called autophagosomes (98). In animal models sepsis, 
denervation and GCS all induced autophagy (98, 126) and autophagy has been implicated in 
congenital human myopathies (127). However, as yet there is not conclusive evidence to 
suggest a role in ICUAP. For example, despite being implicated in diaphragmatic atrophy in 
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critically ill patients (128), increased levels of autophagy regulatory proteins in the muscle of 
critically ill patients was not accompanied by increased mature autophagosomes (129), in fact 
there was a decrease in mature vesicles. It is possible that defective autophagy is in fact 
present in ICUAP and that autophagy has a protective role in healthy muscle (98).  
 Down-regulation of muscle protein synthesis in ICUAP 1.2.3.2.3
As discussed above, it is the overall balance between protein synthesis and breakdown 
which, when disrupted, results in net catabolism that is important when considering muscle 
protein balance in ICUAP.  Human (and animal) studies show variably decreased or increased 
muscle protein synthesis at different stages in the clinical course (40, 130-132). However in 
these studies the rate of protein breakdown still exceeded that of protein synthesis resulting in 
catabolism. Decreased protein synthesis also occurred in response to sepsis and immobility 
(133-135) and in healthy volunteers in response to endotoxin infusion (136). 
  The Insulin-like growth factor-1 (IGF-1)/Akt signalling cascade is recognised as the 
major molecular pathway driving muscle protein synthesis (137, 138).  The binding of IGF-1 to 
its serine/ threonine kinase receptor activates the Mitogen Activated Protein Kinase (MAPK) 
cascade, thus increasing myoblast proliferation and/or the Akt pathway. Akt activates protein 
synthesis via mTOR (the mammalian target of rapamycin protein) and via inhibition of 
glycogen synthases kinase 3 beta (GSK3β) itself an inhibitor of protein synthesis (137, 139). In 
addition Akt regulates and inhibits atrophy pathways via phosphorylation of forkhead box 
(FoxO) proteins and subsequent inhibition of the expression of MuRF-1 and atrogin (140, 141). 
Sepsis and mediators of septic inflammation are well documented inhibitors of IGF-1 
(133). With respect to ICUAP, examples include IGF-1 reduction in the diaphragm of septic 
mice (142) and the observation that CLP-induced muscle protein loss in mice can be prevented 
by implanting a small IGF-1 pellet into the muscle (143). IGF-1 inhibition correlated with 
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decreased muscle protein synthesis and down-regulation of proteins required for translation 
(144).  In a septic rodent model Akt signalling and FoxO phosphorylation were decreased and 
MuRF-1 and atrogin expression increased (145).  
IGF-1 is also sensitive to muscle activity and was increased by muscle contraction and 
reduced by disuse (146). Muscle IGF-1 was reduced in human models of sepsis (133, 136), 
immobility (135), surgery (130) and in critical illness (147). Reduced plasma IGF-1 levels were 
also observed in acute critical illness (147) and were associated with poor clinical outcome 
(148) and development of severe ICUAP (149).  
Anabolic resistance is a further mechanism that may contribute to the inhibition of 
protein synthesis. Anabolic resistance describes a syndrome by which, in the setting of critical 
illness, muscle is unable to respond to anabolic signalling and use the supply of amino acids 
available and is thus unable to maintain adequate protein synthesis (150). The mechanisms 
behind this are unclear, but may include damage to the microcirculation secondary to sepsis 
and an ensuing reduction in the supply of oxygen, nutrients and growth hormones to the 
muscle (151).  
1.2.3.3 TGF-β signalling in muscle atrophy 
The Transforming Growth Factor (TGF)-β superfamily is a group of more than 30 
cytokines that are involved in regulation of diverse and essential biological processes, including 
cell proliferation, differentiation and apoptosis (152). The family can be divided broadly into 
two groups: the TGF-β/ activin/ nodal family and the BMP (Bone Morphogenetic Protein) 
family. GDFs, Growth and Differentiation Factors, may fall into either group (153). The TGF-β 
cytokines can have very different functions from each other and their complex interplay, 
competition for receptor binding and variable effects in different molecular environments 
make understanding their signalling systems very complicated. Despite this they are all 
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characterised by some conserved features; these include a “cysteine knot”, a central structure 
within each monomer. The TGF-β proteins are predominantly secreted in an inactive form and 
cleaved by proteases to release their active component (153). Activity of the TGF-β ligands is 
regulated by, amongst other things, ligand traps; these molecules bind and inactivate the 
ligand often in the circulation or extracellular matrix (152). TGF-β receptors (TGFBR) are 
comprised of 2 subunits and there are currently 7 type 1 and 5 type 2 recognised receptors 
known. Ligands are believed to have specific affinity for their type 1 receptor but may have 
affinity for several different type 2 receptor subunits and competitive binding and partial 
agonists are thought to exist. On extracellular ligand binding, a dimmer of type I receptors and 
a dimmer of type 2 receptors aggregate to form a heterotetremer complex. The intracellular 
component of the type 2 receptors is a constitutively active serine threonine kinase and, when 
in proximity to the type 1 receptor (also a serine threonine kinase), causes its phosphorylation 
(152, 153). The phosphorylated type I receptor activates the SMAD pathway. These activated 
SMAD (small mothers against decapentaplegic) proteins are transcription factors that 
translocate to the nucleus on phosphorylation where, with other specific co-transcription 
factors, they then promote transcription of TGF-β responsive genes. TGF-β subfamily ligands 
activate SMADS 2 and 3, which when phosphorylated bind co-SMAD 4; BMP family members 
phosphorylate SMADS 1,5,8 and there is competition for co-SMAD 4; SMADs 6 and 7 are R-
SMADs, regulatory SMADS that acts as a negative feedback loop to control and regulate 
signalling (154, 155). The multi-protein complex of phosphorylated SMADs serves as a “hub” 
for other regulatory factors and co-transcription factors to come together and activate specific 
signalling pathways.  Non-canonical pathways also exist and are activated independently of the 
SMAD proteins; these include JNK (c-Jun-N-terminal Kinase) and the p38 MAPK/ PI3K 
(Phosphoinositide 3-kinase) pathways. These may serve to augment or antagonise SMAD-
dependant signalling (155). 
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Myostatin, also known as GDF-8, is a member of the TGF-β family, discovered in 1997 
and was found to be a potent negative regulator of muscle mass (156). Myostatin knockout 
mice exhibited hyper-muscularity (156) and hereditary hyper-muscular conditions have been 
identified in, amongst others, cattle (157) and humans (158). Myostatin is almost exclusively 
expressed and secreted from skeletal muscle and, like other TGF-β members, myostatin is 
translated as an inactive pro-peptide and the active N-terminal domain pro-domain is removed 
to produce the active C-terminal domain (159). Myostatin has autocrine, paracrine and 
endocrine functions and is increasingly recognised to be involved in regulation of not only 
muscle mass but also adipocyte function and glucose metabolism (156, 160). Follistatin is a 
circulating protein that acts as the ligand trap for myostatin (161). Myostatin preferentially 
binds the Activin receptor-like kinase (ALK) 4 and 5 type 1 receptors and the Activin 2B type 2 
receptor and can activate both SMAD-dependant and independent pathways (161, 162). 
Activin 2B receptor inactivation reproduced the myostatin knock-out phenotype (163), but 
follistatin knockout resulted in greater muscle hypertrophy than myostatin knockout alone – 
suggesting that follistatin regulates other TGF-β ligands involved in the regulation of muscle 
atrophy (164). Myostatin promoted muscle atrophy through many different pathways 
including induction of the E3 ligases (165) and autophagy (166), inhibition of myoblast 
proliferation and differentiation (162), and suppression of IGF-1 signalling via Akt (167, 168). 
Excessive myostatin activity is implicated in, and has been linked in man to, muscle wasting in 
cardiac failure, cancer and HIV (169-171). Myostatin signalling was also elevated by GCS (172) 
and was negatively correlated with daily activity (173). However, currently a role for mysotatin 
in ICUAP has not been conclusively demonstrated and existing data are contradictory (147, 
174, 175).   
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1.2.3.4 Reduction in force generating capacity in ICUAP 
Early in the course of critical illness abnormal muscle electrophysiology was predictive of 
ICUAP and poor outcomes, and detectable weakness occurred prior to muscle wasting (41). 
Early weakness also occurred in animal models of sepsis and force-generating capacity of the 
diaphragm and limb muscles was reduced independent of any muscle wasting (106, 176-178). 
These changes are likely to be independent of the UP pathway discussed above as they 
occurred within hours of the onset of sepsis (179). Five major potential mechanisms have been 
proposed and are likely all to be relevant to a greater or lesser extent across the spectrum of 
ICUAP: (1) Neuropathy; (2) altered myocyte structure and myofilament integrity; (3) 
Sarcoplasmic reticulum dysfunction; (4) electrical inexcitability; and (5) bioenergetic failure and 
oxidative stress (Figure 1-2).  
 
Figure 1-2 Representation of potential mechanisms reducing force generating potential of skeletal muscle in ICU- 
acquired paresis (ICUAP)  
(1) Neuropathy; (2)  altered myocyte structure and myofi lament integrity; (3) 
Sarcoplasmic ret iculum dysfunction; (4) electr ical inexcitabi lity; and (5) bioenergetic fai lure 
Published in Bloch et al   ERJ 2012 39 (4) : 1000-11 (109) copyright permission granted see 
appendix A1.  
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   Neuropathy and nerve activity.  1.2.3.4.1
As discussed above, ICUAP was initially postulated to be a pure neuropathy, CIN (11, 
180). The neuropathic component of this disease has been less well studied than the 
myopathic component and therefore is less well understood. The 2 are difficult to separate as 
muscle innervation is required for the maintenance of muscle phenotype as well for 
contraction. Furthermore, denervation increased sensitivity to inflammatory mediators and 
promoted myosin loss in a rat model of ICUAP (181).  Nerve biopsy taken early in the course of 
ICUAP is often histologically normal, even in severe cases (99) and an axonal neuropathy is not 
demonstrated until much later (182). However, action potentials in the nerve may be 
abnormal within hours of the onset of critical illness (183). The mechanisms leading to 
neuropathy in ICUAP are not well understood or researched. Suggestions include a membrane 
depolarisation defect that theoretically could occur in a histologically normal nerve; disruption 
of the blood-nerve barrier, potentially caused by microvascular pathology and inflammatory 
mediators (including TGF-β), has been postulated to cause the depolarisation defect (98, 184). 
This is supported by increased activation of endothelial cells in the microcirculation 
surrounding peripheral nerves of patients with ICUAP (185). Additionally a loss of endoneural 
membrane potential has been suggested secondary to local hyperkalaemia and possibly linked 
to renal insufficiency (98, 186). Lastly, the neurotoxicitiy of inflammatory cytokines is well 
recognised (187). 
A full discussion of VIDD is beyond the scope of this thesis and the aetiology and 
pathology of VIDD and ICUAP are difficult to separate, but it is worth noting that traffic in the 
nerve is especially relevant to VIDD. One of the aims of ventilatory support is to reduce the 
work of the respiratory muscles.  The diaphragm has a specific and unique phenotype designed 
to facilitate the fact that it is never immobile and during total mechanical ventilation it is 
subjected to varying degrees of passive stretch. VIDD has been reviewed recently by Jaber et al 
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(188). We should note that diaphragm weakness occurs commonly in intubated patients (44, 
189), and risk of weakness increased with duration of ventilation (190). Furthermore there is 
increasing evidence that those modes of ventilation that promote continued (191) or, in 
rodents, intermittent (192) phrenic activity may attenuate VIDD. 
 Myocyte structure and myofilament integrity;  1.2.3.4.2
The integrity of the myofilament structure, the major components of which are myosin 
and actin, is essential for maximal force generation. Myofilament structure was disrupted by 
mediators of sepsis such as TNF-α (193). Calpains facilitate ubiquitination and proteolysis of 
myofilament components (mainly myosin) by cleavage, acting to provide an amino acid pool. 
However cleavage of myofilaments disrupts the structure of the myofibrils and thus the force 
generating capacity of the fibre is also reduced (194, 195).  Caspases are involved in the 
activation of apoptotic pathways; as multinucleate muscle fibres atrophy, apoptosis begins by 
a slow reduction in number of nuclei (196, 197). There is a convincing body of evidence to 
suggest a pathological role for both caspases and calpains in muscle atrophy in ICUAP; both 
were induced in animal models of sepsis and immobility and were shown to be associated with 
muscle wasting and reduction in the force generating capacity of muscle (196, 198-201). 
Furthermore calpain 3/p94 was linked to human muscle atrophy (202). However, as yet there 
are no human ICUAP data and most animal data were derived from diaphragm work.  Altered 
function of the sarcoplasmic reticulum:  
Intracellular calcium concentration is critical in regulation of muscle contraction. 
Calcium has direct effects on the myosin ATPase during the contraction cycle and regulates 
glycolytic and oxidative energy metabolism. Pathological increases in intracellular calcium 
during sepsis and immobility were observed in limb skeletal muscle (203, 204), potentially 
caused by disruption of the sarcoplasmic reticulum (205) (the sarcoplasmic reticulum stores, 
binds and releases calcium and thus is responsible for calcium homeostasis) resulting in 
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increased sensitivity of contractile proteins to calcium (206). Furthermore, calcium also 
regulated protein breakdown, by activating calpains and ubiquitination (203).   
As calcium is essential for muscle contraction it might be expected that increased 
intracellular calcium would increase the force generating potential of muscle; however, this 
appears not to be the case and this implies that reduced calcium release from the sarcoplasmic 
reticulum is in fact the dominant effect. Furthermore, serum from critically ill patients who 
developed ICUAP reduced the calcium-activated force generated in permeabilised muscle 
fibres. It was suggested that this effect was secondary to blocked calcium release. The serum 
fraction used was low molecular weight, <30 kDa, suggesting a role for inflammatory cytokines 
in this process (207).  
 Electrical in-excitabiltity 1.2.3.4.3
It has been postulated that CIM and CIN coexist as the result of a systemic syndrome 
of electrical in-excitability (17). Consistent with this hypothesis were the findings that both 
nerve and muscle tissue were relatively in-excitable in ICUAP models with altered membrane 
potentials (14, 186, 208, 209) and that nerve histology was often normal, suggesting functional 
rather than structural abnormalities (12, 17). Furthermore, these membrane alterations 
resulted in chronic depolarisation and reduced excitability of the nerve (186) and therefore 
caused functional denervation of the adjacent muscle (22). Cardiac in-excitability in sepsis has 
also been demonstrated by reduced ECG potentials in septic patients (210) lending weight to 
the argument for a generalised syndrome of in-excitability. The mechanisms behind the in-
excitability have been investigated in animal and in vitro models;  for example, denervated rat 
muscle had reduced membrane potential and when also exposed to GCS was unable to 
produce action potentials at all (211). One potentially unifying mechanism that has been 
postulated is sodium channel dysfunction and an overall reduction in the availability of sodium 
channels (212). In denervated, septic and lipopolysaccharide models of ICUAP an embryonic 
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form of sodium channel was expressed (Nav1.5) in muscle in place of the mature form 
(Nav1.4) (213-215), this resulted in a more negative depolarisation threshold, consequently 
99% of the available sodium channels were  inactive  (216) and the muscle fibre was unable to 
produce an action potential. Not all fibres are affected to the same extent and the percentage 
affected determines the severity of weakness (17).  
 Bio-energenetic failure, oxidative stress and glycaemic control:  1.2.3.4.4
Bio-energetic failure is an umbrella term for the combination of tissue hypoxia, insulin 
resistance, and increased oxidative stress resulting from sepsis and critical illness. This 
combination of factors results in reduced glucose uptake and ATP formation, mitochondrial 
dysfunction and increased free radical production (217).  The primary source of energy used by 
muscle is glucose and in the absence of a sufficient supply gluconeogenesis is fuelled by muscle 
proteolysis and amino acids. Glucose uptake in muscle is controlled by GLUT-4 receptors, 
which are insulin-dependent. Critical illness and sepsis result in insulin resistance and thus 
glucose uptake is reduced, which results in reduced ATP production and mitochondrial 
dysfunction.  
Bio-energetic failure may be worsened by both hypoxia and hypercapnia. Oxidative 
stress, in part driven by hypoxia, contributed to muscle wasting (218-220). Hypercapnia 
resulting in systemic and cellular acidosis may also disrupt metabolic function, causing 
decreased ATP and increased free radical production and leading to reduced contractile force 
in both diaphragm and limb skeletal muscle (221-223). However, direct evidence for the 
relative importance of gas exchange abnormalities in ICUAP is lacking ( Figure 1-3). Muscle 
expression of genes encoding electron transport components, levels of mitochondrial proteins 
and mitochondrial oxygen consumption were all suppressed in animal models of sepsis (224-
226). In human studies of acute critically ill patients with septic shock and ICUAP, 
mitochondrial dysfunction in limb muscle was an independent risk factor for mortality (227). 
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However not all studies in humans have shown mitochondrial dysfunction in muscle from 
critically ill patients (228).  
 
 Figure 1-3 Mitochondrial dysfunction in bio-energenetic failure results in increased free radical production and in 
turn further mitochondrial damage.  
Published in Bloch et al   ERJ 2012 39 (4): 1000-11 (109) copyright permission granted 
see appendix A1.  
 
Oxidative stress secondary to increased free radicals has been implicated in pathways 
potentially contributing to ICUAP both via total muscle protein loss (229, 230) and reduced 
force generating potential (224). For example, oxidative stress activated the UP pathway (231, 
232) and calpains and caspases (233-235). Free radicals disrupted the myofilament structure 
(236) and caused sarcolemmal damage, which was subsequently reduced by inhibition of nitric 
oxide synthase (209).  Free radicals are not only produced in the mitochondria in sepsis but 
production by sarcolemmal NAPDH oxidase and nitric oxide synthase (NOS) (195, 224) is also 
increased (237-239). Additionally, pathological effects of sepsis can be reversed with free 
radical scavengers and inhibitors of free radical production (233, 240-242). To date free radical 
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inhibition has only been tested in animal models and as yet the potential of antioxidant 
therapy in human ICUAP is not known (243). Finally, immobility may worsen bioenergetic 
failure with increased free radical production (244), increased microvascular permeability, 
increased insulin resistance and decreased antioxidant potential (59).  
As discussed above, hyperglycaemia may be an important aetiological factor in ICUAP. 
The mechanisms for this are unproven, but may include protection against bio-energetic 
failure via increased controlled uptake of glucose into the skeletal muscle and improved 
availability for mitochondrial function, in part via regulation of GLUT-4 receptors (217). 
Furthermore, insulin also had anabolic effects (245), inhibited the UP (246), was potentially 
anti-inflammatory (247), improved dyslipidaemia (248) and was neuroprotective (249). In a 
human post-mortem study of critically ill patients, increased skeletal muscle protein 
concentration was seen in those who were treated with intensive insulin therapy compared to 
controls (228) and similar results were demonstrated in patients with burns (245) and cancer 
cachexia (250). A further human study of ICUAP demonstrated increased IGF-1 and net protein 
synthesis in those treated with intensive insulin therapy compared to controls (147). However 
the above post-mortem study failed to demonstrate a protective effect of insulin on skeletal 
muscle mitochondria, only on liver mitochondria (228) again highlighting the difficulties of 
translating animal and in vitro work to human pathology.  
1.3 GDF-15 
1.3.1 Background  
Growth and differentiation factor- 15 (GDF-15) is a member of the TGF-β superfamily 
of cytokines. In the late 1990s several different groups independently identified GDF-15 in a 
wide range of different tissues and scenarios (251). As a result GDF-15 is known by several 
other names, including Macrophage Inhibitory Cytokine-1 (MIC-1) (252), Placental TGF-β 
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(PTGFB) (253), Placental Bone Morphogenic Protein (PLAB) (254) and non-steroidal anti-
inflammatory activated gene-1 (NAG-1) (255), according to how the protein was identified. 
GDF-15 was cloned from murine cDNA libraries and identified in many tissues, but found in 
highest levels in macrophages and epithelial cells (256).  As a TGF-β family member, GDF-15 
has the essential conserved elements, the cysteine rich domains and knot, and is secreted as a 
pro-peptide then cleaved into its active dimeric form (251). GDF-15 expression has been 
demonstrated in a wide range of tissues in both human and animal studies; however, it is 
expressed in the highest levels in embryological and developing tissues (251, 257). It is 
important to note that, unlike other TGF-β family members, GDF-15 is relatively poorly 
conserved between species and its expression profile differs in different animals (256, 258). As 
such it is increasingly recognised to have, diverse and divergent functions, but these are often 
related to central/ basic cellular function.  
Despite being widely expressed, it is thought that GDF-15 is actually only expressed by 
the placenta in adult normal physiological conditions and otherwise is only expressed in 
response to stress stimuli including hypoxia, inflammation, sepsis, mechanical stress and tissue 
damage (257). The physiological role of GDF-15 is therefore not yet fully understood. However, 
it has been implicated in a wide range of pathological processes and conditions, including 
cardiovascular (257), pulmonary (259, 260) and renal disease (261), inflammation (252) and 
solid and haematological cancers (262). Furthermore, GDF-15 is found in the circulation and its 
circulating concentration is a strong independent predictor of mortality in numerous 
conditions: for example, acute coronary syndromes and myocardial infarction (257), 
pulmonary artery hypertension (260), chronic renal disease (261) and malignancy (263). This 
relationship with mortality in numerous medical conditions was reflected in a recent study 
where, among elderly individuals followed for 5 years, higher circulatory GDF-15 concentration 
was related to all-cause mortality with a hazard ration of 4 (95% CI 2.7-6.0) and was specifically 
associated with worsening renal and cardiovascular function (264).  
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The mechanism of GDF-15’s action and signalling pathways have not yet been fully 
elucidated. As a member of the TGF-β family, GDF-15 would be expected to activate the well-
recognised TGF-β signalling pathways via a combination of type 1 and 2 receptors. However 
the evidence for this is currently lacking. Mutant TGFBR 1 and 2 cancer cells were resistant to 
the growth inhibitory effects of GDF-15 (265), GDF-15 induced malignant changes in prostate 
cells via the ALK 5 receptor (266) and Breit et al suggested co-localisation of the TGFBR2 and 
GDF-15 in the hypothalamus (267). However other groups have not been able to reproduce 
these results (251). Similarly, there is controversy as to whether GDF-15 activates SMAD-
dependant pathways, those independent of the SMAD protein or indeed both; again the data 
so far are inconclusive. Some data from cardiac myocytes and prostate cancer cells suggest 
that GDF-15 caused SMAD activation (266, 268). However, other groups suggest signalling to 
be uniquely via non-canonical pathways including Akt/ ERK (269), p38/MAPK (270) and NFKB 
(271).  
1.3.2 Rationale for investigation of GDF-15 in muscle wasting and ICUAP 
As discussed above, TGF-β signalling is one of the central pathways involved in muscle 
atrophy. However, despite myostatin’s potency as a negative regulator of muscle mass, the 
role of myostatin in ICUAP is unconfirmed and myostatin inhibition has not always been 
successful in treatment of muscle wasting disease (272).  GDF-15 is expressed in human and 
rodent skeletal muscle (251). However, unlike myostatin, which is largely limited to cardiac and 
skeletal muscle, GDF-15 is also widely expressed in other tissues (256), raising the possibility of 
both autocrine and paracrine functional effects. Furthermore, the structure of GDF-15 is 
predicted to be very similar to that of myostatin, which is also known as GDF-8 (258). Although 
the regulation of GDF-15 expression is not fully understood, its profile as a stress-induced 
cytokine is recognised and similar factors (oxidative stress, hypoxia, inflammation) have been 
demonstrated to induce its expression in various tissues. These factors are importantly also 
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recognised to be aetiological factors in the development of ICUAP and are known to have 
detrimental effects of muscle size and function (see above).  
The functions of GDF-15 in vivo are likely to be divergent and may depend on the local 
environment. For example, in cardiac cells GDF-15 has been shown to be hypertrophy limiting 
and anti-apoptotic in vitro (268); however, in vivo animals lacking GDF-15 showed increased 
cardiac hypertrophy in response to vascular stress (273). Similarly GDF-15 may have a 
protective role by promoting apoptosis in prostate cancer cells (274, 275), conversely it may 
also enhance metastatic potential and angiogenesis (262). GDF-15 was pro-apoptotic and 
protective in atheroma, promoting macrophage apoptosis and increasing plaque stability (276, 
277), and in acute myocardial infarction by protection of the myocardium from infiltration of 
polymorphonuclear leukocytes so protecting against post-infarction myocardial rupture (278).  
However, increasing data support the association between GDF-15 and poor outcomes. For 
example, with relevance to the topic of this thesis, in ARDS (279) (a leading cause of ICUAP) 
where higher circulating GDF-15 levels were associated with poor outcome. Furthermore, GDF-
15 causes cachexia in murine cancer models (267) and in humans is associated with cachexia of 
chronic disease and cancer (262, 280). The mechanism of these effects are not fully 
understood, but it has been suggested that it involves central hypothalamic appetite 
suppression, and neutralising antibodies to GDF-15 are able to reverse the effects in animals 
(280).  
In summary, therefore, our rationale for investigation of GDF-15 in ICUAP is as follows. 
Firstly, GDF-15 is expressed in response to aetiological factors thought to be responsible for 
ICUAP (oxidative stress, inflammation, hypoxia) in many tissues and it is therefore plausible 
that these factors will also drive expression in muscle. Secondly, at least in some 
circumstances, GDF-15 is thought to activate TGF-β signalling, promote apoptosis and limit 
hypertrophy pathways, all of which could contribute to muscle wasting.  Thirdly, increased 
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circulating GDF-15 is generally associated with disease progression outcomes, despite a 
protective role sometimes being suggested; thus, both circulating and muscle GDF-15 may 
drive muscle atrophy. 
1.4 MicroRNA 
1.4.1 Background  
MicroRNAs are small non-coding RNAs that regulate mRNA stability and translation. 
They were discovered in 1993 in the C-elegans nematode worm. The microRNA lin-4 was 
identified and it was recognised that the RNA sequence did not code for a protein, but rather 
had anti-sense complimentary sequences to the 3’-UTR of the lin-14 gene. It was implied from 
this that the microRNA (lin-4) had a role in the regulation of transcription of the lin-14 gene 
(281). Following this let-7 was identified and found to be conserved in many species including 
humans (282). It is now recognised that microRNAs make up approximately 1% of human 
predicted genes but, more importantly, that at least 1/3 of all genes are under regulation of 
microRNAs (283) and that their functions include regulation of most major cellular processes – 
including proliferation, apoptosis and differentiation (284).  
The steps in microRNA biogenesis are complex. Briefly, microRNAs are transcribed 
from the genome as a pri-microRNA, which may be several thousand bases in length. DNA 
sequences for microRNAs may have their own promoter or be within the un-translated regions 
of related genes. Pri-microRNAs contain stem loop sequences encoding the miRNA, which are 
cleaved into a small hairpin structure known as the pre-microRNA. Cleavage is carried out by a 
large structure known as the “microprocessor” made up, in part, of Drosha (an RNA 
polymerase type III like protein). The product pre-microRNA is approximately 70 nucleotides in 
length and is exported from the nucleus by exportin. In the cytoplasm Dicer protein (an 
RNAase) is responsible for the final processing and production of the mature, approximately 23 
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nucleotide, microRNA. Both 3’ and 5’ strands are produced, although it is thought that one is 
usually degraded and that this process may be tissue specific. One strand is incorporated into 
the RISC (RNA-induced silencing complex) where it binds with the target mRNA and acts to 
inhibit translation or destabilise the mRNA itself (284).  
The network of microRNA to mRNA interactions is complex; each microRNA may target 
several, even hundreds, of mRNAs and, in turn, the expression of microRNAs is regulated by 
many different factors (285). Seed-sequence recognition of the 2nd to the 8th 5’-nucleotides 
results in target specificity, but exact sequence specificity beyond this is not required for 
binding in animals (although it is in plants) and, as a result, target prediction is also complex. 
Furthermore many microRNAs function together. These features led to the hypothesis that 
microRNAs fine-tune the balance between transcription and translation and ultimately co-
ordinate gene expression networks (286).  
1.4.2 Muscle microRNAs 
Since their discovery, thousands of microRNAs have been identified in humans and 
their role in health and disease is a rapidly expanding field of research. The importance of 
microRNAs to muscle development and function is demonstrated by the fact that tissue 
specific Dicer knock-out mice (who are unable to produce microRNAs in muscle) develop 
abnormally in the embryonic and perinatal phase and are unable to survive (287). As in other 
tissues, microRNAs have been found to be involved in, and essential for, muscle homeostasis, 
both during embryogenesis and in adult life. Some microRNAs are tissue/ muscle specific and 
known as myomiRs, but many microRNAs that are expressed in muscle are also ubiquitously 
expressed (288, 289).  
The myomiRs are highly expressed in skeletal (and cardiac) muscle and include mainly 
miRs 1, 133a, 133b, 206, 208a, 208b and 499.  Some of these microRNAs are organised into 
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clusters which are transcribed together, such as miR-1/133a (actually existing as miR1-1/133a-
2 and miR1-2/133a-1) and miR-206/133b (290). MiRs 1 and 206 differ by only 4 nucleotides 
and miRs 133a and b are identical except for one final nucleotide. MiRs 1 and 133a are 
expressed in cardiac and skeletal muscle, whereas miR-206 is limited to skeletal muscle and 
miR-208a to cardiac muscle (289). MiRs 208b and 499 are limited to slow-twitch muscle fibres 
and coded for within the introns of the MHC type 1 genes (MyH-7 and MyH7B) (291). Co-
transcription and sequence similarity indicate that these microRNAs are likely to have similar 
targets and functions.  Although the regulation of expression of these myomiRs is not fully 
understood, central myogenic factors are thought to activate myomiR expression, including 
Serum Response Factor (SRF), Myocyte Enhancer Factor-2 (MEF-2), MyoD and myogenin (289). 
MiR-1 and 133a fine-tune the balance between proliferation and differentiation. The 
two processes are exclusive and myoblasts proliferate in the presence of growth factors, but 
on exiting the cell cycle they fuse and differentiate into multinucleate muscle fibres. In in vitro 
models, miR-1 inhibited HDAC-4 (Histone Deacetylase-4) a potent inhibitor of differentiation; 
thus, miR-1 promotes differentiation. In contrast, miR-133a inhibited SRF, thus promoting 
proliferation (290).  MiR-206 also promoted differentiation, preventing down-regulation of 
MyoD (289). MiR-181a is not muscle-specific but is expressed highly in differentiating and 
regenerating muscle and, by suppression of Homeobox Protein A11 (HOX-A11), promotes 
muscle differentiation (292). Furthermore, inhibition of these microRNAs resulted in delayed 
or abnormal proliferation or differentiation (290, 292-294).  
Determination of muscle fibre type is also closely controlled and dependant on genetic 
factors, each specific muscle’s function and external factors (for example activity). MicroRNAs 
208b and 499 are expressed within the gene encoding slow myosin (Myh7). When expressed, 
miRs-208 and 499 down-regulate transcriptional repressors, including Sox-6 (which promotes 
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the type 2 phenotype), and result in promotion and maintenance of the type I phenotype 
(291).   
Our understanding of the role of microRNAs in the maintenance of muscle mass is 
limited but, by regulating atrophy and hypertrophy pathways, myomiRs have been shown to 
be involved. MiRs-1, 133 and 206 inhibited IGF-1-driven hypertrophy by targeting IGF-1 itself 
and its receptor; in turn, IGF-1 and active Akt down-regulated miR-1 potentially via 
suppression of FoxO (288, 295). However, despite an increase in myofibre size in vitro 
associated with miR-206 inhibition, in vivo studies did not demonstrate a significant effect 
(296). Myostatin is also under regulation of microRNAs and, in turn, regulates their expression. 
Interestingly, Texel sheep, which have significant muscle hypertrophy, demonstrate a mutation 
in the 3’-UTR of the myostatin gene; this results in a novel binding site for miRs-1 and 206 
resulting in myostatin degradation and increased muscle hypertrophy (297). In normal tissue 
miR-27, 208b and 499 act to target and inhibit myostatin, thus promoting hypertrophy (293). 
Myostatin knock-out mice show increased levels of miRs 1, 133 and 206 however a direct link 
between myostatin and their regulation has not yet been demonstrated (298). Firgure 1-4 
summaries a basic understanding of the role of muscle microRNA in muscle homeostasis.  
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Figure 1-4 Schematic representation of the current understanding of the role of microRNAs in muscle 
homeostasis. 
SFR- serum response factor, HDAC –  histone deacetylase, HOX-A11 –  Homeobox protein 
A11, IGF-1 –  Insulin- like growth factor-1,  FoxO –  Forkhead box protein.  
1.4.3 Rationale for investigation of MicroRNAs in ICUAP in relation to GDF-15 
MicroRNAs have been implicated many muscle diseases (299), including congenital 
muscle diseases such as Duchene’s Muscular Dystrophy (DMD) (300), inflammatory 
myopathies (301) and secondary muscle diseases such as muscle wasting related to COPD 
(302). Well-recognised animal models of DMD have been used to investigate the role of 
microRNAs and, for example, miR-206 was significantly increased in the diaphragm and 
adductor pollicis of the Mdx mouse model of Duchenne’s muscular dystrophy (300, 303) and 
similar patterns were seen in humans with DMD (303) and myotonic dystrophy type 1 (304); 
however, results depend on the model used and the muscle sampled (288). Interestingly, 
circulating miR-206 was found to be a useful biomarker in human patients with DMD (305). In 
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COPD, Lewis et al showed that down-regulation of miR-1 in the quadriceps muscle was 
associated with muscle atrophy and functional down-regulation of SRF (302). Inflammatory 
myopathies have been shown to be associated with a general down-regulation of myomiRs 
and the authors postulated that this would result in generally deranged muscle homeostasis 
(301). MicroRNAs are essential for muscle regeneration following injury or insult (288, 292) 
and it is therefore consistent that they should be dysregulated in conditions with abnormal or 
inadequate regeneration; however, this has not previously been investigated in ICUAP.  
Additionally, inflammatory cytokines have been shown to regulate microRNA 
expression (288, 301) and TGF-β signalling and myostatin, central to muscle atrophy, are 
increasingly recognised to be under microRNA control (293). Finally, therefore these data led 
to the hypothesis that muscle microRNAs would be dysregualted in ICUAP and may also be 
under GDF-15 regulation.  
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1.5 Summary, aims and hypotheses  
Understanding of the molecular mechanisms of ICUAP provides the opportunity to 
identify potential future therapeutic targets. ICUAP is a common and sometime devastating 
disease for which there are no pharmacological therapies at present and for which physical 
rehabilitation currently provides the only potential intervention. Therefore, the aim of this 
thesis is to investigate the role of GDF-15, a potential novel modulator of muscle mass, in 
ICUAP. Additionally, with investigation of muscle microRNA expression in ICUAP, the findings 
may provide insight into the pathological mechanisms of ICUAP. Therefore the main 
hypotheses of this thesis can be stated as follows: 
1. GDF-15 will be elevated in the blood and muscle of ICUAP patients. 
2. MicroRNA will be dysregulated in the muscle of ICUAP patients. 
3. In vitro, GDF-15 will regulate expression of muscle atrophy related genes and 
muscle microRNAs.  
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Chapter 2 Methods 
 
2.1 Clinical Methods 
2.1.1 Ethical approval  
Ethical approval for the clinical studies carried out as part of this thesis was secured 
either from the National Research Ethics Committee (10/H0722/9) or under a generic 
permission to draw blood granted to the National Institute for Health Research (NIHR) 
Biomedical Research Unit at the Royal Brompton Hospital ethical approval (10/H0504/9). 
Written informed consent was obtained from all participants, except when the participant was 
unable to consent for themselves, in which case written informed assent was obtained from 
the participant’s next of kin. This only occurred when participants were sedated and ventilated 
on ICU. 
2.1.2 Assessment of quadriceps muscle bulk 
Quadriceps muscle size was assessed with B-mode ultrasound (US) imaging using a 
10MHz 12L-RS probe (Logiq E, GE Healthcare, UK). US cross-sectional area of the rectus 
femoris (US RFcsa) and mid-thigh muscle layer thickness (MLT) were measured using well 
established techniques (40, 42, 306, 307) .  The patient was positioned supine on the bed with 
their legs flat and leg muscles relaxed. The anterior superior iliac spine (ASIS) and the point 
60% of the distance from the ASIS to the superior border of the patella were identified. The US 
probe was positioned perpendicular to the axis of the leg and the scanning depth set to 
visualise the femur in the same image. Where the entire RFcsa could not be visualised in a single 
US image a point 66% or 80% of the distance between the ASIS and patella was also used. The 
same point was used for follow-up measurements for each patient. MLT was always measured 
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at the 60% point. Three separate consecutive images were taken and RFcsa and MLT estimated 
using Image-J software (National Institutes of Health, USA). The average of these three 
measurements was used.  To calculate RFcsa a line was drawn round the interior echogenic line 
delineating the RF muscle (42). The area was then calculated using Image-J software (Figure 
2-1). The MLT was defined as the depth of a vertical line drawn from the interior edge of the 
superior aspect of the RF muscle to the upper edge of the femur (Figure 2-1) (306).  
Inadequate ultrasound images were defined as those where the edges of the RF muscle could 
not be defined well enough to calculate the RFcsa or MLT. 
Figure 2-1 Assessment of quadriceps muscle size by rectus femoris cross-sectional area (RFcsa) and mid-thigh 
muscle layer thickness (MLT).  
Image on the left taken at  60% of the distance between the anterior superior i l iac  spine 
and the superior border of the pate lla and demonstrates that the whole cross sectional area of 
the rectus femoris muscle is not v is ible in a s ingle ultrasound image.  The MLT is  demonstrated 
on this image. Image on the r ight is at 80% and shows the whole cross sectional area at this 
level and the measurement of the RF c s a  is  i l lustrated.  
2.1.2.1 Inter-observer variability 
In collaboration with a colleague in the same group, Dr Dinesh Shrikrishnapalasuriyar, 
the inter-observer variability of our technique was assessed. The US RFcsa of volunteers from 
the muscle lab was measured by both myself and Dr Shrikrishnapalasuriyar and Graphpad 
Prisim (GraphPad Software, California, USA) was used to generate a Bland Altman plot of the 
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results (Figure 2-2). The Bias was found to be 0.1 cm2 with a standard deviation of 0.29 cm2 
and 95% limits of agreement -0.68-0.46 cm2.  
 
Figure 2-2 Bland Altman plot of ultrasound rectus femoris cross-sectional area (US RFcsa) to assess inter-observer 
variability. 
Bland Altman plot of difference between measurements by two observers of RFcsa. 
Dotted l ine represents bias -0.11 cm
2
,  Dashed l ine represents 95% limits of agreement -0.68-
0.46cm
2
.  n=10 
2.1.2.2 Definition of a significant change in US RFcsa 
In order to define a significant change in RFcsa overtime the coefficient of variation for 
the technique, when carried out by myself on ICU patients, was calculated.  To calculate the 
coefficient of variation the RFcsa for the first 10 patients studied was repeated on two separate 
occasions, on the same day, and a Bland Altman plot was generated (Figure 2-3). The 
coefficient of variation of the percentage difference was found to be 5.60 and therefore a 
significant change in US RFcsa was defined as greater than 9.24%, based on the assumption that 
1.65xCV approximates the 95% confidence limits.  
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Figure 2-3 Bland Altman plot of ultrasound rectus femoris cross-sectional area (US RFcsa) to assess repeatability 
and define a significant change.  
Bland-Altman plot of difference in repeated measurements of RFcsa in ICU patients.  
Dotted line represents bias -0.1 cm
2
.  Dashed l ines demonstrate l imits of agreement -0.25- 
0.45cm
2
.  n=10 
2.1.3 Assessment of muscle strength  
Muscle strength assessment was attempted using two techniques; the Medical 
Research Council strength score (MRC-SS) and manual muscle testing of maximal voluntary 
contraction of the quadriceps (QMVC).  
2.1.3.1 Medical Research Council - strength score (MRC-SS) 
The MRC-SS is a clinical tool used to assess global peripheral muscle strength. It 
involves the clinical assessment of strength of three muscle groups in each of the four limbs. 
Each movement’s strength is assessed by the assessor and graded 0-5 (Table 2-1). The total 
score therefore ranges from 0 (complete paralysis) to 60 (normal strength) (3, 18). This test is 
widely used in both clinical practice and research. It has also been used to define ICUAP;  
where a score of less than 48 in a patient with the appropriate medical history defines ICUAP 
(3). The test relies on the cooperation and understanding of the patient and is therefore 
unsuitable in a large proportion of ICU patients (308). The MRC-SS had  good reproducibility 
and inter-observer variability in the general population (308), however in critical care patients 
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only moderate consistency was demonstrated for the diagnosis of ICUAP (308). Furthermore 
the test was not adequately discriminatory in elective cardiothoracic patients recruited for the 
studies in this thesis – all of whom scored 60 at pre-operative recruitment – and at follow up 
all but 4 (of whom two were still intubated and ventilated and therefore unable to complete 
the test) scored 60 despite reportedly feeling weaker and having documented loss of muscle 
bulk on US.  
Strength for each movement tested Score 
Normal Power 5 
Active movement against resistance 4 
Active movement against gravity 3 
Active movement but not against gravity 2 
Visible contraction but no limb movement 1 
No visible contraction 0 
Movements tested on each side: Arm abduction, Elbow flexion, wrist 
extension, Hip flexion, Knee extension, Ankle dorsiflexion.  
Table 2-1 Medical Research Council Strength Score  
 
2.1.3.2 Quadriceps maximal voluntary contraction (QMVC) 
The gold standard for assessment of quadriceps strength is the measurement of 
quadriceps maximal voluntary contraction (QMVC) using the technique described by Edwards 
et al (309). This involves the measurement of isometric contraction against a non-extendable 
strap attached to a strain gauge. However this technique requires a significant volume of non-
mobile equipment including a modified chair, the strain gauge and the computer equipment to 
analyse the measurements. Therefore to facilitate measurement of strength at the bedside 
within the ICU and on the wards, a handheld dynamometer was used instead. This has the 
advantages of being mobile, quick and easy to carry out in a ward setting. A Lafayette manual 
muscle tester (device 01163 MMT, Lafayette Instruments Europe Ltd, Leicestershire, UK) was 
used with the smooth curved attachment. The patient was positioned sitting with the leg 
flexed at 90 degrees over the edge of the bed or chair. The assessor held the dynamometer in 
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contact with the patient’s mid-shin. The patient was asked to kick out their leg with maximal 
power which the assessor matched to prevent movement of the leg. The movement was 
continued for five seconds and the dynamometer recorded the maximal strength in kilograms 
maintained for one second as per the Lafayette instructions manual.  
In a trial of 8 healthy volunteers the quadriceps strength was assessed by both the 
quads chair and the handheld dynamometer. A Bland Altman analysis of the results showed 
that the techniques vary significantly with the quads chair always recording a higher strength 
(Bias 8.5 kg) and the 95% limits of agreement being between -9kg and 26kg (Figure 2-4).  
However the two techniques did correlate (r=0.75, p=0.03 – Pearson’s) and for the purposes of 
the study assessment of change in strength was required and therefore in view of the logistical 
issues with using the quads chair, measurement of quadriceps strength was attempted with 
the hand-held device.  
 
 
Figure 2-4 Bland Altman plot of measurement of quadriceps strength with the quads chair and handheld 
dynamometer.  
Dashed l ines represent 95% limits of agreement -9-26Kg%. Dotted l ine represents bias 
8.5kg (SD 8.9Kg). n=8 
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This technique clearly involves cooperation and understanding from the patient as well 
as the ability to sit with the knee flexed over the edge of a bed or chair. Therefore it is 
unsuitable in many ICU patients and was not attempted on the intensive care unit. The 
assessment of muscle strength in elective patients was attempted. However repeatability and 
reliability were found to be poor with a large volitional component. Furthermore for many 
patients the maximum power of their quadriceps was greater than that which I was able to 
match with my arm. Finally post operatively patients were unable to complete the test in the 
majority of cases due to pain from their sternal wounds.  
2.1.4 Risk Scoring Systems 
2.1.4.1 European System for Cardiac Operative Risk Evaluation (EuroSCORE) 
Pre-operative elective cardio-thoracic patients at the Royal Brompton Hospital are 
routinely scored for operative risk. The EuroSCORE was developed across 128 European 
cardiothoracic centres with the aim to predict early post operative mortality and complications 
(310). It has an additive and logistic version both of which have been validated for their ability 
to predict post-operative mortality, complication and ICU length of stay (311, 312). The 
additive EuroSCORE was chosen for the purposes of this thesis as it is readily accessible and 
can be manually calculated.  Table 2-1 shows calculation of the additive EuroSCORE, which can 
also be done online at www.EuroSCORE.org. In the original study in 1999 a score of 0-2 was 
classified as low-risk, 3-5 medium-risk and > 6 as high-risk. However in a subsequent study the 
risk of complications and increased length of ICU stay was found to rise at a score of > 5 (311). 
Therefore we used a cut off of >5 if the surgical team had not already classified the patient as 
“high-risk” for inclusion into the study discussed in chapters 3 and 6, where larger numbers of 
patients were required: and >6 for the interventional study (chapter 5) where a longer ICU stay 
and inpatient stay was essential for the study protocol (predicted ICU stay for a patient with a 
EuroSCORE > 6 was a mean of 6.1 days in the Messaoudi et al study (311)).  
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Calculation of the additive EuroSCORE 
Patient-related factors Score 
Age (per 5 years or part thereof over 60 years) 1 
Sex Female 1 
Chronic 
pulmonary 
disease 
Longterm use of bronchodilators or steroids for lung disease 1 
Extracardiac 
arteriopathy 
Any one or more of the following: claudication, carotid occlusion or 
>50% stenosis, previous or planned intervention on the abdominal aorta, limb 
arteries or carotids 
2 
Neurological 
dysfunction 
disease 
Severely affecting ambulation or day-to-day functioning 2 
Previous cardiac 
surgery 
Requiring opening of the pericardium 3 
Serum 
creatinine 
>200 micromol/L preoperatively 2 
Active 
endocarditis 
Patient still under antibiotic treatment for endocarditis at the time of 
surgery 
3 
Critical 
preoperative 
state 
Any one or more of the following: ventricular tachycardia or fibrillation 
or aborted sudden death, preoperative cardiac massage, preoperative 
ventilation before arrival in the anaesthetic room, preoperative inotropic 
support, intraaortic balloon pump or preoperative acute renal failure (anuria or 
oliguria<10 ml/hour) 
3 
Cardiac-related factors Score 
Unstable angina Rest angina requiring iv nitrates until arrival in the anaesthetic room 2 
LV dysfunction Moderate or LVEF30-50% 1 
 Poor or LVEF <30 3 
Recent 
myocardial 
infarct 
(<90 days) 2 
Pulmonary 
hypertension 
Systolic PA pressure>60 mmHg 2 
Operation-related factors Score 
Emergency Carried out on referral before the beginning of the next working day 2 
Other than 
isolated CABG 
Major cardiac procedure other than or in addition to CABG 2 
Surgery on 
thoracic aorta 
For disorder of ascending, arch or descending aorta 3 
Post-infarct 
septal rupture 
 4 
Table 2-2 EuroSCORE calculation.  
Adapted from www.EuroSCORE.org LVEF –  left ventricular ejection fraction,  PA –
pulmonary artery, CABG –coronary artery bypass graft  
2.1.4.2 Sequential Organ Failure Assessment Score (SOFA) 
The SOFA score was developed in 1994 as a means of quantifying organ failure in 
critical care patients (313). Since then it has been widely validated in different ICU populations 
and has been validated for both sequential use and as a prognostic marker of outcome (314). 
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This enables the score to be used during ICU admission as a marker of the patient’s severity of 
organ failure/ illness. The SOFA score also has the significant advantage of being easy to use 
and unlike other scoring systems, for example the acute physiology and chronic health 
evaluation (APACHE) scores (315), it is possible to manually calculate with data readily 
available on the intensive care unit. Furthermore despite this it performs almost as well as a 
prognostic marker for outcome  when used as a single time point (314) or when assessing 
response to treatment (316). Table 2-3 shows how to calculate the SOFA score however there 
are also free online platforms to facilitate this for example www.mdcalc.com.  
SOFA score 1 2 3 4 
For respiration with respiratory 
support PaO
2
/FiO
2 
(mmHg) <400 <300 <200 <100 
Platelets x10
3
/mm
3
 <150 <100 <50 <20 
Bilirubin  μmol/L 20-32 33-101 102-204 >204 
Cardiovascular hypotension MAP <70 
Dopamine < 5 
or 
Dobutamine 
any dose 
Dopamine >5 
or 
Cathecolamines 
<0.1 
Dopamine >15 
or 
Cathecolamines 
> 0.1 
Glasgow Coma Score 13-14 10-12 6-9 <6 
Creatinine μmol/L or 
(Urine output mls/24 hours) 
110-170 171-299 
300-400 
(<500) 
>400 
(<200) 
Table 2-3 Sequential Organ Failure Assessment score.  
Adapted from Crit Care Med. 1998 Nov;  26(11):1793-800. (313)  
2.1.5 Blood sampling, handling and storage of samples 
Approximately 15mls of blood was collected from the patients using standard 
techniques; one full serum tube and two EDTA (ethylenediaminetetraacetic acid) tubes. Whole 
blood was aliquoted and the remaining samples were centrifuged at 1,500xg for 10 minutes to 
enable separation of plasma and serum. To avoid repeated freeze thaw cycles 500µl aliquots 
were stored at -80oC until required. Samples were processed and frozen within 2 hours of 
collection.  
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2.1.6 Muscle biopsy, handling and storage of samples 
Quadriceps muscle biopsies were collected from the rectus femoris muscle by two 
different techniques – Surgical or Bergstrom. Both sets of biopsies were then handled in the 
same way. 
Surgical biopsies were taken by the surgical teams, either at the time of the initial 
cardiothoracic surgery, a subsequent procedure (for example tracheostomy) or in some cases 
if the patient was fully anticoagulated on the ICU. This technique involved an open biopsy with 
direct visualisation of the muscle in order to control bleeding, if it occurred, with diathermy. 
Open surgical biopsies were taken under full sedation/ anaesthesia, using sterile techniques 
and only by the surgical team. The wound was closed with sutures and dressed appropriately.  
Bergstrom biopsies (317) were taken if the patient did not meet the above criteria. The 
mid-point of the rectus femoris muscle was identified by ultrasound with the patient supine in 
bed. Sterile technique was used throughout the procedure. 5-10mls of 1% lignocaine was 
infiltrated and a small incision with a scalpel made in the skin. The bergstrom needle was then 
inserted into the muscle and a 50ml syringe used to apply suction. Several small pieces of 
muscle tissue were biopsied. The wound was then closed with steri-strips and dressed 
appropriately.  
Following collection the biopsies were put into ice-cold saline while the wound was 
closed and the patient made comfortable. Biopsies, where appropriate, were divided into 
several pieces and the final biopsy weight size ranged from 10-100mg. Biopsies were then 
either snap frozen in liquid nitrogen or cork mounted in O.C.T. (VWR International, UK) using 
isopentane freezing. The biopsies were stored at -80oC until batch processing.  
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2.2 Molecular Methods 
All reagents were supplied by Sigma-Aldrich (Dorset, UK) unless otherwise stated.  
2.2.1 General solutions  
Solution Ingredients 
PBS (x1) 138mM NaCl, 2.8mM KCl, 8mM NaH2PO4, 1.5mM KH2PO4 in dH2O adjusted to pH 7.4 
TBE (x10) 890mM Tris-Base, 890 mM Boric Acid, 20mM EDTA adjusted to pH 8 with HCl 
2YT 1.6% Bacto-tryptane, 1%Bacto-yeast extract, 0.09% NaCl in dH2O 
Table 2-4 General Solutions 
 
2.2.2 Cell culture and differentiation  
Mouse C2C12 skeletal myoblasts were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) (Life Technologies, Paisley, UK) with Penicillin (100μ/ml) and Streptomycin 
(100μ/ml) (Life Technologies). DMEM was supplemented with 10% v/v Foetal Calf Serum (GE 
Healthcare, Little Chalfont, UK) for growth media (GM) and 2% v/v Horse Serum (GE 
Healthcare) for differentiation media (DM). Stock cells were cultured at 5% CO2, 37
oC and 
maintained at sub-confluent levels by trypsinisation (Life Technologies) every 2-3 days (split 
ratio 1:6) for up to 15 passages.   
Cells were seeded at 5 x 104 cells/ ml in 6 (2mls/ well) or 96 (125µl/ well) well culture 
plates as appropriate for the experiment. For differentiation purposes C2C12 cells were seeded 
in 6 well plates and allowed to proliferate in GM until 70-80% confluent (approximately 3 
days). They were then transferred to DM which was refreshed every 2-3 days. Differentiated 
myotubes were clearly visible by day 5-7 and early myotube formation could be seen by day 3.  
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2.2.3 Cell stretch experiments 
2.2.3.1 Cell culture for stretched cells  
C2C12 cells were seeded onto 6 well, type I collagen coated, BioFlex® plates (Flexcell 
International Corporation, USA). These plates have a flexible membrane base to allow 
extension and stretch of the cell layer which is cultured on them. BioFlex® plates are available 
with different surface coating on the flexible membrane. The best coating for C2C12 growth 
was established by testing cell growth on lipopolysaccaride coating, pre-coated collagen plates 
and re-coated collagen plates against growth on un-coated plastic (standard plates). C2C12 
cells grew best on un-coated plastic, they did not thrive at all on lipopolysaccaride or re-coated 
collagen and they grew more slowly on the collagen coated surface (Figure 2-5), but were able 
to reach sufficient levels of confluence. Cells were stretched when 100% confluent in DM for 
24 hours with or without myostatin treatment at 20ng/ml (R&D systems, UK) and harvested 
immediately. Stretched cells were both harvested for RNA extraction and used in luciferase 
assay experiments (see below for methodology).  
 
Figure 2-5 Relative growth of C2C12 cells on uncoated plastic or collagen coated plates.  
A-C2C12 cells are seen proliferating more slowly on a collagen coated plate (placed at 
the bottom of a normal well)  than on B - the uncoated plast ic.   
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2.2.3.2 Cell stretch using Flexcell® FX-4000™ apparatus 
Cells were stretched using Flexcell® FX-4000™ apparatus. A cell monolayer was 
cultured on a flexible membrane (see above).  The Flexcell® apparatus allowed the application 
of cyclic mechanical stretch (CMS) by applying a regulated vacuum below the flexible 
membrane which is stretched over a loading post (Figure 2-6). The same tension was applied 
across the membrane and therefore equal stretch across the cell layer. The frequency, 
duration and degree of stretch applied can be regulated using the central Flexcell® computer 
(www.dunnlab.de). Stretch was applied at 15% and later 6% at a frequency of 20 cycles per 
minute based on (318, 319) and previous work by the group.  Cells were harvested directly 
after the allocated stretch time.  
Figure 2-6 Flexcell® FX-4000
TM
 apparatus.  
A -  Flexcel l® FX-4000™ system. B -  Diagram to il lustrate the application of  the vacuum to 
the flexible membrane over the loading post  (320,  321)  www.dunnlab.de.  
2.2.3.3 Cell Viability and damage assays following cell stretch.  
Cell stretch techniques can result in significant damage and loss of viability to cells, 
therefore cell viability and damage was assessed during the development of the methods.  
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Cell viability was determined with an MTT assay: 1mg of Yellow tetrazolium MTT (3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazoliumbromide) was dissolved in warmed Serum Free 
media. Cells were incubated for 30 minutes in 1.5mls per well of MTT media. Media was 
removed and 1.5mls of dimethylsulfoxide (DMSO) solution per well added. The cells were 
agitated for 15 minutes then 100µl of solution was transferred to a 96 well plate and 
absorption measured at 550nm. This assay relies on the cleavage of Yellow terrazolium MTT by 
viable cells into purple formazan in order to release NADPH. The amount of formazan is 
proportional to the number of viable cells (322).  
Cell damage was determined measuring release of Lactate dehydrogenase (LDH) into 
the media of stretched cells. LDH was quantified using the commercially available Cytotoxicity 
Detection Kit (Roche, UK) according to the manufactures guidelines.  
Cell viability was not decreased (MTT, p=0.70, n=1 in triplicate) and cell damage did 
not increase significantly (LDH, p= 0.39, n=1 x 6) following 24 hours of 15% stretch.  
2.2.3.4 Method development 
Cyclic mechanical stretch is an established technique used as an in vitro model of 
muscle activity (323). C2C12 cells were allowed to become 100% confluent prior to 
differentiation. This is in contrast to normal cell culture techniques which would begin the 
differentiation process at about 70-80% confluency. This was done as attempts to stretch cells 
at the start of differentiation from a lower confluency or following 3 days differentiation in 
differentiation media resulted in the cells peeling off the membrane. 100% confluency should 
ensure cell to cell contact and by starting the stretch at the start of differentiation 
differentiating cells may be less fragile. Furthermore although the protocols described in the 
literature vary substantially, it has been established that applying stretch at the start of 
differentiation will cause C2C12 cells to form parallel myotubes (324) . Thus each cell will be 
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subjected to unidirectional stretch, which may be more representative of normal physiological 
activity (323) and therefore the differentiating myoblasts may withstand it better.  
RNA was extracted from stretched cells however the variability of the conditions 
resulted in extremely variable expression of target genes and house-keeping genes. 
Interleukin-6 (IL-6) mRNA expression was used as a positive control to demonstrate that the 
stretch protocol was appropriately affecting the cells (as per (318, 325)). Initially cells were 
stretched at 15%, but a greater increase in IL-6 mRNA was seen with 6%, however neither 
reached statistical significance. Choice of house-keeping genes is obviously important in these 
conditions as it is expected that stretch would affect both metabolic rate and cytoskeletal 
structure of the cell (326). GAPDH, RPLPO and 18S were found to correlate well with each 
other and to be stably expressed across the samples, however in preliminary experiments 18S 
was found to be less reliably stable between the conditions, therefore the geometric mean of 
GAPDH and RPLPO was used, this is also consistent with the other cell experiments in this 
thesis and previous experience of the group. Further analysis of mRNA expression was not 
attempted due to the wide variability of gene expression and the inconsistency of results of 
preliminary experiments.  6% stretch was used for further luciferase activity based stretch 
experiments.  
2.2.4 GDF-15, Myostatin and TGF-β treatment 
Effect of GDF-15 (50ng/ml), Myostatin (20ng/ml) and TGF-β (2.5 ng/ml) (all R&D 
systems, UK) were examined in different experiments. The treatment doses were based on the 
work carried out previously by the group. These treatments are all dissolved in 0.1% Bovine 
Serum Albumin (BSA) with 20mM Hydrogen chloride (HCl), a solution of which was therefore 
used as the control treatment. 
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2.2.5 Luciferase assays 
SMAD activation and phosphorylation is one of the main signalling pathway 
mechanisms activated by the TGF-β family. Receptor binding of TGF-β ligands results in the 
activation of the serine/ threonine receptors: and subsequent phosphorylation of the SMAD 
2/3 complex (153). This then co-localises with SMAD 4 and translocates to the nucleus where it 
acts as a co-transcription factor for TGF-β responsive genes. Activated SMADs bind specific 
nucleic acid sequences within the promoter region of the gene in order to promote the 
transcription of that gene; these regions have “CAGA” repeat sequences. The CAGA-(12)-
luciferase assay relies on the transfection of a DNA vector plasmid which contains 12 CAGA 
repeats adjacent to a minimal promoter and the sequence for firefly (Photinus pyralis) 
luminescent protein. The transcription of the firefly luciferase therefore relies on the activation 
of SMAD proteins and their binding to the CAGA region, as there is a high repeat number of 
the CAGA sequence this assay should be a sensitive marker of SMAD activity. However the 
assay is also dependant on the transfection efficiency and the density of cells. Therefore firefly 
luciferase activity is normalised to the relative activity of renilla (Renilla reniformis) luciferase. 
The renilla luciferase plasmid (pRL-TK) is transfected at the same time as the reporter firefly 
plasmid (p(CAGA)12–luc) and is itself under the independent control of the thymidine kinase 
(TK) promoter.  
2.2.5.1 Preparation of DNA plasmids 
All plasmids used in the current experiments were already available in the lab.  Dr Paul 
Kemp acquired the p(CAGA)12-luc plasmid from Prof. Susumu Itoh (sitoh@md.tsukuba.ac.jp) 
Faculty of Medicine, University of Tsukuba.  pCDNA.3 -an empty vector control and pRL-TK 
were commercially available from Promega, UK.  
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To make plasmid stocks 40µl of competent JM 109 bacteria (Promega, UK) were mixed 
with 5µl of concentrated DNA plasmid and incubated for 15 minutes on ice. Subsequently they 
were heat-shock transformed at 42oC for 90 seconds and then incubated in 500µl 2YT media 
(Table 2-4) at 37oC for 45 minutes. Following this the bacteria were plated on ampicillin 
(100μg/ml) containing agar plates and cultured over night at 37oC. The DNA plasmids also 
contain the genetic sequence for ampicillin resistance; therefore all colonies which grow will 
have been successfully transformed. These colonies are then picked and the bacteria allowed 
to multiply in 4ml 2YT media supplemented with 100ug/ml ampicillin at 37oC overnight under 
agitation.  DNA was extracted from the bacterial culture using QIAprep® Spin Miniprep kits 
(Qiagen, UK) as per the manufactures guidelines.  
Plasmid identity was confirmed using restriction digests. This involved 1 hour 
incubation of 4µl of DNA with the specified restriction enzymes (see below). The digest 
reaction contained the restriction enzymes in a ratio of 1:1   total volume of 1µl, 2 µl 10x buffer 
and if a double digest was being performed - 0.5µl 0.1% BSA but not for a single digest. The 
final volume was then made up to 20µl per reaction with dH2O. The products were then run on 
a 2% TBE- agarose gel. This was made by dissolving 2% Agarose (Bioline, UK) in 0.5xTBE (for a 
75ml gel 1.5mg agarose in 75ml 0.5 TBE Table 2-4), this was then allowed to cool and 5μl 
ethidium bromide (10mg/ml) added. Following setting the gel was submerged in 0.5xTBE in 
the gel tank. Samples were mixed with 5x loading buffer (Bioline) and run for 45 minutes to 1 
hour at 140V alongside standard DNA ladders (Hyperladder I and II Bioline). Appropriate band 
size was predicted from the known plasmid map (Table 2-5).  DNA was then quantified using a 
NanoDropTM machine (BioRad, UK).  
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Plasmid Restriction enzymes Predicted bands (bp) 
pCDNA.3 Pst1 
1356 
4072 
p(CAGA)12-luc Hindi III, BamH1 
1950 
>2800 
pRL-TK EcoR1, Sma1 400 
 Table 2-5 Restriction digests for plasmid identification 
 
2.2.5.2 Transfection of DNA plasmids 
C2C12 cells were seeded in the appropriate plate for the experimental protocol at a 
concentration of 5x104 cells per ml. Cells were transfected when approximately 60% confluent 
on the first day after seeding. The protocol here is described per single well of a 6 well plate 
and volumes scaled up or down as appropriate.  A total of 2µg DNA was transfected per well. 
The DNA mix consisted of 100µl Optimem (GIBCO, Life technologies) and a mix of plasmids as 
follows: p(CAGA)12-luc - 1.45µg, pRL-TK - 0.05µg and pCDNA.3 – 0.5µg. pCDNA.3 was used as a 
control empty vector for another plasmid (FHL-1) which was co-transfected as part of another 
experiment. That experiment is not discussed further in this thesis, however these 
transfections were carried out at the same time and therefore in order to keep the DNA mix 
ratios constant the empty vector was added to all experimental wells. The DNA mix was 
combined with a second mix of 100µl Optimem with 10µl Lipofectamine (Invitrogen); the two 
were incubated together at room temperature for 15 minutes. During this time the cells were 
washed twice with serum free DMEM. Cells were then incubated for 4.5 hours at 37oC with the 
transfection mix diluted to a volume of 1ml per well in serum free media. Subsequently the 
media was replaced with GM and cells returned to the incubator as normal.  
2.2.5.3 Luciferase assays 
Luciferase assays were carried out using the Dual-Luciferase® reporter assay system 
(Promega, UK). Following transfection and appropriate treatment cells were washed twice 
with PBS (Table 2-4) and lysed in passive lysis buffer (1 ml/ well of a 6 well plate, 15 minutes 
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incubation at room temperature under agitation). 10µl lysate was transferred to a white 
plastic 96 well plate and the Dual-luciferase® reporter reagents used as per the manufactures 
guidelines. This involved the addition of a 1st step firefly luciferase substrate and luciferase 
activity was read on a Luminark micro-plate spectrophotometer (BioRad) plate reader. 
Immediately after this the “stop and glo” reagent was added to the wells in order to read the 
renilla luminescence in the same way. Firefly luciferase activity was normalised to that of 
renilla for the same well.  
2.2.5.4 Over-expression of miR-181a 
To examine the effect of miR-181a on TGF-β activation of the SMAD dependant 
luciferase reporter discussed above, a miR-181a mirVana microRNA mimic (Invitrogen) was 
transfected into C2C12 myoblasts as follows. Transfection was carried out on day one post 
seeding C2C12 cells in 96 cells plates. Per well of a 96 well plate 0.5µl of a 20µM stock 
(10nmols) of mirVana mimic or negative control was mixed in 12.5µl of Optimem to make the 
microRNA mix. The lipofectamine mix consisted of 0.5µl of Lipofectamine 2000 (Invitrogen) 
was diluted separately in 12.5µl of Optimem. Following 5 minutes incubation at room 
temperature the two mixes were combined and incubated at room temperature for a further 
20 minutes. During this time cells were washed twice with serum free DMEM. 100µl per well 
of serum free DMEM was then added to the transfection mix and cells incubated with 126µl 
per well for 4 hours at 37oC. Following which the media was changed to GM and the cells 
incubated overnight. The following day p(CAGA)12-luc and pRL-TK plasmids at a ratio of 3:1 
were transfected as above. TGF-β treatment occurred on the next day for 6 hours and 
following this, cells were lysed and luciferase activity read as described above.  
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2.2.6 RNA extraction  
2.2.6.1 RNA extraction from Cells 
Cells experiments requiring RNA extraction were carried out in 6 well plates. Cells were 
seeded at 5x104 cell/ml (using 2 mls per well). When ready for harvesting, cells were washed 
twice with ice cold PBS. Cells were lysed in 1ml of Triazol (Life Technologies, UK) with vigorous 
scraping. The Triazol was then aspirated, transferred to a 1.5ml microcentrifuge tube and 
vortexed in order to facilitate further cell membrane breakdown. 200µl chloroform were then 
added and following thorough vortexing the sample was allowed to settle at room 
temperature for 2-3 minutes. Following centrifugation at 12,000xg for 15 minutes at 4oC the 
supernatant, upper aqueous phase, was carefully transferred to another microcentrifuge tube 
without disturbing the protein layer. 500µl of isopropanol were added to the supernatant, 
mixed and allowed to incubate for 10 minutes at room temperature. Samples were centrifuged 
as above for 10 minutes and the RNA pellet precipitated onto the bottom of the tube. The 
supernatant was carefully removed without disturbing the pellet, which was subsequently 
washed twice with 75% ethanol. The ethanol was then removed and the pellet was allowed to 
air dry until all the remaining ethanol had evaporated. The RNA was then dissolved in 30µl of 
dH2O.  
RNA was quantified using a NanoDropTM machine and absorption read at 230nm, 
260nm and 280nm before storage at -80oC. RNA purity was checked using the 260:280 and 
230:260 ratios calculated by the NanoDrop: a ratio of 2 for both reflects pure RNA.  
2.2.6.2 RNA extraction from Human Tissue 
Human muscle samples were homogenised in 500ml of ice cold Triazol using a 
Precellys 24™ Tissue homogeniser (Stretton Scientific, UK). The technique involved the rapid 
agitation of the sample in tubes containing ceramic beads (CDK-14) which crush and 
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breakdown the tissue. Samples were homogenised with 2 x 10 second cycles at 5,500rpm on 
the Precellys machine – which were repeated if necessary. Following centrifugation for 3 
minutes at 10,000xg to remove debris, the Trizol was transferred to a different 
microcentrifuge tube and the RNA extracted as above with adjusted volumes for 500µl of 
Triazol.   
2.2.6.3 MicroRNA extraction from Plasma 
These methods were based on those described by Kroh et al (327). As discussed in the 
introduction the regulation of circulating levels of microRNAs is not fully understood and as 
such there are presently no established “housekeeping” microRNAs that can be used to control 
for the efficiency of RNA extraction. Therefore this method uses an exogenous control 
microRNA (C-39, a microRNA from the nematode worm c-elegans) that is spiked it at the start 
of the process at a constant concentration.  
4mls of Qiazol (Qiagen, UK) was vortexed thoroughly with 400µl of thawed plasma.  
5µl of a 5fmol/µl stock solution of C-39 RNA (Invitrogen) was added to each sample. Following 
vigorous vortexing with 800µl of chloroform samples were allowed to settle for 2-3 minutes. 
Samples were then centrifuged at 2,500xg for 25 minutes at 4oC and the upper aqueous phase 
removed. From this step onwards the Qiagen miRNAeasy RNA and small RNA extraction kit 
was used as per the manufacturer’s guidelines (Qiagen). The final elution was carried out with 
50µl volume of RNAase free water.  
The above method was compared with a manual technique of RNA extraction – using 
isopropanol and pellet precipitation. The same sample was tested in both techniques with the 
same amount of C-39 control RNA. The samples were then tested for C-39 and miR-1. The 
Qiagen kits resulted >10-times more efficient extraction of RNA and therefore this technique 
was used.  
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2.2.7 cDNA synthesis and quantative PCR (qPCR) for mRNA. 
Reverse transcription (RT) for mRNA analysis. 150ng of RNA for each sample was 
diluted in 11ul of RNAse- free water. The RNA was denatured at 65oC or 5 minutes and then 
cooled on ice for 2 minutes. A 9μl reaction mix containing 1ul Omniscript (Qiagen), 2μl 10x 
buffer (Qiagen), 2μl- 5mM dNTPs (Qiagen), 0.5μl Random Primers (Promega, UK), 0.5μl RNAse 
inhibitor – (Ribolock – Thermo Scientific, UK), 1μl DTT (Qiagen) and 2μl water was then added 
and the samples incubated at 42oC for 2 hours. The cDNA was then diluted to a final volume of 
200μl and stored at -20oC. 
In order to test the genes of interest primers were selected from the literature. The 
primer sequences were run on the NCBI “primer blast” programme 
(www.ncbi.nlm.nih.gov/tools/primerblast) against the mRNA sequence of interest which 
determined the predicted size of PCR product. PCR was then carried out using a standard 
thermal cycler (where necessary at different annealing temperatures) and the products run on 
a TBE- 2% agarose gel as described above in order to identify a single product of the 
appropriate size.  
qPCR was carried out using SYBR® green based reactions in fast optical 96 well plates 
(Life Technologies). Reaction mix consisted of 3μl of sample cDNA, 2μl of a 2μM primer mix 
containing both forward and reverse primers, 10μl of fast SYBR (Quantifast® - Qiagen) and 5μl 
dH2O. Plates were sealed with MicroAmp optical adhesive film (Life Technologies) and 
centrifuged for 1 minute at 200xg to ensure mixing and removal of air bubbles.  qPCR was 
carried out using an ABI 7500 fast thermal cycler with the following thermal profile (ABI, Life 
technologies):  5 minutes 95oC activation step, 40 cycles of 95oC for 10 seconds and 60oC 
annealing for 30 seconds (GDF-15 primers were annealed at 65oC). A melt curve was then 
performed to further exclude non-specific binding products. All reactions were carried out in 
duplicate with a negative water control. The baseline and threshold were set manually for 
88 
 
each gene and when appropriate kept constant across different PCR plates. The mean cycle 
threshold (Ct) was then taken for the duplicates and analysed using ½^Ct. Samples were 
excluded if the melt curve showed non-specific amplification or inconsistency between 
duplicates. Table 2-6 lists primers used and Table 2-7 lists the housekeeping genes used for 
normalisation of mRNA expression in the experiments carried out in this thesis. Housekeeping 
genes for human mRNA normalisation were tested using NormFinder (328), this software 
allows both intra and inter-group variation to be assessed. GAPDH, RPLPO and 18S were 
assessed. The geometric mean of the three genes provided the most stable marker both 
between the groups and between the samples overall. For microRNA in human muscle 
samples U6 provided the greatest stability between and within the groups.  
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mRNA Sybr Green Primers  
Human GAPDH F-  GGTGGTCTCCTCTGACTTCAACA 
R – GTTGCTGTAGCCAAATTCGTTGT 
 
 RPLPO 
F – TCTACAACCCTGAAGTGCTTGATATC 
R – GCAGACAGACACTGGCAACATT 
 
 18S 
F- GTAACCCGTTGAACCCCATT 
R- CCATCCAATCGGTAGTAGCG 
 
 Murf-1 
F- CCTGAGAGCCATTGACTTTGG 
R -CTTCCCTTCTGTGGACTCTTCCT 
 
 Atrogin-1 
F- GCAGCTGAACAACATTCAGATCAC 
R -CAGCCTCTGCATGATGTTCAGT 
 
 CYR61 
  F- ACTTCATGGTCCCAGTGCTC 
  R - TGCTGCATTTCTTGCCCTTTT 
 Myostatin 
F-ACATGAACCCAGGCACTGGT 
R-GGTTGTTTGAGCCAATTTTGC 
 
 IGF-1 
  F - CCACGATGCCTGTCTGAGG 
  R - TTTCAACAAGCCCACAGGGT 
 MyoD1 
F-GACGGCATGATGGACTACAG 
R - AGGCAGTCTAGGCTCGACAC 
 
 MHC 1 
  F - CCC TGG AGA CTT TGT CTC ATT AGG 
  R - AGC TGA TGA CCA ACT TGC GC 
 MHC 2a 
  F - TCA CTT ATG ACT TTT GTG TGA ACC T 
  R - CAA TCT AGC TAA ATT CCG CAA GC 
 MHC 2x 
F - TGA CCT GGG ACT CAG CAA TG 
R - GGA GGA ACA ATC CAA CGT CAA 
 
 Myogenin 
  F - ACC CTA CAG ATG CCC ACA AC 
  R - GGA AGG CCA CAG ACA CAT CT 
 CTGF 
  F- AACCGCAAGATCGGCGT 
  R - CCGTACCACCGAAGATGCA 
 GDF-15 
  F- TGCCCGCCAGCTACAATC 
  R-TCTTTGGCTAACAAGTCATCATAGGT 
Mouse RPLPO 
F-GGACCCGAGAAGACCTCCTT 
R-TGCTGCCGTTGTCAAACACC 
 
 GAPDH 
F-ACTCCACTCCACGGCAAATTCA 
R- CGCTCCTGGAAGATGGTGAT 
 
 Murf-1 
F-CGGGCAACGACCGAGTGCAGACGATC 
R-CCAGGATGGCGTAGAGGGTGTCAAAC 
 
 Atrogin 
  F-TCAGCCTCTGCATGATGTTC 
  R-TGGGTGTATCGGATGGAGAC 
 CYR61 
F- GGATGAATGGTGCCTTGC 
R- GTCCACATCAGCCCCTTG 
 
 CTGF 
  F- TGGCGAGATCATGAAAAAGA 
  R - AGATGTCATTGTCCCCAGGA 
 MyoD1 
  F - GTGGAGATGCGCTCCACTAT 
  R -CTCTGATGGCATGATGGATT 
 IL-6 
  F- TAGTCCTTCCTACCCAATTTCCC 
  R- TTGGTCCTTAGCCACTCCTTC 
microRNA primers  
5s 
F-ATCTCGGAAGCTAAGCA 
R- GGTCTCCCATCCAAGTACT 
 
U6 CTCGCTTCGGCAGCACA 
miR-1 CCGGTGGAATGTAAAGAAGTATGTAT 
miR-133a GTCCCCTTCAACCAGCTG 
miR-181a ATTCAACGCTGTCGGTGAGT 
miR-206 TGGAATGTAAGGAAGTGTGTGG 
miR-499 GGCTTAAGACTTGCAGTGATGTTT 
Universal reverse GTACTGCGCGTGGAGAGGAAT 
Table 2-6 qPCR Primers  
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Condition Genes 
Human mRNAs Geomean (RPLPO, GAPDH, 18S) 
Human microRNAs U6 
Mouse mRNAs Geomean (RPLPO, GAPDH) 
Mouse microRNAs Geomean (5s,U6) 
Table 2-7 Housekeeping genes.  
These genes were selected on the basis of being stable  between the experimental  
groups being compared .   
2.2.8   qPCR quantification of microRNA.  
Reverse transcription for microRNA quantification used in the studies presented in this 
thesis involves the addition of a “polyA-tail” to the cDNA template using the NCODETM VILOTM 
microRNA cDNA synthesis kit (Invitrogen). The kit also includes a universal reverse primer 
which recognises this polyA tail and is used with a microRNA specific forward primer for qPCR. 
This is necessary as the microRNA are only about 22 nucleotides in length and are otherwise 
difficult to amplify with standard qPCR techniques.  
For reverse transcription of RNA from human muscle samples 150ng of RNA was 
diluted in 11μl of water, however this was increased to 1000ng for cell culture RNA samples as 
expression of microRNA in C2C12 cells is low. RNA was again denatured at 65oC for 5 minutes 
and cooled for 2 minutes on ice. Following which a reaction mix of 2μl 10x superscript enzyme 
mix, 4μl of 5x reaction mix and 3μl of water was added and the samples incubated at 37oC for 
2 hours followed by 5 minutes heat deactivation at 95oC. Sample were then diluted x10 (x5 for 
cell culture experiments) before storage at -20 oC. MicroRNA isolated from plasma cannot be 
quantified by u.v. absorption spectroscopy and concentration of some microRNA of interest 
was very low, therefore 14μl of RNA was added and additional water was excluded from the 
reaction mix.  
qPCR was carried out as described above, but the reaction mix was adjusted for use of 
the universal reverse. The reaction mix therefore included 10μl SYBR, 0.4μl of Universal Primer 
(10mM) and 0.4μl specific microRNA primer (10mM) and 6.2μl of water, combined with 3μl of 
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appropriate cDNA. Table 2-6 lists primers used and Table 2-7 the genes used for normalisation 
of these qPCR data. Samples were excluded if the melt curve was showed non-specific 
amplification, Figure 2-7 shows example melt curves. 
2.2.8.1 Across plate standardisation of microRNA qPCR data. 
For the study discussed in chapter 3 (MicroRNAs as potential biomarkers of acute 
muscle wasting) different microRNAs in 168 separate samples, in duplicate, were quantified. In 
order to ensure accurate quantification between plates a standard curve for each microRNA 
that was quantified was generated. This was done by amplifying the specific microRNA from a 
plasma pool and sequentially diluting it. These standards were kindly provided by Dr 
Donaldson from the same group. The standards were then run alongside the samples on each 
plate and the results checked for linearity and compared to each other. They were then used 
to calculate the concentration of microRNA relative to the standards in arbitrary units (AU).  
2.2.9 Protein Extraction  
2.2.9.1 From Cells 
Cells experiments requiring protein extraction were carried out in 6 well plates. Cells 
were seeded at 5x104 cell/ml (using 2ml per well). When ready for harvesting cells were 
washed twice with ice cold PBS and then lysed in 500µl of NP40 lysis buffer (Table 2-8) with 
1:100 Protease and Phosphatase inhibitors. Samples were stored at -20oC 
2.2.9.2 From Human Tissue 
Muscle samples were homogenised in NP40 with Protease and Phosphatase (1:100) 
using the Precelley’s methods described above. The samples were then centrifuged at 
10,000xg to remove debris and the soluble protein fraction collected and stored at -80oC.  
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2.2.9.3 Protein quantification 
Bradford assays were used to determine protein concentration of the samples. The 
sample was diluted with water to ensure the NP40 did not interfere with the assay and also to 
ensure that the resulting concentration fell within the linear portion of the assay’s standard 
curve. 10μl of appropriately diluted sample (5-40 times) was incubated under agitation with 
90μl of Bradford reagent for 15 minutes. The absorption was then read at 620μm using a 
Luminark micro-plate spectrophotometer (BioRad) and the concentration calculated against 
the standard curve. Standards were prepared with appropriate weights of BSA dissolved in 
water.  
  
Figure 2-7 Example melt curves. 
Left panel shows example melt curve from qPCR amplication of MHC2x mRNA from 
human ICUAP and control  muscle samples, r ight panel shows the same for MiR -1.  
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2.2.10 Western Blotting  
Table 2-8 describes the solutions used for western blotting.  
Solution Ingredients Working concentration/ notes 
General solutions   
NP40 lysis buffer (x2) 
300mM NaCl,  
20mM Tris, 
10mM EDTA, 
2% Igepal-NP40 
In dH2O 
pH7.4 
1x 
Add protease and phosphatase 
inhibitors (both 1:100) before use. 
RSTB sample buffer (x2) 
4% SDS,  
20% glycerol,  
10% 2-mercaptoethanol, 
10% 1M Tris (pH6.8) 
1x 
Running Buffer (x10) 
250mM Tris,  
1.9M glycine,  
35mM SDS  
in dH2O 
pH8.3 
1x 
Transfer Buffer (x10) 
200mM Tris,  
1.5M glycine  
in dH2O 
1x add 20% methanol at the time of 
use 
TBS (x10) 
200mM Tris,  
1.4mM NaCl  
In dH2O 
pH7.6 
For TBS-T; 
Add 1% Tween 20 prior to dilution 
to 1x 
Acrylamide gels   
Resolving gel (10%) 
3.33ml -30% acrylamide,  
2.5ml -1.5M Tris,  
100μl -10% SDS,  
50μl -10% APS,  
5μl -TEMED,  
4.02ml - dH2O. 
Enough for 2 gels 
Stacking Gel 
0.86ml -30% acrylamide,  
1.26ml -0.5M Tris,  
50μl -10% SDS,  
20μl -10% APS,  
5μl -TEMED,  
2.11ml - dH2O. 
Enough for 2 gels 
Table 2-8 Solutions for western blotting  
 
2.2.10.1 Western blotting procedure 
 Protein samples were diluted 1:1 with sample buffer and heat denatured at 95oC for 5 
minutes. Samples were separated using SDS poly acrylamide gel electrophoresis.  The resolving 
gel solution was poured into a glass plate cast, covered with water saturated butanol and 
allowed to polymerise. Following  washing to remove the butanol the stacking gel was set 
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above the resolving gel with the appropriate comb used to produce sample loading wells. 
Samples were then loaded and the gel run in a BioRad gel tank at 140 volts until the standard 
protein ladder could be seen to have run and separated sufficiently. The protein was then 
transferred to a PDVF membrane (BioRad) (activated in methanol) at 14V using a semi-dry 
transfer technique (Semi-dry blotter - BioRad) and transfer buffer with 20% methanol (Table 
2-8) which for the proteins examined required a 70 minutes transfer time. 
Membranes were blocked in 5% milk-TBST (Marvel non fat milk) for 30 minutes at 
room temperature. Membranes were then incubated at 4oC overnight (or 1 hour at room 
temperature) with primary antibodies prepared in 5% milk-TBST at appropriate concentrations 
(see Table 2-9 ). Prior to incubation with secondary horseradish peroxidise (HRP) conjugated 
antibodies (also diluted in 5% milk-TBST) membranes were washed 3 times in TBST. Following 
1 hour incubation at room temperature with secondary antibody the membranes were 
washed as before. The blots were then imaged using ECL chemiluminescent reagents (GE 
Healthcare) and light sensitive Kodak film (Life technologies). The resulting image was scanned 
for analysis in Image J.   
Primary antibody specificity was checked by ensuring that the protein band occurred 
at the predicted molecular weight using a standard ladder (BioRad) and also by loading a 
negative control (no sample) alongside the protein samples to ensure no binding. Secondary 
specificity was checked by incubating a membrane in secondary antibody only and ensuring no 
signal was created. Table 2-9 lists the antibodies used.  
Normalisation for protein loading and transfer efficiency was achieved with either 
tublin quantification or ponceau red staining. For Ponceau red stating membranes were 
washed briefly with Ponceau red solution and then rinsed in TBST. The image was then 
scanned and analysed in Image J.  
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Primary Antibody Dilution Secondary HRP Antibody Dilution 
For human tissue    
TGFBR1 (AF-241-NA) 
R&D systems 
1 in 500 
Rabbit anti goat HRP (P0449) 
Dako 
1 in 3000 
For murine cell culture    
TGFBR1 (H-100 R) 
SantaCruz 
1 in 400 
Goat anti Rabbit HRP (P0448) 
Dako 
1 in 6000 
TGFBR2 (L21: sc-400 R) 
SantaCruz 
1 in 400 
Goat anti Rabbit HRP (P0448) 
Dako 
1 in 3000 
α-Tubulin (Ab4074) 
Abcam 
1 in 1000 
Rabbit anti goat HRP (P0449) 
Dako 
1 in 3000 
Table 2-9 Antibodies used for western blotting.  
TGFBR1 and 2 –  TGF-β receptor type 1 and 2 respectively, HRP –  Horse Radish 
Peroxidase .   
2.2.10.2 Quantification of protein by Western blot.  
Western blot images were scanned and analysed using Image J. Appropriate bands in 
each lane were identified and selected with individual uniform rectangles. The pixel profile of 
each band was then plotted by the Image J software. Protein concentration is relative to the 
intensity of the signal which is represented by the area under the curve of the plot. This is 
manually delineated, to exclude background, and calculated for each band. For Ponceau 
staining the intensity of the whole lane was calculated. The target protein level was then 
normalised to either the Ponceau (human samples) or α-tubulin (cell culture samples).  
For the quantification of the TGF-β type 2 receptor in ICUAP muscle, 26 human tissue 
samples were quantified. In order to standardise between gels a pool of samples at 2 different 
concentrations and 2 individual samples were run on each gel. These were then used to 
standardise the intensity of each sample relative to the other gels.  
2.2.11 ELISA 
Plasma levels of myostatin (Immundiagnostik, Bensheim, Germany) and GDF-15 (R&D 
systems, Abingdon, UK) and IGF-1 (Mediagnost, Reutlingen, Germany), were quantified using 
commercially available ELISA kits. These kits have all been reported as reliable in the literature 
and the quoted inter-plate co-efficients of variation (CV) of the ELISAs were 4.7-6.0% for GDF-
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15, and 2.25-6.79% for IGF-1, the Myostatin ELISA did not report a CV.  Assays were performed 
according to the manufacturer’s instructions and ELISA plates were read on a microplate 
spectrometer (BioTek Powerwave XS). Results were analysed as per the manufactures 
guidelines using the supplied standard curve samples and all samples were analysed in 
duplicate. 
2.2.12 Histology of muscle samples 
O.C.T embedded, cork mounted quadriceps muscle biopsy specimens were sectioned 
(10μm) and Heamatoxylin and Eosin (H&E) stained by the histology department at Imperial 
College.  
2.2.12.1 Muscle fibre diameter 
H&E stained sections were imaged using an Olympus CKX41 microscope at 10x magnification. 
The fibre diameter was measured in Image J for between 33-105 fibres (depending on the 
quality and quantity of sample available) and the mean fibre diameter calculated for each 
individual. The minimal Feret’s diameter of the fibre was measured, this was defined as the 
smallest distance between parallel edges of each fibre (http://www.curecmd.org/wp-
content/uploads/scientists/sop/MDC1A_M.1.2.002.pdf). This distance should therefore reflect 
the true diameter if the fibre has been cut cross-sectionally or longitudinally.  
2.2.12.2 Immunoflourscencent staining for fibre type 
Sections were air dried and marked with a wax pen (DAXO). They were then washed 
briefly with PBS-1%Tween (PBST) and subsequently blocked with 5%milk-PBST for 30 minutes. 
Primary MHC and laminin antibodies were prepared (as per Table 2-10) in PBST and the 
sections incubated for 1 hour at room temperature in the antibody solution. Following 3 x 5 
minute washes in PBST sections were then incubated with Alexaflor®-conjugated secondary 
antibodies for 1 hour at room temperature in the dark. A negative control for the secondary 
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antibody (i.e. no primary antibody) was included to assess secondary antibody specificity. 
Following repeated washing as above sections were allowed to air dry and were then fixed 
with Fluromount (sigma) and a glass coverslip. The immunofluorescent signal was recorded 
using a Zeiss Axiovert 200 microscope and Velocity software (Perkin Elmer, Massachusetts, 
USA).  MHC 1, 2a, 2x (seen as unstained fibres) and hybrid fibres (stained for both MHC 1 and 
2a) were then identified, counted and diameter measured using Image J software.  
Primary Antibody Dilution Secondary Fluorescent Antibody Dilution 
MHC staining     
MHC 1 (A4.840) DSHB 1 in 25 Alexaflor® -350 anti mouse IgM (A-31552)  1 in 500 
MHC 2a (N2.261) DSHB 1 in 50 Alexaflor® - 488 anti mouse IgG (A-11059) 1 in 200 
Laminin (4H8-2) Abcam 1 in 500 Alexaflor® - 568 anti rat IgG (A-11079) 1 in 500 
Nuclear p-SMAD 2/3 staining     
pSMAD2/3 (11769R) Santa-Cruz 1 in 1000 Alexaflor® - 488 anti rabbit (A-11034) 1 in 500 
Laminin (4H8-2) Abcam 1 in 500 Alexaflor® - 568 anti rat IgG (A-11079) 1 in 500 
4’, 6‐diamino‐2-‐phenylindole 
(DAPI) Invitrogen 
1 in 
10,000 
 
 
NA 
Table 2-10 Antibodies used for Immuno-flourescence.  
DSHB - Developmental Studies Hybridoma Bank, California, Alexaflor® supplied by Life 
Technologies.  
2.2.12.3 Localisation of pSMAD-2/3 
In a separate analysis sections were stained for nuclear localisation of phosphorylated-SMAD 
2/3. The protocol above was modified, sections were fixed with 4% paraformaldehyde and 
then permeabilised with 0.3% Triton X100 in PBS-Tween, to ensure nuclear permeability to the 
antibody, prior to blocking with 5% BSA in PBS-Tween. Antibodies were also prepared in BSA. 
Nuclei were stained with 4’, 6‐diamino‐2-‐phenylindole (DAPI, Invitrogen; stock concentration 
at 5mg/ml diluted to 1:10000 in 1xPBS). Prior to drying and mounting slides were incubated for 
2 minutes with DAPI and then washed as above. Using Velocity software all stained nuclei were 
counted and marked for each section. Following this, those nuclei staining for p-SMAD2/3 
were also marked and the percentage of positive nuclei was calculated. The exposure, 
brightness and thresholds were set as the same for all images.  
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2.3 Statistical methods 
Data were handled and analysed and figures constructed using Graphpad Prisim 6 
software. For all analyses a p value of < 0.05 is taken to be statistically significant.  
2.3.1 Statistical handling and analyses of demographic data and results from the 
clinical studies. 
Statistical methods were discussed with Winston Banya (Medical statistician, NHLI, 
Imperial College). 
Chapter 3 - Demographic data are quoted as mean ± standard deviation (SD) unless 
otherwise stated. Student’s t-tests (for normally distributed data) or Mann-Whitney tests were 
used where appropriate for between group analyses. Categorical data are expressed as n or % 
and compared by chi-squared analyses. Myostatin, GDF-15 and IGF-1 concentrations were 
non-parametrically distributed and therefore the median with interquartile ranges (IQR) are 
used to describe the data. Repeated measures Friedman’s test with Dunn’s correction for 
comparison of all time points to the pre-operative baseline was used for within group analysis.  
Chapter 4 – The control group of this study consisted of only 7 individuals and 
therefore the data was considered to be non-parametric. Demographic data are therefore 
described as median with interquartile range (IQR) unless otherwise stated. Mann-Whitney 
tests were used for between group comparison and Pearson’s for correlation between data. 
Categorical data are expressed as n or % and compared by chi-squared analyses.  Bonferroni 
correction was used where multiple tests of correlation were carried out. 
Chapter 5 –There were only 12 patients included in the final analysis, demographic 
data were non-parametrically distributed and are described as median (IQR) unless otherwise 
stated. In this interventional study, which is described fully in chapter 5, one leg underwent 
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neuromuscular electrical stimulation (NMES) for 1 week and the other was used as a control. 
Change in mRNA and microRNA expression and US RFcsa
 at baseline and at the end of the study 
were analysed using Wilcoxon matched pairs sign rank test of the change relative to baseline. 
The effect of NMES compared to control was compared using Mann-Whitney U tests.  
Chapter 6 – Raw and fold-change microRNA data were non-parametrically distributed 
and therefore expressed as median and IQR. Within group analysis was carried out as for 
chapter 3 and Komglov-Smirnov test used for between group analysis of microRNA fold-change 
as the two groups had different variance. In order to test the discriminatory value of a rise in 
miR-181a as a biomarker for acute muscle wasting Graphpad Prism 6 was used to generate a 
Receiver Operating Characteristic (ROC) curve and calculate the relative sensitivity and 
specificity of different fold change rises. www.medcalc.org was used to calculate the positive 
and negative predictive values.  
2.3.1.1 Analysis of in vitro data. 
Data from cell culture experiments can be considered to be parametrically distributed. 
Each experiment was repeated on 3 different occasions/ passages in triplicate unless 
otherwise stated (n=3 in triplicate). For each occasion the data was expressed relative to the 
mean of the control condition for that experiment and the individual un-averaged data points 
for each condition then analysed with a students’ T-test. Data are presented as the mean and 
standard deviation.  
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Chapter 3 Investigation of circulating mediators of muscle homeostasis 
and Growth and Differentiation Factor-15 in acute muscle wasting 
following high risk cardiothoracic surgery. 
3.1 Rationale 
As discussed in the introduction, acute muscle wasting in critical illness is likely to be a 
result of a dynamic imbalance between muscle atrophy and hypertrophy pathways (40, 74). 
However, in part because of the heterogeneity of the ICU population and other factors such as 
the different lengths of stay and underlying medical problems, this has been difficult to 
demonstrate in human critical care models of muscle wasting.  Myostatin and IGF-1 are 
recognised to be potent drivers of muscle atrophy and hypertrophy respectively (137, 329) and 
changes in the circulating levels of both have been associated with muscle wasting conditions 
(130, 133, 173, 330, 331). However although both increased myostatin and decreased IGF-1 
have been implicated in the development of ICUAP (149, 332), the relative pattern of change 
in the circulating levels of these mediators during the acute development of muscle wasting 
has not been established.  
As discussed in the introduction GDF-15 is a stress induced cytokine and a member of 
the TGF-β family. The rationale behind the hypothesis that GDF-15 might be a potential driver 
of acute muscle wasting and ICUAP is discussed fully in the introduction. Briefly this is that 
factors thought to aetiological in the development of ICUAP (hypoxia, inflammation etc..) are 
recognised to drive GDF-15 expression in other tissues (e.g. liver and heart) and that GDF-15 
has been shown to drive pro-apoptotic and hypertrophy limiting molecular pathways and drive 
cachexia in murine models (98, 251).  
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Therefore in order to investigate the balance of circulating regulators of muscle 
homeostasis and to test the novel hypothesis that GDF-15 might be associated with acute 
muscle wasting, high-risk elective cardiothoracic patients were recruited pre-operatively and 
studied for the first post-operative week. High-risk cardiothoracic patients are at risk of 
prolonged ICU stay and consequently at risk of developing acute muscle wasting/ ICUAP. These 
patients provided a relatively homogeneous cohort to study, the opportunity to track changes 
in muscle bulk prospectively and measure levels of circulating mediators comparing them to 
“healthy” baseline. This study also had the potential to form the basis a novel human model of 
acute muscle wasting associated with intensive care admission.  
Some of the results from this chapter have been published (Crit Care Med 2013 Apr 
41(4):982-989) (333). The journal has granted permission for the reuse of all material from this 
paper in this thesis. See Appendix A1 
3.2 Hypothesis  
The above rationale led to the following hypotheses: 
1) Circulating levels of known mediators of muscle homeostasis would change 
dynamically following cardiac surgery; specifically a rise in myostatin and fall in 
IGF-1 was expected. These changes would be different in those who developed 
muscle wasting when compared to those who did not.  
2) Circulating GDF-15 levels would rise post-operatively and be associated with 
muscle wasting.  
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3.3 Patients studied and study design 
The principle inclusion criterion for this study was a high-risk elective cardiothoracic 
surgical procedure requiring post-operative admission to adult critical care. High-risk was 
defined by the patient’s EuroSCORE (>5) and/ or the surgical team (where the patient was 
deemed high risk by the surgical team despite a lower EuroSCORE – for example taking into 
account the cardiac anatomy, number and nature of previous surgeries or clinical rather than 
numeric age) (310-312). Adults undergoing elective cardiac surgery at the Royal Brompton 
Hospital were screened for inclusion into the study. Pre-existing muscle or neuromuscular 
disease, malignancy or contraindication to serial blood sampling excluded patients from the 
study. In order to reflect a relatively true healthy baseline, patients were only included if they 
were stable preoperatively and not suffering from acute illness or requiring emergency 
surgery. Written informed consent was obtained from all those involved and the study was 
approved by the local ethics committee (10/H0504/9) through the Biomedical Research Unit at 
the Royal Brompton Hospital. 
Patients were assessed pre-operatively; this involved review of medical history, 
physical examination and collection of demographic data. Muscle mass was assessed by 
measuring the cross-sectional area of the right rectus femoris muscle by US RFcsa, assessment 
of muscle strength by MRC-SS and handheld dynamometry of QMVC. Pre-operative 
(“baseline”) blood samples were collected.  Bloods for repeat sample analysis were taken on 
the 1st and 2nd postoperative days and at day 7 (or at discharge if earlier). The latter two time 
points were considered identical for the purposes of analysis; only 4 patients (3 in the non-
wasting patient group and 1 in the wasting group) were in fact discharged earlier than day 7. 
Similarly the US RFcsa, MRC-SS and QMVC were also repeated at day 7 or discharge. Total 
hospital length of stay and 30 day survival data were collected.  
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Patients were classified as those who developed muscle wasting or those who did not 
depending on the change in RFcsa at the end of the week. Greater than 9.24% loss of muscle 
bulk was classified as muscle wasting, based on the coefficient of variation of repeated 
measurements as described in the methods chapter.  
Data were non-parametrically distributed and are therefore described as median with 
the interquartile range in brackets (IQR) unless otherwise stated. 
3.4 Results 
3.4.1 Patients and change in RFcsa 
Cardiothoracic operating lists were screened weekly and 50 patients were identified 
who met the inclusion criteria. Of these 5 declined consent and 3 were retrospectively 
excluded due to technically inadequate muscle US images meaning that it was not possible to 
categorise them as having developed muscle wasting or not. Therefore, 42 patients were 
included in the study. Of these, 23 (55%) developed muscle wasting, as defined above, with a 
mean muscle loss of 24.6 ± 13.7% (paired students T-test p<0.001). There was no significant 
change in muscle bulk in those who did not develop muscle wasting (1.3 ± 5.9% p=0.149) 
(Figure 3-1).  
Table 3-1 shows the demographic data, co-morbidities and critical care data for both 
groups of patients and demonstrates that the non-wasting and wasting patients were well 
matched. Not all patients underwent cardiac bypass: one patient in the non-wasting group 
underwent an off-pump coronary artery bypass procedure and 3 underwent transcutaneous 
aortic valve insertion; in the wasting group 2 patients had off-pump procedures. However 
circulating plasma levels for GDF-15, myostatin and IGF-1 in these patients were not different 
from the rest of their group. Length of stay on ICU was short in both groups and most patients 
had an uncomplicated recovery. At day 7, 2 patients were still on ICU. One patient’s prolonged 
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hospital stay was due to social problems. Only one patient died at 21 days post-operatively in 
the wasting group; no patients died in the non-wasting group.  
 
Figure 3-1 Change in Rectus Femoris Muscle Cross Sectional Area (RFcsa) in high-risk elective cardiothoracic 
patients following cardiac surgery.  
A: US RFc s a  measured in elective cardiothoracic  patients pre -operatively and on the 7
t h
 
post-operative day. Development of muscle wasting defined as >9.24% loss in muscle bulk. Non -
wasting patients (n=19) sol id l ines, wasting patients (n=23) dotted l ines. B: US RF c s a  expressed 
as change from baseline %. Non -wasting patients change in US RF c s a  1.3% ± 5.9 and wasting 
patients 24.6% ± 13.7 (mean ± SD).  
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Non-wasting patients 
(n=19) 
Wasting patients 
(n=23) 
pvalue 
(T-test, 
#
Mann-Whitney 
*Chi-squared) 
Demographic data    
Age (years) 65.7 ± 17.2 62.0 ± 16.2 0.47 
Sex (m/f) 9/10 12/11 0.76* 
BMI (kg/m
2
)
¥
 26.6 ± 4.6 24.7 ± 4.1 0.18 
EuroSCORE 5.3 ± 1.8 5.5 ±2.6 0.76 
Pre-op LVEF %ƚ 60.8 ± 15.0 56.6 ± 16.4 0.41 
Pre-op Creatinine  (µmol/L)
¥
 81.3 ± 23.6 77.3 ± 17.1 0.52 
Pre-op Creatinine clearance 
(ml/min) 
¥
 
84.7 ± 36.1 86.8 ± 34.7 0.66 
Pre operative co-morbidities (n)    
Ischaemic heart disease 10 8 0.24* 
Structural heart disease 9 11 0.97* 
Dysrhythmia 2 3 0.80* 
Systemic hypertension 7 5 0.94* 
Pulmonary hypertension 1 2 0.66* 
Hypercholesterolemia 7 10 0.66* 
Congenital cardiac disease 3 6 0.42* 
Diabetes 3 1 0.21* 
Obstructive lung disease 3 2 0.45* 
Statin therapy 8 10 0.93* 
ACE inhibitor or receptor 
blocker therapy 
3 4 0.89* 
Critical care data    
Total bypass time (mins)ƚƚ
 
115 ± 39 117 ± 35 0.91 
Total cross-clamp time
 ƚƚ 89 ± 43 86 ±28 0.87 
ICU length of stay, days  
(median (IQR)) 
1 (1-2.5) 2 (1-3) 0.62 
#
 
Hospital length of stay, days 
(median (IQR))
 8 (7-11) 9 (8-10.5) 0.44 
#
 
Mean blood glucose during 
critical care admission (mmol/l) 
7.48 7.35 0.56 
IV insulin therapy whilst in 
critical care (n) 
10 10 0.59* 
Mean insulin dose during critical 
care admission, if treated with 
IV insulin (units/hr) 
2.16 1.91 0.46 
Exposure to NMBs (n) 0 0 NA 
Exposure to corticosteroids (n) 3 4 0.89* 
Table 3-1 Demographic data:  
Demographic data, co-morbidities and critical care data for non-wasting (n=19) and 
wasting (n=23) high-risk elective cardiothoracic patients. Data presented as mean ±  SD unless 
otherwise stated. 
¥
 Weight unavai lable for 2 patients in the wasting group therefore n=21,
 ƚPre 
operative EF not avai lable for 1 patient in each group.  ƚ ƚ  4 patients in the non-wasting and 2 in 
the wasting group did not undergo bypass. Pre -op –  preoperative, LVEF –  left ventricular 
ejection fract ion, NMBs –  neuromuscular blocking agents given other than at the time of 
surgery. IQR –  interquart ile range.  
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3.4.2 Assessment of muscle strength 
The MRC-SS was not adequately discriminatory in the elective cardiothoracic patients 
recruited for this study. All scored 60 at pre-operative assessment – and at follow up all but 
four still scored 60 despite reportedly feeling weaker and documented loss of muscle bulk on 
US. Of the four not scoring 60, two were still intubated and ventilated and therefore unable to 
complete the test and the two patients able to complete the test (one in each group) both 
scored 54/60. 
The handheld dynamometry assessment of QMVC was unfortunately also found to 
have poor repeatability and reliability with a large volitional component. Furthermore for 
many subjects the maximum power of their quadriceps was greater than that which I, as the 
assessor, was able to match with my arm (this problem has also been reported by other 
members of our group and collaborating groups). Finally, post-operatively subjects were 
unable to complete the test in the majority of cases due to pain from their sternal wounds. 
Less than half of the patients had adequate strength measurements; therefore, these were not 
analysed.  
3.4.3 Myostatin 
Median baseline plasma myostatin did not differ significantly between groups (non-
wasting patients 11.5ng/ml [IQR 8.1-18.2] and 9.3ng/ml [IQR 6.3-13.3] in those who did 
develop muscle wasting, p=0.29 Mann Whitney).  
Repeated measures Friedman’s tests (with Dunn’s correction) were used to assess the 
change in myostatin. Contrary to our hypothesis, plasma myostatin concentration fell 
significantly in both groups at D1 and D2. At D1 in non-wasting patients it fell to 53% of 
baseline (median 7.8ng/ml [IQR4.5–11.3], P<0.0001) and wasting patients it fell to 55% of 
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baseline (median 5.0ng/ml [IQR 4.2 – 6.6], p<0.001). In both groups plasma myostatin returned 
to baseline levels at day 7 (Figure 3-2).  
 
Figure 3-2 Plasma Myostatin Concentration.  
Plasma Myostatin concentration (ng/ml)  in non-wasting (n=19) and wasting patients 
(those with >9.24% muscle loss:  n=23)  pre -operatively (PO), on day 1 (D1), day 2 (D2) and on day 
7 (D7).  Data presented as box and whisker plots with median, interquart ile ranges and 5 -95% 
percentiles. * p<0.05, ** p<0.01, *** p<0.001, ns -  not signif icant, repeated measures 
Freidman’s test  with Dunn’s correction for comparison with pre -operative basel ine.  
3.4.4 IGF-1 
Baseline plasma IGF-1 did not differ significantly between the groups (non-wasting 
patients, median 113.0ng/ml [IQR83.3–174.6], wasting patients median 136.5ng/ml [IQR117.9-
170.4], p=0.24 Mann Whitney).  
Repeated measures Friedman’s tests (with Dunn’s correction) were used to assess the 
pattern of change in IGF-1 levels after surgery. The IGF-1 plasma concentration fell significantly 
at D1 and D2 after surgery in both groups; non-wasting patients D1 median 90.5 ng/ml (IQR 
50.4–129.7), 74% of baseline, and wasting patients D1 median 98.4 ng/ml (IQR 67.1–120.1), 
75% of baseline (p<0.001 for both). In the non-wasting group the IGF-1 concentration returned 
to baseline by D7 median 92.9ng/ml (IQR 63.1–156.2) (p>0.05). However, in wasting patients it 
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remained significantly reduced at D7 median 108ng/ml (IQR 80.9 – 144.0), (p<0.01)(Figure 
3-3).  
Figure 3-3 Plasma IGF-1 concentration  
Plasma IGF-1 concentration (ng/ml)  in non-wasting (n=19) and wasting patients (those 
with >9.24% muscle loss: n=23) pre-operatively (PO),  on day 1 (D1), day 2 (D2)  and on day 7 
(D7). Data presented as box and whisker plots with median, interquart ile ranges and 5 -95% 
percentiles.  *p<0.05, ** p<0.01, *** p<0.001, ns -  not significant, repeated measures Freidman’s 
test with Dunn’s correction for comparison with pre -operative basel ine.  
3.4.5 GDF-15 
Baseline plasma GDF-15 did not differ significantly between the groups; median GDF-
15 in non-wasting patients 1093 pg/ml (IQR 601.5-1790) and in wasting patients 892.7 pg/ml 
(IQR 579.1–1560) (p=0.52 Mann Whitney).  
Repeated measures Friedman’s tests (with Dunn’s correction) were used to assess the 
pattern of change in GDF-15 levels after surgery. In contrast to myostatin, GDF-15 levels 
increased; median GDF-15 at D2 was 4576pg/ml (IQR 3035–5238) in non-wasting patients, and 
3659 pg/ml (IQR 3160-5919) in wasting patients (p<0.001 for both groups). In the non-wasting 
patients the increase in GDF-15 returned to baseline by D7 -median 1786pg/ml (IQR 1087–
2697) (p>0.05); however in the wasting group the level remained significantly elevated at D7 -
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median 2630pg/ml (IQR 1330–3797) (p<0.01), Figure 3-4.  These data suggest that those who 
developed muscle wasting were exposed to high levels of GDF-15 for longer.   
Using the fold-change from baseline GDF-15 the area under the curve of the rise in 
GDF-15 was calculated for each patient, this reflects the cumulative exposure to increased 
GDF-15 levels. The median area under the curve for wasting patients 14.1 (IQR 9.6–21.8) was 
higher than those without wasting 9.9 (IQR 7.2–20.4); however, this did not achieve statistical 
significance (p=0.12 MW), Figure 3-5.  
Figure 3-4 Plasma GDF-15 Concentration  
Plasma GDF-15 concentration (pg/ml) in non-wasting (n=19) and wasting patients (those 
with >9.24% muscle loss: n=23) pre-operatively (PO),  on day 1 (D1), day 2 (D2)  and on day 7 
(D7). Data presented as box and whisker plots with median, interquart ile ranges and 5 -95% 
percentiles. * p<0.05, ** p<0.01, *** p<0.001, ns -  not signif icant, repeated measures 
Friedman’s with Dunn’s correction for comparison with pre -operative baseline.  
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Figure 3-5 Area under the curve of rise in GDF-15.  
Fold-change in GDF-15 concentration compared to baseline on days 1, 2 and 7 
postoperatively.  Data presented as mean and error bars represent the standard deviat ion of  the 
fold-change at that t ime point. Area under the curve calculated from fold -change for each 
individual .    
3.5 Discussion 
3.5.1 Summary of findings 
This study demonstrates that acute muscle loss detectable on US following cardiac 
surgery is common, being detectable in 55% of the population studied, despite the fact that 
these patients generally had short ICU stays and an uncomplicated post-operative course.   
Secondly, these data are consistent with the hypotheses that acute muscle wasting 
occurs as a result of a dynamic imbalance in the regulation of muscle homeostasis and that 
GDF-15 may represent a novel driver of muscle wasting. A reduction in circulating IGF-1 levels 
that recovered to baseline by day 7 in non-wasting patients, but not in those who developed 
muscle wasting (Figure 3-3) was observed. However, circulating myostatin behaved in the 
opposite way to that expected and was suppressed in the acute phase. Furthermore, those 
patients who developed muscle wasting experienced a more sustained rise in GDF-15, which 
did not recover to baseline by day 7, when compared to those who did not (Figure 3-4). 
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Together these data suggest that an imbalance in GDF-15 and IGF-1 occurs in patients who 
develop muscle wasting and is sustained in a direction that would be expected to promote 
muscle wasting. In all patients the balance of regulators of muscle homeostasis is upset by the 
insult of cardiac surgery. In those who do not develop muscle wasting the balance is restored 
as levels of IGF-1 and GDF-15 return to pre-surgery levels by day 7. Conversely in those who 
develop muscle wasting IGF-1 remains reduced and GDF-15 remains increased at day 7 
indicating that the balance of these two factors has not been restored. This lack of restoration 
of the normal regulation of these synthetic and atrophic factors may contribute to muscle 
wasting in this group (Figure 3-6).  
Figure 3-6 Schematic representation of the imbalance of circulating regulators of muscle mass following 
cardiothoracic surgery. 
 
3.5.2 Discussion  
Circulating myostatin levels changed in the direction opposite to that which was 
expected (329), as they were suppressed in the acute phase and recovered by day 7 in both 
wasting and non-wasting patients. As myostatin is a well recognised negative modulator of 
muscle mass (329), it would be reasonable to expect that circulating levels would be elevated 
in patients who developed quadriceps atrophy.  However evidence to support this from the 
acute phase of critical illness has been contradictory despite myostatin levels (both plasma and 
muscle) having been elevated in a variety of muscle wasting conditions (158, 171, 329, 330, 
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334, 335). An example of this contradiction is that myostatin mRNA and protein from skeletal 
muscle of patients in the acute phase of critical illness was elevated in one study by Constantin 
et al (332), but in another study by Jespersen et al in fact showed lower myostatin mRNA in 
patients compared to controls (147). Furthermore data, from another study of a large ICU 
cohort (208 patients) with prolonged stays on ICU, showed different results in different 
muscles examined: myostatin mRNA from the rectus abdominis (taken immediately after 
death) of the prolonged stay ICU patients was lower than controls, but did not change in the 
vastus lateralis (175). Animal models have also suggested that myostatin may drive acute 
muscle wasting secondary to sepsis or inflammatory insult (336). A rat model, which included 
immobility, ventilation and neuromuscular blockade, but not sepsis, showed acute elevation of 
myostatin mRNA in  hind-limb muscle, followed by suppression over the next week in a gene 
microarray analysis (337).  However, consistent with data from the current study, myostatin 
mRNA in muscle and circulating plasma myostatin reduced significantly in rats following cecal 
ligation and puncture (338).  
The current study suggests that GDF-15 rather than myostatin is more likely to be a 
driver of acute muscle atrophy in this patient cohort. GDF-15 expression is increased in 
response to stress, hypoxia and inflammation in vitro (257, 339) and in a variety of animal and 
human chronic disease settings (262, 339, 340). All the patients in the current study 
underwent the significant acute inflammatory insult of cardiac surgery and therefore it is 
unsurprising that all experienced an acute rise in circulating GDF-15. The findings of an 
association between GDF-15 and acute muscle wasting following the physiological stress of 
cardiac surgery are consistent with the understanding that GDF-15 is released under situations 
of physiological stress (257, 262). Furthermore a more prolonged exposure to elevated levels 
of GDF-15 was associated with the development of muscle wasting following cardiac surgery 
and it is possible that this reflects a driving mechanism for acute muscle wasting. This would be 
consistent with in vitro studies in which GDF-15 promoted apoptosis and suppressed 
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hypertrophy in cancer cells and cardiomyocytes (268, 341) and in vivo mouse models where 
mice deficient in GDF-15 showed both increased cardiac hypertrophy and loss of cardiac 
function in response to pressure overload compared with wild type mice. (273). These effects 
may in fact be beneficial in cardiac tissue. Beneficial effects of GDF-15 in cardiac tissue also 
include protection of the myocardium from infiltration by polymorphonuclear leukocytes and 
protection against myocardial rupture following infarction (278).  However GDF-15 is also 
linked to pathological effects in cardiac tissue and its role is likely to be bidirectional depending 
on the environment (257).  A similar situation is seen in prostate cancer cells where GDF-15 
both promoted apoptosis (274, 275), and enhanced metastatic potential and angiogenesis 
(262). With respect to the role of GDF-15 in muscle wasting, a pathological link was first 
suggested when GDF-15 expressing tumours implanted into mice were found to cause cancer-
related cachexia, an effect which could be reversed with GDF-15 antibodies (267). In that study 
a central anorexic effect of GDF-15 was suggested as the cause and thus reduced food intake 
was reversed by the antibodies (267). Unfortunately the food intake of patients in the current 
study was not recorded and it is not known if it was different between the two groups.  
Data from the current study are consistent with the current understanding of the role 
of IGF-1 in muscle homeostasis. Muscle IGF-1 was reduced in human models of sepsis (133, 
136), immobility (135), surgery (130) and in critical illness (147). Reduced plasma IGF-1 levels 
were also observed in acute critical illness (147), and associated with poor clinical outcome 
(148) and development of severe ICUAP (149).  
It is important to note that in the current study these factors have been measured in 
plasma and not in the muscle itself. The significance of this is unknown. As discussed, 
variations in circulating levels of myostatin and IGF-1 have been associated with muscle 
wasting conditions and it is likely that these mediators and GDF-15 act in both a paracrine and 
endocrine manner – however the muscle concentration of these proteins cannot be known 
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from this study and their muscle effect is only assumed to be augmented by a raised circulating 
level or vice versa.  
3.5.3 Critique of the method 
The overall clinical outcome for these patients was generally good despite the high-risk 
nature of their surgery. They had short ICU hospital stays and mortality was very low. With this 
in mind it is not surprising, therefore, that these patients only really demonstrated sub-clinical 
wasting which was not associated with significant weakness (all but 2 post-operative MRC-SS 
were unchanged). This may be one of the reasons that differences in the baseline values of the 
myostatin, IGF-1 and GDF-15 were not detected between the two groups of patients.   Of 
course, the study may also have been underpowered to detect a difference due to the 
relatively small number of patients in each group and the wide range of baseline values. 
Importantly the sub-clinical nature of the muscle wasting studied may mean that these 
patients are not truly comparable to a true weak ICUAP cohort. Nevertheless, the validity of 
the approach is supported by the observation that IGF-1 decreased acutely in all patients, and 
remained suppressed in those who developed muscle wasting, consistent with prior 
observations (147, 149). A larger prospective study involving more patients and particularly 
those with clinically obvious ICUAP would be desirable as a next step to confirm the findings.  
ICUAP is a heterogeneous disorder that occurs in a very mixed cohort of patients. The 
advantage of the model used in the current study is that its prospective nature, the relative 
homogeneity of the patient cohort and the uniformity of the insult allow some of the 
heterogeneity to be controlled for and thus specific factors in the pathophysiology of acute 
muscle wasting can be considered. However it is therefore difficult to know how much can be 
extrapolated to a more general ICU population in whom, for example, sepsis and prolonged 
stays on ICU with significant prolonged immobility are common. Muscle wasting was common 
and therefore in the future this model may be useful in an RCT of a preventative treatment for 
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ICUAP. However it is important to note that although muscle wasting did develop in 55% of 
these patients, it could be described as subclinical - in that patients were almost all mobile and 
in significantly limited by the loss of muscle bulk and therefore in order to pick up a clinically 
significant improvement in loss of muscle bulk caused by an intervention this model may not 
be ideal.  
Another important consideration is that bypass itself is well recognised to cause 
changes in the circulating levels of inflammatory molecules (342).  However bypass time was 
not significantly different between the two groups of patients (Table 3-1). Furthermore four 
patients in the non-wasting group and two in the wasting group did not undergo bypass and 
these patients had similar circulating plasma levels of myostatin, IGF-1 and GDF-15 as the rest 
of the group. 
Finally this study would be significantly improved by an adequate assessment of 
muscle strength in all patients studied and an assessment of mobility and activity over the 
week. The former would help describe the degree of clinical injury to the muscle that occurred 
and potentially better characterise the patients. The latter would potentially add to our 
understanding of the relevant factors in the development of acute muscle wasting in this 
situation. Of note all but seven of the patients were out of bed by day one (5 in the wasting 
and 2 in the non-wasting group, which was not statistically different) and had standard 
physiotherapy however this was not formally quantified and their activity was not monitored 
(for example by a pedometer). 
3.5.4 Conclusion 
Despite a good clinical outcome, 55% of high-risk elective cardiothoracic patients 
developed measurable muscle wasting in this cohort. This was associated with a dynamic 
imbalance in the circulating regulators of muscle homeostasis and a sustained elevation in 
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GDF-15 was associated with acute muscle loss. This study identifies GDF-15 as a potential 
driver of muscle wasting and strengthens the hypothesis that GDF-15 will be important in the 
pathogenesis of ICUAP. Despite the flaws discussed above this is a valid model of acute muscle 
wasting with several advantages which means that it could be used in the future to further 
understand the pathophysiology of acute muscle wasting.  
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Chapter 4 GDF-15 regulation of muscle microRNAs in the pathogenesis 
of ICUAP 
4.1 Rationale 
As already discussed in the introduction there is a strong rationale for the investigation 
of the role of GDF-15 in the pathogenesis of ICUAP. This was strengthened by the results 
discussed in Chapter 3 where a sustained rise in the concentration of plasma GDF-15 was seen 
in those who developed muscle wasting at 1 week, but not in those who did not develop 
muscle wasting, where GDF-15 levels returned to baseline. Furthermore Dr Jen Lee (a member 
of our group) demonstrated that GDF-15 treatment of C2C12 cultured myotubes caused a 15% 
loss of myotube diameter (Figure 4-1) (333), suggesting that GDF-15 may indeed have a direct 
effect on muscle. However the potential mechanisms for this were not understood.  
Acute muscle wasting is thought to occur as a result of disturbed muscle homeostasis 
with an imbalance between hypertrophy/protein synthesis and satellite cell recruitment and 
atrophy/muscle protein breakdown, apoptosis and autophagy (40). MicroRNAs are involved in 
the regulation of muscle cell proliferation, differentiation and regeneration and, therefore, are 
essential for the maintenance of normal muscle homeostasis (288). Although the regulation of 
microRNA expression is not fully understood, their regulation by inflammatory cytokines is 
recognised (301) and, in turn, microRNAs modulate inflammatory signalling (301). One 
important signalling pathway in muscle homeostasis which microRNAs (for example, miRs-1, 
133a, 181a and 499) have been shown to interact with is the TGF-β signalling pathways (290, 
343-346).  This, alongside emerging evidence of their role in other myopathies (301), for 
example Chronic Obstructive Pulmonary Disease (COPD) (302), led to the hypothesis that the 
regulation of microRNA expression might be one mechanism by which GDF-15 could promote 
ICUAP.  
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In addition, hyperglycaemia is the only aetiological factor in the development of ICUAP 
that has been well described and demonstrated in clinical trials (48, 51). GDF-15 expression in 
human umbilical vein cells was up-regulated by hyperglycaemic conditions in vitro (347). If 
GDF-15 were under similar regulatory pathways in muscle, up-regulation of GDF-15 driven by 
hyperglycaemia might provide another mechanistic insight into the aetiology of ICUAP and 
therefore this was also investigated. 
 
 
Figure 4-1 Effect of GDF-15 treatment of C2C12 myotubes.  
GFP transfected myotubes following treatment with control (A) or GDF-15 50ng/ml (B) 
for 48 hours on day 8 of differentiation (x10 magnification  –  scale bar represents 100 µm). (C):  
Box and Whisker plots show median, interquart ile range and 5th and 95th centi les. Day 8 
cultured myotubes were exposed to GDF -15 (50ng/ml)  or vehicle control (0.1% BSA with 20mM 
HCL) for 48 or 96 hours. Diameter of the myotubes was then calculated. Mean control myotube 
diameter was 26.3 ± 9.0 µm versus 22.3 ± 7.5 µm for the GDF -15 treated myotubes at 48 hours. 
This equates to a 15% reduc tion in diameter following GDF -15 treatment; p=0.011 (Mann-
Whitney). At  96 hours, mean control myotube diameter was 26.6 ± 9 µm and 22.7 ± 8 µm for 
GDF-15 treated myotubes (14% reduction p=0.003 Mann -Whitney) Data courtesy of Dr J  Lee. 
Copyright permission obtained from Crit  Care Med 2013 Apr 41(4):982 -989, see appendix A1.  
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4.2 Hypothesis 
The above rationale led to the following main hypotheses 
1. GDF-15 plasma concentration and muscle mRNA expression would be elevated 
in ICUAP patients. 
2. MicroRNA expression would be different in the muscle of ICUAP patients 
compared to controls. 
3. GDF-15 treatment of C2C12 myotubes would result in increased expression of 
atrophy related genes and disruption of microRNA expression. 
4. Hyperglycaemia would increase GDF-15 mRNA expression in vitro and 
increased GDF-15 in vivo would be associated with impaired glucose tolerance, 
diabetes or insulin resistance.  
4.3 Patients studied and study design 
The principle inclusion criterion for this observational study was a clinical diagnosis of 
ICUAP. The diagnosis was made in accordance with standard diagnostic criteria (15). Where 
patients were alert and cooperative this included MRC-SS evaluation (n=8), but in the majority 
their level of consciousness precluded MRC-SS scoring. In these cases, in line with Stevens’ 
criteria, patients were required to have visible evidence of muscle wasting and functional 
evidence of muscle weakness, and other causes of muscle wasting and weakness to have been 
excluded. If used a MRC-SS of less than 48/60 was required. All adults admitted to ICU at the 
Royal Brompton Hospital for more than one week were screened. Exclusion criteria included 
preadmission neuromuscular disease resulting in significant wasting or weakness, malignancy 
or contraindications to biopsy such as extreme clotting diatheses. Control participants were 
elective high-risk cardiothoracic surgery patients, with MRC scores 60/60 pre-operatively, in 
whom a biopsy was taken at the start of surgery.  This population was chosen to control for 
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the complex co-morbidities of the ICUAW patients. These patients were also involved in 
another study, which is discussed in Chapter 5 of this thesis. In these participants a biopsy was 
taken at the start of their surgery. Written consent was obtained from patients and controls or 
assent from the next of kin where the patient lacked capacity. National Research Ethics 
Committee approval for this study was secured (10/H0722/9). Participants underwent 
measurement of the mid-thigh muscle layer thickness (MLT), muscle biopsy and blood 
sampling (see methods Chapter 2). MLT was used for this study to enable comparison between 
individuals at the most standardised level of the rectus femoris muscle (i.e. 60% of the distance 
between the anterior superior iliac spine and supra-patella border). Despite being validated in 
ICU patients (306) the MLT does have potential flaws, including the impact of variable 
extracellular water/oedema on the measurement. However the rectus femoris cross sectional 
area (RFcsa) was not measurable in all the participants, because the whole muscle was often 
not visualised in a single US image and therefore the MLT was used.  
Data were non-parametrically distributed and are therefore expressed as median with 
interquartile range (IQR) in brackets unless otherwise stated.  
4.4 Results 
4.4.1 Patients 
Twenty-nine patients meeting the inclusion criteria (or their relatives) were 
approached. Four declined, 5 were too unwell and the remaining 20 consented/ assented; the 
Consort diagram for the study is shown in Figure 4-2. Seven control high-risk elective 
cardiothoracic patients were recruited, with a median euroSCORE of 9 (range 7-14). 
Demographic data, co-morbidities, reason for ICU admission and clinical data from their ICU 
stay are shown in Table 4-1. Patients and controls were well matched in terms of age and 
baseline body mass index, however all the controls were male.  By the nature of their selection 
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all the control patients had either ischaemic heart disease (IHD) or other cardiac disease and 
no controls had a history of respiratory disease; whereas a history of cardiac disease (excluding 
IHD) was less common in the ICUAP patient group. 
  
Figure 4-2 Consort diagram of recruitment of ICUAP patients into the observational study.  
  
All ICU patients > 1week stay screened 
41 meeting inclusion criteria at initial 
screening 
29 approached 
20 enrolled 
12 found to be unsuitable 
4-Not weak 
3 - Unable to consent/ assent 
5 - Change of medical status 
 
4 – refused consent/ assent 
5 – too unwell  
123 
 
 Controls n=7 Patients n=20 
P value 
(MW/ Chi squared) 
Demographics    
Age (yrs) 69 (63-74) 64 (51-78) 0.39 
Sex (m/f) 7/0 15/5 0.14 
BMI (baseline) (kg/m
2
) 24 (22-29) 27.8 (26.0-30.8) 0.21 
MLT* (cm) 2.9 (2.0-3.3) 1.7 (1.4-2.5) 0.08 
Co-morbidities (n)    
IHD 4 of 7 8 of 20 0.42 
Other cardiac disease 6 of 7 6 of 20 0.01 
Respiratory 0 of 7 6 of 20 0.10 
COPD 0 of 7 2 of 20  
Diabetes 1 of 7 4 of 20 0.73 
Statin use 4 of 7 6 of 20 0.20 
Type of Cardiac surgery (n)    
CABG 1   
Valve surgery 2   
Mixed 4   
Reason for ICU admission (n)    
Post cardiac Surgery  8  
Cardiac  3  
Respiratory  9  
    Pneumonia  2  
    COPD  2  
    ARDS/ ECMO  3  
    Other respiratory  2  
ICU data    
MRC score at diagnosis 
# 
 36 (34 -40)  
Day on ICU of biopsy  (days)  20 (15-29)  
SOFA score at time of biopsy  11 (8-14)  
Total ICU LOS (days)  42 (23-51)  
Awake at biopsy  (n)  6  
Fed at time of biopsy  6  
NMB (n)  11  
Corticosteroids (n)  12  
Sepsis (n)  20  
Mean CRP (mg/l) ¥  136 (103-194)  
Mean pO2 (kPa) ¥  12.68 (12.12-14.41)  
Mean CO2 (kPa) ¥  5.7 (5.31-6.09)  
Mean pH ¥  7.41 (7.40-7.44)  
Mean Blood Glucose (mg/dl) ¥  7.6 (7.1-8.0)  
Mean Cumulative insulin  dose(Units) ¥  456 (345- 894)  
Died  (1yr  mortality)  8  
Table 4-1 Demographics and clinical data of patients and controls in the observational study of ICUAP.  
Basic  basel ine demographic data, co -morbidit ies and ICU data (where applicable) for 
patients with ICUAW and controls.  Data presented as median (inter -quarti le range) or number 
(n).  BMI  -body mass index, MLT –  muscle layer thickness,  IHD –  ischemic heart  disease, ICU –  
intensive care,  LOS –  length of stay, NMB –  neuromuscular blockers. * -  n=5 for controls and 
n=13 for patients.
 #
 n=8 (6 on the day of biopsy, 2  in the preceding 48 hours).  ¥ during ICU stay 
up to the point of biopsy.  
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4.4.2 Muscle Layer Thickness (MLT) 
Adequate US images were obtained for only 5 controls and 13 patients; this was partly 
due to technical factors including problems with the US machine and also oedema in patients 
preventing adequate visualisation of the muscle. As expected the mid-thigh MLT of patients 
tended to be lower than controls (Patients 1.7 [IQR 1.4-2.5] cm versus controls 2.9 [IQR 2.0-
3.3] cm [p=0.079]) Figure 4-3 . 
Figure 4-3 Muscle Layer Thickness (MLT).  
Mid-thigh MLT measured by ultrasound for patients  (n=13) and controls  (n=5) . Data 
presented as median and error bars represent interquarti le range. Mann -Whitney  
4.4.3 Histology 
Unfortunately some O.C.T. mounted specimens were damaged by ice crystal artefact 
and as a result adequate muscle histology specimens were available for only 4 of 7 controls 
and 7 of 20 patients.  
Fibre size: The mean muscle fibre diameter for each individual was calculated from 33-
105 fibres per subject. Median mean fibre diameter was 56.4µm (IQR 49.5-62.2) in controls 
and significantly lower in patients, 47.5 µm (IQR 41.9-51.6) (p=0.042).  The frequency 
distribution of fibre size also confirmed that the patients had smaller fibres when the 
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percentage of total fibres measured is considered (Figure 4-4).Fibre type: Immunofluorescent 
staining of histology specimens also showed fibre atrophy; the mean type 1 fibre diameter was 
15% smaller in patients than controls (p<0.001 t-test) and type 2a fibres were 24% smaller 
(p<0.001 t-test). Fibre type staining also showed a non-significant shift in fibre proportion 
towards type 2 fibres; the median proportion of type 1 fibres was 44% (IQR 33-38) and 24% 
(IQR 21-39), p=0.109, and of type 2a fibres was 33% (IQR 28-38) and 45% (IQR 11-72), p=0.715 
in controls and patients, respectively (Figure 4-5).  
 
Figure 4-4 Muscle biopsy specimens from the rectus femoris of ICUAP patients (n=7) and controls (n=4).  
Haematoxylin and Eosin staining of  muscle biopsies from control subjects (A) and 
patients (B) at 10x magnification. C - mean fibre diameter of patients and control s. D –  
percentage distr ibution of all  f ibres measured (33 -107 measured per subject).  Data presented as 
median and error bars represent inter -quarti le range, ** p<0.01 Mann Whitney.   
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Figure 4-5 Immunostained muscle biopsy specimens for fibre typing.  
 Muscle biopsy specimens from the rectus femoris of ICUAP  patients (n=7) and controls 
(n=4).  Immunostaining of control (A) and patient (B) for dif ferent muscle fibre types  (the same 
individuals as seen in the above figure) . Blue –  MHC 1, green –  MHC 2a,  red –  laminin;.  type 2x 
fibres do not stain and can be seen as black f ibres (10x  magnif icat ion).  
C -  mean fibre type proportion of different MHCs 1,2a, 2x and dual staining 1/2a fibres.  
4.4.4 GDF-15 in the plasma and muscle GDF-15 mRNA expression in ICUAP 
Median plasma GDF-15 concentration was 2454 pg/ml (IQR 600-3118) in controls and 
7239pg/ml (IQR 5613-13295) in patients (p=0.001) (Figure 4-6). At the time of biopsy, plasma 
GDF-15 in the patient group correlated with the patient’s SOFA score, a marker of critical 
illness severity  (r=0.64, p=0.002) (316).   
Rectus femoris muscle mRNA expression of GDF-15 was higher in patients than 
controls (median 2.03-fold higher than controls [IQR 1.2-3.1], p=0.006, Figure 4-6). 
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Figure 4-6 GDF-15 in ICUAP patients and controls.  
GDF-15 in ICUAP patients (n=20) and controls (n=7) measured in plasma (A) and rectus 
femoris muscle biopsy mRNA expression (B).  Dotted line figure A represents 1 ,200pg/ml –  the 
upper l imit of normal plasma GDF-15. ** p< 0.01, *** p<0.001 –Mann-Whitney.  Correlat ion of 
plasma GDF-15 with Sequential Organ Failure Score (SOFA) at the t ime of sampling (C). r= 
Pearsons r value for correlat ion.  Data presented as me dian and error bars represent 
interquarti le range.  
4.4.5 Muscle mRNA expression in ICUAP 
Myostatin and IGF-1 are mediators of muscle atrophy and hypertrophy respectively 
(137, 329) and therefore mRNA expression of both was measured. Neither was significantly 
differently expressed between patients and controls (Figure 5-7). MuRF-1 and atrogin are 
muscle-specific ubiquitin ligases responsible for muscle protein breakdown (110, 111). 
Expression of atrogin was elevated significantly in the patients (median 3.42-fold higher than 
controls [IQR 1.7-7.9], p=0.003), but MuRF-1 was not significantly different (Figure 5-7). 
MyoD1 and myogenin are markers of differentiation and increased expression is seen in 
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regeneration (292, 348). MyoD1 was not significantly different in patients compared to 
controls; however, myogenin mRNA expression was significantly higher in the patients (median 
2.86-fold higher [IQR 1.67-3.73], p=0.002) (Figure 4-7).Although MHC gene mRNA expression 
does not directly translate to protein level or muscle fibre-type microscopically, it was 
hypothesised that MHC gene expression would be different between patients and controls. 
Type 1 and 2a MHC mRNA expression was significantly lower in patients compared to controls 
(Figure 4-8).However, MHC type 2x mRNA expression was not significantly different.  
4.4.6 microRNA expression 
MicroRNA expression in the rectus femoris muscle of ICUAP patients was different 
from that of controls. The expression of three muscle-specific microRNAs (myomiRs), MiR-
1,133a and 499, were significantly lower in patients than controls. Median patient myomiR 
expression as a percentage of control expression: miR-1 39% (IQR 22-69%), p=0.003; miR-133a 
38% (IQR 28-47%), p<0.001; and miR-499 in ICUAP patients was 27% (IQR 17-41%) of control 
expression p=0.002 (Figure 4-9). MiR-206, another myoMiR, was not different between the 
two groups. MiR-181a (a non muscle-specific microRNA) was also significantly lower; median 
miR-181a expression in patients was 56% (IQR 42-77%) of control values (p=0.009; Figure 4-9).   
Furthermore log [GDF-15 mRNA] showed a significant negative correlation with the log 
[microRNA expression] of miRs 1, 133a, 181a and 499, but not miR-206. Log [plasma GDF-15] 
showed a similar pattern but did not reach statistical significance for miR-181a (Figure 4-9).  
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Figure 4-7 Muscle mRNA expression.  
Relative normalised muscle mRNA expression of different genes in controls (n=7) and 
patients (n=20). Data presented as median and error bars represent interquart ile range. ** 
p<0.01 Mann-Whitney. IGF-1 -  Insul in l ike growth factor-1,  MuRF-1 –  muscle ring f inger-1, 
MyoD1 –  myogenic  differentiat ion -1.  
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Figure 4-8 Muscle MHC expression.  
Relative normalised MHC expression (Types 1,  2 and 2x) in patients (n=20) and controls 
(n=7). **p<0.01, *** p<0.001 Mann-Whitney. Data presented as median and error bars 
represent the interquartile range.  
  
131 
 
Figure 4-9 Rectus femoris muscle microRNA expression of different microRNA.  
Rectus femoris muscle microRNA expression of different microRNA in Patients with 
ICUAP (n=20) and controls (n=7)  .** p<0.01, ***p<0.001 Mann-Whitney. Table shows Correlation 
of Log [miR expression] with log [plamsa GDF-15] and log [GDF-15 mRNA expression] Pearson’s r  
values and p values (Bonferroni -corrected for multiple testing) are l isted. Data presented as 
median and error bars represent inter quarti le range.  
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4.4.7 TGF-β receptor type 2 
TFG-β type-2 receptor (TGFBR2) protein was quantified using western blot. A 
prominent band was seen at the expected 65KDa level; however, a further unexpected small 
band was also seen. Quantification was carried out taking into account only the expected band 
and normalised to Ponceau staining of the membrane. There was no significant difference in 
the normalised TGFBR2 concentration between patients and controls.  
 
Figure 4-10 Muscle TGF-β type-2 receptor (TGFBR2) protein concentration.  
(A) Representative Western blot of TGFBR2. Lanes labelled as X1, X2= protein pools  for 
normalisat ion,  C=control,  P=patient. (B) Normalised TGFBR2 in controls (n=7) and patients 
(n=20) data presented as median and error bars represent interquart ile range.  
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4.4.8 TGF -β signalling in ICUAP muscle  
CYR61 (Cysteine-Rich, Angiogenic Inducer-61), is a downstream marker of TGF-β 
signalling (349) whose mRNA expression in ICUAP muscle was significantly higher than in 
control muscle (median 11.18- fold higher than controls [IQR 5.32-15.75] p=<0.0002). However 
CTGF (Connective Tissue Growth Factor), another TGF-β responsive gene (349), was not 
elevated (Figure 4-11).  
TGF-β receptor activation results in SMAD2/3 phosphorylation. The phosphorylated 
SMAD complex then re-locates to the nucleus to act as a co-transcription factor and activate 
TGF-β signalling pathways (153, 154).  Immuno-stained muscle sections demonstrated a higher 
percentage of nuclei staining positive for phosphorylated-SMAD-2/3 protein in patients 
(median 92% (IQR 87-95%)) than controls (median 79% (IQR 78-86%)), p=0.04 (Figure 4-11). 
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Figure 4-11 TGF-β Signalling in ICUAP muscle.  
A - CYR61 (Cysteine-Rich, Angiogenic Inducer-61) and CTGF (Connective Tissue Growth 
Factor) mRNA expression in controls (n=7) and patients (n=20) . B - Images show control ( left)  
and patient (r ight) 20x magnification muscle sections stained for p -SMAD2/3 (small mothers 
against decapentaplegic ) localisat ion. Blue –  (DAPI) nuclear, Red –  Laminin, Green - p-SMAD2/3. 
Expanded area demonstrates nuclear and pSMAD2/3 local isation. Lower images show p-
SMAD2/3 fluorescence only of the same field of view. Graph shows percentage of pSMAD2/3 
positive nuclei for controls (n=4) and patients (n=7) ,  *p=<0.05, *** p<0.001 Mann Whitne y. Data 
are presented as median and e rror bars represent interquart il e range.  
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4.4.9 GDF-15 effects on in vitro C2C12 cells  
In vitro data results are expressed as mean ± standard deviation.  
4.4.9.1 GDF-15 did not affect SMAD-dependant luciferase activity 
Treatment of C2C12 myoblasts with GDF-15 at doses from 0-100ng/ml for 24 hours 
from the point when they became confluent and would therefore have been starting 
differentiation did not activate SMAD dependant CAGA-(12)-luciferase activity. Myostatin 
treatment (used here as a positive control) resulted in a small but significant increase (mean 
1.4±0.2-fold increase, p=0.003) Figure 4-12. 
 
Figure 4-12 GDF-15 effects on SMAD dependant CAGA-12-driven luciferase activity. 
 C2C12 myoblasts were transfected with CAGA -(12) f iref ly and PRLTK renil la luc iferase 
plasmids. When confluent and therefore undergoing differentiation C2C12 cells  were treated 
with GDF-15 at increasing doses, BSA control or Myostatin as a posit ive control.   Following 24 
hours treatment, relative luciferase activ ity was quantified. **<0.01 T -test. Data presented as 
mean and error bars represent standard deviat ion. N=2 in tr iplicate.   
4.4.9.2 microRNA array 
The effects of GDF-15 and myostatin were tested on differentiating C2C12 myoblasts. 
Cells were cultured until confluent and then allowed to begin differentiation over 3 days; 
subsequently they were treated with control, GDF-15 (50ng/ml) or myostatin (20ng/ml) for 6 
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or 24 hours. No significant changes were seen in the expression of MuRF-1, atrogin-1, CYR61, 
CTGF, myoD1 or myogenin with either treatment or at either time point (results not shown). 
Therefore in order to identify the signalling pathways altered by GDF-15 which might result in 
the myotube atrophy that was demonstrated by Dr Lee, a microRNA array was carried out.  
RNA samples from differentiating myoblasts treated for 6 and 24 hours were used; in 
addition, Dr Lee donated RNA from 8 day differentiated mature myotubes which had been 
treated for 4 days with GDF-15. The array was carried out in collaboration with the Genome 
Centre at St Bartholomew’s and the London Hospital, London.  
Appendix A2 shows the significant hits identified by the array. The results from this 
array suggested that GDF-15 had a more significant effect on differentiated myotubes over a 
longer time period and therefore these conditions were replicated for further experiments.  
4.4.9.3 mRNA expression in GDF-15 treated myotubes 
8 day differentiated myotubes were treated with either GDF-15 (50ng/dl), myostatin 
(20ng/dl) or BSA control for 4 days. GDF-15 treatment resulted in a significant rise in MuRF-1 
and atrogin-1 mRNA expression with a 1.4±0.6-fold greater expression than control for each. 
Myostatin treatment resulted in a 1.7±0.7-fold increase in MuRF-1 mRNA expression but no 
significant change in atrogin-1. Neither treatment resulted in a significant change in CYR61, 
CTGF or MyoD1 (Figure 4-13).  
4.4.9.4 microRNA expression in GDF-15 treated myotubes 
GDF-15 treatment of differentiated myotubes (as above 4.4.9.3) resulted in a 
significant decrease in the expression of the myomiRs miR-1 and miR-133a and also in miR-
181a. Myostatin treatment tended towards a similar pattern, however the reduction only 
reached statistical significance for miRs-133a and 181a. MiR-206 tended towards a reduction 
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following both treatments, but miR-499 was unchanged (Figure 4-13). Table 4-2 shows the 
values of expression in table form.  
Figure 4-13 GDF-15 and myostatin effects on mRNA and microRNA expression in myotubes. 
 8 day differentiated myotubes were treated with control ( 0.1% Bovine serum albumin 
with 20mM HCL),  GDF-15 (50ng/ml) or Myostatin (20ng/ml) in differentiation media for 4 days. 
Data presented as mean and error bars represent the standard deviation. *p<0.05  students t-
test for comparison of treatment to control.  N=4 in tr iplicate.  
 
MicroRNA Control GDF-15 Myostatin 
1 1 ± 0.92 0.32 ± 0.19 * 0.38 ± 0.40 
 
133a 1 ± 0.85 0.42 ± 0.28 * 0.31 ± 0.27 * 
181a 1 ± 0.74 0.50 ± 0.31 * 0.41 ± 0.29 * 
206 1 ± 0.86 0.48 ± 0.27 0.46 ± 0.30 
499 1 ± 0.62 0.69 ± 0.38 0.78 ± 0.40 
Table 4-2 microRNA expression in C2C12 cells treated with GDF-15 or myotatin. 
 8 day differentiated myotubes were treated with control ( 0.1% Bovine serum albumin 
with 20mM HCL),  GDF-15 (50ng/ml) or Myostatin (20ng/ml) in differentiation media for 4 days.  
Data expressed relative to control  mean ± standard deviation .  *p<0.05 students’t -test for 
comparison of treatment to  control.  N=4 in triplicate.  
4.4.9.5 TGF-β receptor type 1 and 2 protein concentration in GDF-15 treated myotubes 
8 day differentiated myotubes were treated as above (4.4.9.3) and western blot for 
TGF-β receptors type 1 and 2 (TGFBR1 and TGFBR2) showed a possible trend towards an 
increase in receptor protein with myostatin (20ng/dl) and GDF-15 (50ng/dl) treatment 
compared to control (Figure 4-14). However the results of one experiment were not 
statistically significant and attempts to repeat the experiment did not show the same pattern 
on western blot (results of repeat experiments not shown). 
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Figure 4-14 TGF-β receptor type 1 and 2 protein (TGFBR1 and 2).  
Western blots to show TGFBR1 and TGFBR2 protein concentration in GDF -15 and 
myostatin treated C2C12 cells.  8 day differentiated myotubes were treated for 4 days with (B)  
vehicle control (0.1% bovine serum albumin with 20mM HCL) , (G) GDF-15 (50ng/ml) or (M) 
myostatin (20ng/ml). Lower panel represents tubulin used as a loading control.   Graph shows 
quantif icat ion of western blots normalised to tubulin.  
4.4.10 MiR-181a over-expression reduced TGF-β signalling 
Treatment of C2C12 myoblasts with TGF-β1 (2.5ng/ml) caused a 24-fold induction of 
CAGA-12-driven luciferase activity. Full details of this experiment can be found in the Methods 
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Chapter (Chapter 2). In brief, following seeding, myoblasts were transfected with mimic-miR-
181a or a negative control and TGF-β signalling activation was assayed with transfected CAGA-
(12)-luciferase reporter. Cells were treated with TGF β1 (2.5ng/ml) for 6 hours, harvested and 
assayed for luciferase activity immediately. Transfection of miR-181a into cultured myoblasts 
resulted in a 45% reduction in response to TGF-β treatment (Figure 4-15).  
Figure 4-15 Over-expression of mir-181a reduced TGF-β signalling.  
Myoblasts were transfected with miR -181a or negative control,  then CAGA-12 firefly and 
Renil la Luciferase plasmids. Fol lowing 6 hours treatment with TGF-β  (2.5ng/ml) relat ive 
luciferase activ ity was quantif ied.  N=3 in triplicate and data are normalised to their 
contemporary control.  * p=<0.05 T -test data presented as mean and e rror bars represent the 
standard deviat ion.   
4.4.11 Investigation of the potential relationship between GDF-15 and glucose 
metabolism  
4.4.11.1 In ICUAP patients 
Plasma GDF-15 protein concentration in patients with ICUAP correlated strongly with 
the cumulative insulin dose received – this was corrected for length of stay (i.e. total insulin 
dose (units)/ ICU LOS (days)). However it did not correlate with mean blood glucose and 
muscle GDF-15 mRNA did not correlate with glucose or insulin (Figure 4-16). 
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Figure 4-16 Correlation of total insulin exposure in ICUAP patients  with plasma GDF-15 
Graph shows correlation of total insulin dose / ICU length of stay (LOS) with plasma GDF-
15. pearsons r value and p value.  
4.4.11.2 Effect of glucose concentration of GDF-15 and miR-181a expression in C2C12 
myotubes 
Increasing glucose concentrations in the differentiation media of 8 day differentiated 
myotubes for 4 days did not result in any change in either GDF-15 or miR-181a expression 
(data not shown). Glucose concentration was tested over a range from - 6000µg/ml ( 5.6 to 33 
mmol/L) . 
4.4.11.3 Plasma GDF-15 in COPD patients with diabetes mellitus or impaired glucose 
tolerance.  
Plasma GDF-15 concentration was quantified in specimens donated from a cohort of 
44 COPD (Chronic Obstructive Pulmonary Disease) patients by a collaborating group (Professor 
Emma Baker, St George’s Hospital; Ethical approval was secured by the George’s team 
10/H0721/75). These COPD patients were taking part in another study to investigate the role 
of diabetes in COPD-related muscle wasting. The patients were classified according to their 
glucose tolerance status as normal (n=24), impaired glucose tolerance (n=8), newly diagnosed 
141 
 
diabetes (n=7) or established diabetes on treatment (n=5). Of this last group, one was on 
insulin therapy, two on metformin, one on gliclazide and one on metformin and gliclazide. The 
basic demographic data for the groups are described in Table 4-3.  Kruskall-Wallis ANOVA test 
of the plasma GDF-15 concentration in the different groups revealed that they differed 
(p=0.037); those with established diabetes on treatment had significantly higher plasma GDF-
15 concentration that all other groups (Figure 4-17). However plasma GDF-15 did not correlate 
with plasma glucose, HbA1c or insulin resistance (as measured by the homeostasis model 
assessment-2 score [HOMA2 IR]). Furthermore there was no acute change in GDF-15 during 
the standard glucose tolerance test in patients with or without diabetes (n=16 in total tested). 
However these data did confirm findings by Dr Patel (also in our group) from a separate COPD 
cohort that GDF-15 negatively correlated with US RFcsa and QMVC (data not shown).  
 Normal (n=24) IGT (n=8) New DM (n=7) DM (n=5) 
Age (years) 72.5 (64.3-79.0) 67.0 (61.3-69.5) 72.0 (67.0-79.0) 81 (69.5 - 82.0) 
Sex (m/f) 16/8 4/4 4/3 5/0 
BMI (kg/m
2
) 23.3 (19.9-27.3) 23.4(21.4-25.0) 29.0(25.3-32.1) 24.7(22.4-27.0) 
FEV1 (l/s) 1.19 (1.04-1.77) 1.25 (1.12-1.65) 1.5 (0.92-1.81) 1.45 (1.04-1.64) 
HbA1C (%) 39.5 (36.3-41.8) 39.5 (34.8-42.5) 49.0 (46.0-54.0) 39.0 (44.5-88.0) 
HOMA2IR 0.86 (0.66-1.15) 1.06 (.74-1.62) 2.02 (1.10-3.07) 1.05(0.94-1.47) 
QMVC 26.1 (22.3-36.9) 32.2 (29.1-37.3) 18.7 (12.4-25.9) 23.4 (23.0-32.1) 
US RFcsa (cm
2
) 4.10 (3.53-4.68) 4.92 (3.94-6.14) 4.13 (3.20-4.70) 3.29 (2.46-5.89) 
Table 4-3 Demographic data of St George’s hospital COPD patients.  
IGT –  impaired glucose tolerance, DM –  diabetes mellitus. Data expressed as median 
(interquarti le range). BMI-body mass index, FEV1-forced expiratory volume in 1 second, HbA1c -
glycated haemoglobin,  HOMA2 -IR-homeostasis assessment model -2 of insulin resistance, QMVC-
quadriceps maximal voluntary contraction, US  RF c s a -rectus ultrasound  femoris cross sectional 
area.  
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Figure 4-17 Plasma GDF-15 concentration in COPD patients classified according to glucose tolerence. 
IGT –  impaired glucose tolerence, nDM –  new diagnosis of Diabetes Melitus (DM),  DM – 
DM on treatment. Kruskall -Wall is ANOVA test confirms that the groups are different p=0.037  
4.5 Discussion 
4.5.1 Main findings 
The findings of this study support the main hypothesis of this thesis and chapter, that 
GDF-15 and microRNAs are important in the pathogenesis of ICUAP. Firstly, both circulating 
GDF-15 and muscle GDF-15 mRNA expression were elevated in patients with ICUAP compared 
to controls (Figure 4-6).  Secondly, the expression of microRNAs known to be important in 
muscle homeostasis and the modulation of TGF-β response were suppressed in ICUAP muscle 
(Figure 4-9). Thirdly, the results of stimulating differentiated myotubes in vitro demonstrated 
that GDF-15 can drive the reduction in these microRNAs and that suppression of miR-181a may 
increase tissue sensitivity to TGF-β family signalling (Figure 4-13,Figure 4-15). Taken with the 
increased TGF-β signalling in ICUAP muscle (Figure 4-11), these data support the hypothesis 
that GDF-15 is a mediator of acute muscle wasting in the critically ill and demonstrate that this 
activity may result from down-regulation of microRNAs leading to increased sensitivity to TGF-
β signalling. 
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4.5.2 Discussion 
GDF-15 is released from various tissues in response to stress stimuli such as hypoxia 
and inflammation (262); therefore the increase in circulating GDF-15 in ICUAP patients is likely 
in part at least to be due to their critical illness. This is consistent with the previous study 
(Chapter 3) (333) and is supported by the observation that patients’ plasma GDF-15 correlated 
with their SOFA score in the current study  (Figure 4-6) and that elevated GDF-15 in patients 
from a different study with Acute Respiratory Distress Syndrome predicted poor outcome 
(279).  Furthermore, factors thought to be involved in the pathogenesis of ICUAP, like 
hyperglycaemia, inflammation and oxidative stress (74, 109), stimulated GDF-15 expression in 
other tissues (262, 347) and therefore also possibly drive the observed increase in GDF-15 
expression in ICUAP muscle.   
Dr Lee’s data suggested that GDF-15 had a direct effect on muscle, which was 
contradictory to the hypothesis of Johnen et al namely that a central anorexic effect was 
caused GDF-15-driven muscle wasting (267). Consistent with a direct effect on muscle, in the 
current study GDF-15 treatment of C2C12 myotubes up-regulated the muscle specific ligases 
MuRF-1 and atrogin-1 (Figure 4-13) and, as previously discussed from the literature, GDF-15 
was pro-apopototic and hypertrophy limiting (257, 268, 273).  Furthermore, in the COPD 
patients studied in this analysis and in a previous analysis in our group (Dr Mehul Patel: 
unpublished observations) GDF-15 was associated with RFCSA but not with BMI or weight, 
suggesting a greater effect in muscle than on lipid stores. 
Atrogin-1 was also elevated in the ICUAP patients compared to controls (Figure 4-7). 
The rise in atrogin-1 is consistent with active muscle wasting, and both atrogin-1 and MuRF-1 
have previously been proposed as mediators of ICUAP (332).  MuRF-1 and atrogin-1 are 
responsible for muscle protein ubiquitination, a precursor event to proteolysis.  MuRF-1 and 
atrogin expression can be driven by myostatin. However, neither MuRF-1 nor myostatin mRNA 
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were elevated in the patients’ muscle in the current study (Figure 4-7). Human studies of short 
term immobilisation and acute illness (40, 350) have shown increased MuRF-1; however, this 
rise was lost in the longer term (175, 350) and both human and animal data concerning 
myostatin are inconsistent (40, 147, 175, 332, 337).   
It is expected that ICUAP occurs as result of an imbalance in muscle homeostasis with 
a relative decrease in protein synthesis and hypertrophy pathways and a net breakdown in 
muscle protein/increased in atrophy. Therefore myostatin would be expected to rise and IGF-1 
fall in patients compared to controls but the expression of neither mRNA differed significantly 
in the current study (Figure 4-7). As discussed in Chapter 3, data concerning the role of 
myostatin in ICUAP is often contradictory and indeed, contrary to the hypothesis, myostatin 
fell in the plasma of patients following cardiac surgery (Chapter 3 (333)). With respect to IGF-1, 
IGF-1 was increased in the muscle of burns patients with muscle wasting (351) and our group 
has previously found an increase in IGF-1 mRNA in COPD-related muscle wasting (302). 
Conversely, other groups have found decreased IGF-1 mRNA in human and animal muscle in 
response to local infection and injury (130, 133, 142). The different mRNA expression patterns 
seen in muscle in response to critical illness may be caused by differences in the time points 
examined, the muscles sampled and the injury to which the muscle was exposed. For example, 
it has recently been shown that after an initial period of reduced muscle protein synthesis a 
longer lasting phase of increased catabolism becomes predominant (40).  Therefore it is 
important to note that the ICUAP patients in the current study had been on ICU for a median 
of 20 days – which represents a later time point in the disease than that assessed by the other 
studies mentioned above.  
As a member of the TGF-β super-family it would be reasonable to suggest that GDF-15 
may signal via the phosphorylation of SMAD proteins (262). However there are few data to 
support this (251). Treatment with GDF-15 for 24 hours did not increase activity of the SMAD-
145 
 
dependant CAGA-(12)-luciferase reporter in differentiating myoblasts (Figure 4-12) and this 
was consistent with experiments carried out by Dr Lee in proliferating myoblasts (data not 
shown). However, Xu et al showed increased SMAD2/3 activation in neonatal cardiac myocytes 
following GDF-15 treatment (273) and Heger et al also showed SMAD activation (268). 
However in Herger’s study, GDF-15 (3ng/ml) was found to promote hypertrophy and protect 
against apoptosis, which is contrary to the study by Xu et al, where mice over expressing GDF-
15 from adenoviral vectors or exposed to GDF-15 intravenously where protected against 
pressure –overload induced cardiac hypertrophy. The receptor(s) through which GDF-15 acts is 
not yet described and although it is likely to be one of or similar to the TGF-β receptors it may 
be that GDF-15 mainly signals via SMAD-independent pathways. Also it is technically difficult 
to balance the expression of the CAGA-(12)-luciferase plasmid (which becomes weaker as the 
cells divide and differentiate) with the expression of TGF-β receptors on the C2C12 cells which 
may increase as cells mature and thus enable a response. Consistent with the suggestion that 
GDF-15 has a more profound in vitro effect on differentiated myotubes than on less mature 
cells were the results of the microRNA array. Very few positive targets were seen in the array 
overall; however, at 24 hours no targets were identified at all for GDF-15 treatment of 
differentiating C2C12 myoblasts, whereas at 4 days differentiated myotubes did show some 
interesting targets (see Appendix A2 Table A-3). The results of microRNA array gene expression 
experiments can be normalised and corrected in multiple ways. Individual gene expression in 
this array was normalised to the total background signal and the false detection rate (FDR) 
correction was used to correct for multiple testing. This normalisation is obviously different 
from that used for specific gene PCR analysis where “house-keeping genes” are used (in this 
case the geomean of GAPDH and RPLPO expression). It may be that this technical difference 
and the stringency of the correction for false positives/ detection can account for the 
disappointing results from the array.  
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Essential muscle microRNAs (288, 289, 292, 293) were significantly suppressed in the 
muscle of ICUAP patients when compared to controls (Figure 4-9). GDF-15 treatment of 
myotubes suppressed expression of the same microRNAs (with the exception of miR-499, 
possibly due to very low miR-499 expression in C2C12 myotubes) and log GDF-15 mRNA 
expression in muscle and log GDF-15 protein concentration in the plasma of ICUAP patients 
was inversely correlated with expression of muscle microRNAs (Figure 4-9).  Therefore 
suppression of these microRNAs may be one mechanism by which GDF-15 disrupts normal 
muscle homeostasis to promote atrophy. This suggestion is also supported by several other 
lines of evidence. For example, knock down of these microRNAs prevented normal myoblast 
proliferation and myotube differentiation (289, 292, 293). MiR-1 promoted growth via 
targeting Histone Deacetylase-4 (HDAC4) and preventing its up-regulation of muscle-specific 
ligases and the ubiquitination pathway of muscle protein breakdown (290). Thus the observed 
reduction in miR-1 in the patients may account, in part, for the demonstrated increase in 
atrogin-1.  
Consistent with a protective role for the microRNAs that were down regulated in the 
muscle of patients with ICUAP is their ability to down-regulate components of TGF-β signalling 
pathways. For example, miR-1 and 499 targeted and inhibited myostatin signalling; miR-1, 
again via inhibition of HDAC4, protects follisatin expression and thus promotes inactivation of 
myostatin; miR-499 targets the myostatin promoter directly and both miR-1 and 499 are 
predicted to target the activin IIB receptor (345, 346). MiR-133awhich is known to promote 
myoblast proliferation (290, 352), targeted and down regulated TGF-β family receptor type 2 
and TGF-β1 itself (344). MiR-181a, promoted muscle recovery following injury (292), and also 
protected against TGF-β signalling via down-regulation of TGF-β type 1 receptors (343). 
Furthermore over-expression of miR-181a in cultured myoblasts resulted in a functional 
suppression of TGF-β signalling in the current study (Figure 6). 
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 MiRWalk is an online tool which combines databases of predicted and proven 
microRNA targets to  generate lists of potential gene targets of specific microRNAs (353). 
Combining all of the targets (predicted by at least 4 databases in miRwalk) of the suppressed 
microRNAs in our ICUAP patients in a pathway analysis using DAVID (an online tool for the 
functional analysis of large gene lists (354, 355)), highlights the TGF-β signalling pathway as 
one of the major pathways likely to be regulated. Indeed the TGF-β pathway was the third 
most statistically significant pathway identified with a p-value of 0.005 and a 2.2-fold 
enrichment score (Appendix A3 Table A-4).  
The above data and results led to the hypothesis that GDF-15 dependent down-
regulation of microRNA in ICUAP muscle would increase sensitivity to TGF-β signalling and thus 
promote muscle atrophy (Figure 4-18). Such an increase in sensitivity would result in increased 
downstream TGF-β signalling without an increase in the TGF-β ligands, such as myostatin, 
being necessary. Muscle of ICUAP patients did show features consistent with increased TGF-β 
signalling, such as increased expression of CYR61 (a TGF-β responsive gene, whose roles 
include regulation of proliferation (349) and modulation of inflammation including attracting 
inflammatory cells (356)) and increased proportion of nuclei containing phosphorylated SMAD-
2/3 (Figure 4-11). By contrast, in vitro experiments in the current study in myoblasts or 
myotubes stimulated by GDF-15 did not show increased SMAD-dependent luciferase reporter 
gene activity or increased CYR61 expression (Figure 4-12, Figure 4-13). CTGF is a member of 
the same family of proteins as CYR61, known as the CCN family (CTGF/ CYR61/Nephroblastoma 
over-expressed protein family), and it too is thought to be TGF-β responsive (349). However, 
CTGF was not elevated in ICUAP patients’ muscle. The reasons for this inconsistency are 
unclear and highlight the complexity of these systems and difficulties in translating bench 
experiments to human studies.  
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Figure 4-18 Schematic representation of the interaction between microRNAs and TGF-β (transforming growth 
factor-β) signalling.  
Stars represent those microRNA that maybe suppressed by growth and differentiat ion 
factor -15 (GDF-15)  in Intensive Care Unit Acquired Paresis resulting in a promotion of  muscle 
atrophy. HDAC4 –Histone Deacetylase 4, MuRF -1 - Muscle Ring Finger-1, SMAD-small mothers 
against decapentaplegic.  
It is possible that GDF-15 sensitisation of muscle to TGF-β signalling is not unique to 
ICUAP.  Down-regulation of muscle microRNAs is consistent with changes our group have seen 
in COPD-associated muscle dysfunction (302) and that others have reported in inflammatory 
myopathies (301). Furthermore Dr Patel (also in our group) has also recently demonstrated 
increased GDF-15 in the plasma and muscle of COPD patients (manuscript in preparation).  
Two targets identified from the literature (292, 343, 344) and the MiRWALK analysis 
(353) were TGFBR1 and TGFBR2. Down-regulation of the targeting microRNA (specifically miRs-
133a and 181a) driven by GDF-15, should therefore result in an increase of the target protein. 
Attempts to demonstrate this in vitro were unsuccessful (Figure 4-14) and the patients did not 
show increased TGFBR2 protein (Figure 4-10). However Di Giovanni et al did demonstrate 
increased TGFBR2 in acute quadriplegic myopathy patients (357). Accurate protein 
quantification via western blot can be difficult especially from tissue samples. Further 
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optimisation of the in vitro experiments may also have achieved better results. Further work to 
quantify these and other potential targets of the down-regulated microRNA is needed in order 
to better describe the proposed mechanism. 
Another important role of microRNA is in the regulation of regeneration following 
injury (288, 292, 358). Regeneration involves activation, proliferation and differentiation of 
satellite cells into myoblasts and then myoblast differentiation and incorporation into mature 
fibre at the same time as increased protein synthesis (292). For example, MiR-181a was highly 
expressed in regenerating multinucleate muscle fibres following tissue injury and up-regulated 
during active in vitro differentiation (292). Inhibition of miR-181a resulted in inhibition of 
myoD1 and impaired differentiation (292). Furthermore HDAC-4, an important inhibitor of 
skeletal muscle differentiation (359, 360), is also an established target of microRNAs 1, 133a 
and 206 (289, 361).  Over-expression of HDAC4 inhibited myoD1 expression and impaired 
differentiation (360); however, despite down-regulation of microRNA-1 and 133a, no 
difference in myoD1 and myogenin was seen in vitro in response to GDF-15 treatment; and 
myoD1 was unchanged whilst myogenin was actually elevated in ICUAP muscle. Overall 
therefore the data from the current study would support a role for GDF-15 in the promotion of 
atrophy, but not the down-regulation of hypertrophy and regeneration. However it is 
important to note that myoD1 is only expressed highly in committed satellite cells and at the 
start of differentiation and myogenin only during active differentiation (361). Therefore 
mature myotubes may not have been the ideal environment to test this theory and a longer 
treatment of differentiating myoblasts may have had better effects. Also, satellite cells only 
account for a small percentage of cells in mature muscle fibres therefore changes in these cells 
would be difficult to detect in the background of a muscle biopsy specimen. Dr Lewis 
(previously in our group) demonstrated increased HDAC4 protein in the muscle of COPD 
patients in association with reduced miR-1 (302), but more work is needed to carefully 
examine these pathways in ICUAP muscle and the potential link between GDF-15 and 
150 
 
impairment of differentiation/regeneration via down regulation of microRNAs.. MicroRNAs are 
also involved in regulation of fibre type balance. MiR-499 is essential for type 1 fibre 
differentiation and maintenance (288). Loss of type 1 fibres has been linked to miR-499 in 
animal models (291) and human diseases (302). ICUAP patients showed significantly lower 
miR-499 compared to controls (Figure 4-9) and significantly lower MHC 1 expression (as well as 
type 2a) (Figure 4-8). More importantly a shift towards type 2 fibre predominance in patients 
was also suggested (Figure 4-5). Unfortunately this did not reach statistical significance, 
possibly due to the small number of subjects for whom histological analysis was possible 
and/or the fact that a reduction in miR-499 is likely to be an early event in the loss of type 1 
fibres with a longer duration of illness needed to develop a significant fibre shift. Immobility is 
a contributing aetiological factor in ICUAP and reduced miR-499 was associated with low 
physical activity in COPD patients (302) and models of disuse atrophy also showed loss of type 
1 fibres (104). Not only may immobility at least in part drive the shift in fibre type, but the loss 
of type 1 fibres (high endurance, slow fibres) and fibre shift towards type 2 (glycolytic, fast 
fibres) will contribute to the lack of muscle endurance and impaired muscle function. The only 
treatment interventions currently available involve increasing muscle activity (362). This 
impaired muscle phenotype may make rehabilitation more difficult for patients and therefore 
is an important aspect of the disease to address.  
4.5.3 Critique of the methods 
This study analysed a relatively small patient population in a specialist cardiothoracic 
ICU.  Given the importance of GDF-15 in cardiovascular disease, caution should be exercised in 
generalising our data to a broader ICU population.  The upper limit of normal for plasma GDF-
15 is 1200pg/ml (260). It is likely that our control patients had higher plasma GDF-15 because 
of their underlying cardiovascular disease. This is consistent with a study of more than 1000 
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cardiothoracic patients where high euroSCORE was associated with raised circulating GDF-15 
concentration (363). 
Rather than using healthy controls, our control population was selected to match the 
baseline medical co-morbidities of this ICU’s patient population allowing the effect of a 
prolonged critical illness on muscle to be examined while minimising confounding factors.  
However, the controls were not truly healthy and, due to the high-risk nature of their disease, 
were likely to have been relatively inactive and therefore potentially have some degree of 
muscle disuse. As a result, this choice of control group may have had the disadvantage of 
making it more difficult to detect a difference between them and the patients. For example, 
the patients clearly all had significant muscle disease resulting in ICUAP, but the US MLT was 
not statistically different between the two groups. This was exacerbated by the technical 
difficulties related to the ultrasounds themselves and, as with the O.C.T. mounted samples 
that had suffered ice crystal damage, the small numbers of data points available reduced the 
power of the study to detect true differences between the two groups.  
Another important factor to consider is the feeding status of these patients, since the 
original effect observed in mice with tumours which over-express GDF-15 was proposed to be 
due to suppressed appetite (267).  All of the control subjects were fasted at the time of biopsy 
(performed during surgery) while 6 out of 20 patients (30%) were fed at the time of biopsy (2 
parentrally, 4 nasogastrically). Theoretically the metabolic status of the muscle and the 
balance between catabolic and anabolic signalling may be different in those who are fed and 
those who are not. To address this concern, we reanalysed our data excluding the fed patients. 
No changes in the patterns of mRNA or microRNA expression that have been described were 
seen – except with respect to MuRF-1. When fed patients are removed from the patient cohort 
MuRF-1 becomes statistically significantly elevated (median MuRF-1 mRNA in starved patients 
1.5-fold (SD 1.1-2.3) higher than in controls p=0.01). Starvation is thought to increase catabolic 
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drive (364) and it may be that MuRF-1 expression is particularly sensitive to this. Feeding in 
critically ill patients is currently a contentious topic. There is increasing evidence that 
continuous feeding is detrimental to the ability of muscle to use amino acids from the 
circulation and it maybe that this is an aetiological factor in the development of ICUAP (40, 
365). Feeding effects cannot, of course, explain our in vitro observations. 
As discussed, hyperglycaemia is an important aetiological factor in the development of 
ICUAP and it was hypothesised that hyperglycaemia might increase GDF-15 in ICUAP patients; 
this is potentially one way in which it might drive acute muscle wasting. However better 
documented outcomes for patients with tightly controlled blood glucose levels has led to ICU 
units adopting an “intensive insulin therapy” regime to maintain blood glucose within pre-
defined levels (247). Therefore examining the relationship between blood glucose and GDF-15 
in this setting is difficult. The median, mean blood glucose over the ICU stay for the patients in 
the current study was 7.6 with an interquartile range of 7.1-8.0, indicating that glucose was 
well controlled in these patients. The total cumulative insulin dose over the ICU stay has 
previously been reported in ICU studies (40) and may reflect insulin resistance/ glucose 
metabolism. However it is difficult to know what this figure really means as it could also be 
related to length of stay on ICU. Therefore in this study we have corrected the total cumulative  
insulin dose for length of stay on ICU (i.e. total insulin received in units / ICU LOS in days).  
Cumulative insulin dose, corrected for length of stay, correlated strongly with plasma 
GDF-15, but not muscle GDF-15 mRNA expression (Figure 4-16). This might suggest that, 
although muscle GDF-15 is not under insulin regulation, GDF-15 release from other tissues is 
regulated at least in part by insulin- and glucose-dependant mechanisms. In human umbilical 
cells high glucose treatment elevated GDF-15 expression (347), but here treatment of C2C12 
myotubes with increasing glucose concentrations did not show the same effect. One of our 
collaborating groups has been examining the relationship between glucose tolerance, diabetes 
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and muscle wasting in COPD patients and this provided the opportunity to test the hypothesis 
of a link between impaired glucose tolerance/ metabolism and GDF-15. Plasma GDF-15 in 
these patients was associated with QMVC and US RFcsa as previously described by Dr Patel 
(manuscript in preparation) but there was no association with measures of hyperglycaemia 
(HbA1C), insulin resistance (HOMA2 IR) or acute change during a glucose tolerance test. 
However, when patients were categorised according to their glucose tolerance as normal, 
impaired, a new diagnosis of diabetes mellitus or an established diabetic on treatment, those 
on treatment had significantly higher plasma GDF-15 than the other groups (Kruksall-Wallis 
ANOVA p=0.037). It should be noted, however, that there were only 5 individuals in the 
treated diabetic group and it is difficult to know how to interpret these results. The ICUAP 
model in patients whose glucose is so tightly controlled does not allow for full exploration of 
the potential link between hyperglycaemia/ insulin and GDF-15. Therefore, optimisation of the 
in vitro experiments or an animal model of hyperglycemia might provide better models in 
which to examine this hypothesis.  
Myostatin was used in these experiments as a positive control. Myostatin is a well-
established negative regulator of muscle mass, signalling via the activin IIb receptor to activate 
SMAD phosphorylation and drive atrophy pathways (329). As such, in the current study 
myostatin did increase SMAD-dependant activity of the CAGA-(12)-luciferase reporter in 
transfected C2C12 cells and myostatin elevated MuRF-1 expression in cultured myotubes, 
confirming that the model behaved as expected, with the exception that the elevation in 
atrogin-1 did not reach statistical significance (Figure 4-13). Myostatin has been shown to 
induce expression of both MuRF-1 and Atrogin-1 in various models (137, 165, 329), but not 
always together. These inconsistencies can probably be accounted for by the differences in the 
models, duration and dose of treatment, and it is likely that myostatin can drive the expression 
of both ubiquitin ligases in different molecular environments (137). Myostatin itself is known 
to be under the control of various muscle microRNAs as discussed above and a reduction in 
154 
 
miRs-1, 133a and 206 has previously been described in myostatin knockout mice (298). In the 
current experiments myostatin affected microRNA expression as expected, and in the same 
pattern as GDF-15, with suppression of miRs 1, 133a, 181a and 206. However the reduction in 
miR-206 did not reach statistical significance for either GDF-15 or myostatin and miR-1 was 
only reduced significantly by GDF-15 (Figure 4-13).  
4.5.4 Conclusion 
In conclusion, this study supports a role for GDF-15 and microRNAs in the 
pathogenesis of ICUAP. Furthermore, the data support the hypothesis that GDF-15 driven 
down-regulation of muscle microRNAs would not only disrupt muscle homeostasis, but 
increase sensitivity to TGF-β signalling and thus promote muscle atrophy. In ICUAP muscle 
there was evidence of increased activity of atrophy pathways, but not of down-regulation of 
hypertrophy or regeneration. This is consistent with studies demonstrating that, following the 
initial phase of reduced protein synthesis, muscle atrophy in clinical illness is due to a more 
prolonged catabolic phase (40). From a clinical perspective this study has demonstrated 
potential therapeutic targets in both GDF-15 and muscle microRNAs. This will be discussed 
further in the final discussion of this thesis.  
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Chapter 5 An interventional study of neuromuscular electrical 
stimulation in patients at risk of acute muscle wasting on the 
cardiothoracic ICU. 
5.1 Rationale 
As discussed in the introduction, early mobilisation and rehabilitation are the only 
treatments for ICUAP that are currently available in clinical practice (80). Studies have shown 
that early mobilisation can reduce length of stay and improve ICU outcomes (366). However 
the ability to mobilise a patient on ICU can be limited by cardiovascular instability and sedation 
and therefore the time at which early mobilisation is started is often delayed until the patient 
is medically stable and awake. Neuromuscular electrical stimulation (NMES) is an appealing 
option for the treatment or prevention of acute muscle wasting on the ICU as it can be 
delivered before the patient is awake and able to cooperate and does not result in limb 
movement that might compromise the patient’s medical care. For this reason NMES has been 
included in a published guideline on rehabilitation following critical illness and the treatment 
and prevention of ICUAP (367); however, despite the strength of the evidence to support the 
intervention in healthy subjects with isolated muscle weakness (for example, following injury) 
(368) there is very little good evidence in the ICU setting (80). A recent systematic review 
identified 11 studies, only 6 of which were randomised controlled trials – three of which 
remain on-going and therefore have not yet published results (369). A total of 9 studies (3 
randomised controlled trials, 5 contralateral-control or non-randomised and 1 crossover 
design trial) were included for analysis of results. The conclusions from this and a previous 
systematic review (96) suggest that NMES in the critical care setting is safe and may be 
beneficial with respect to loss of muscle function; however, they both note heterogeneity of 
the studies included and lack of understanding as to how these results may translate into long-
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term outcomes. Furthermore, none of the completed trials in ICU patients took muscle 
biopsies or attempted to evaluate the molecular mechanisms involved in the muscle response 
to NMES.  
Therefore, the rationale of the current study was to investigate the potential of NMES 
to modulate molecular mechanisms of muscle wasting, in particular the role of myostatin, and 
potentially attenuate loss of muscle mass in elective cardiothoracic patients known to be at 
risk of ICUAP. Unfortunately, as will be apparent from the rest of this chapter, recruitment to 
the study was difficult and, as a result, the final results are significantly underpowered.  
Although the role of myostatin in ICUAP is unconfirmed, it is a potent negative 
regulator of muscle mass (329) and a member of the TGF-β superfamily known to signal via the 
SMAD proteins. Our group has previously shown that myostatin mRNA expression is negatively 
related to daily physical activity and muscle bulk in COPD patients (173). Furthermore, as 
discussed in previously, sensitivity to, and drivers of, TGF- β signalling are likely to be 
important in the development of ICUAP. Therefore, in order to complement the clinical study I 
aimed to investigate the effect of cyclic mechanical stretch on myostatin signalling in vitro.  
A true in vitro model of physical activity is difficult to produce. Muscle cells are 
designed to contract in response to electrical stimuli and muscle tissue is very sensitive to 
changes in mechanical stimuli and force. However, even at a cellular level in vivo the muscle 
architecture is made up of multinucleate mature myotubes and these exist as part of the 
greater muscle fibre; these conditions are obviously difficult to reproduce in cell culture. 
Contraction is one part of the cycle of muscle activity; however as one muscle contracts the 
counteractive muscles are passively stretched, therefore stretch is also part of the normal 
muscular activity cycle. Stretch is sensed at a cellular level by changes in the cytoskeletal 
architecture. Stretch sensors are present within the myofilament and also at the membrane-
membrane interface. The molecular response to stretch in muscle cells is not fully understood, 
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but is thought to involve activation of calcium channels in the sarcoplasmic reticulum in 
response to changes in the architectural interactions between the cytoskeletal elements (eg, 
actin:myosin, tintin and dystrophin)(370-372). Stretch of C2C12 cells in vitro has been widely 
studied and shown, amongst other things, to promote differentiation (373), increase myofibre 
size (374-376), alter myosin expression (319, 377), and prevent atrophy (378); these effects 
would potentially mimic the beneficial effects of exercise/ activity in vivo. Therefore, in these 
experiments stretch is a surrogate for activity, which, although not fully representative of an in 
vivo active muscle cell or muscle fibre, is accepted and used widely as a working model (for 
further examples (319, 377-380)).  
5.2 Hypotheses 
The above rationale led to the following main hypotheses: 
1) mRNA expression of drivers of muscle atrophy, in particular myostatin and GDF-15, 
would be reduced by NMES in elective cardiothoracic surgical patients on ICU. 
2) NMES would prevent acute muscle atrophy as measured by US RFcsa. 
3) Cyclical mechanical stretch would protect against myostatin signalling in vitro. 
5.3 Study design  
Ethical approval for this study was secured from the National Research Ethics 
Committee (10/H0722/9). As an interventional trial it was registered on clinicaltrials.gov 
(NCT01321320).  
5.3.1 Original protocol 
An interventional, double-blind, randomised controlled trial (RCT) was designed to 
examine the effect of NMES or sham-NMES on a single leg in comparison to the untreated leg 
in high-risk elective cardiothoracic patients. Following recruitment and consent patients would 
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be randomised to receive either single leg NMES or sham-NMES; which leg was treated was 
also randomised. Randomisation lists were generated by Dr Winston Banya, NHLI medical 
statistician. Randomisation was to be stratified according to euroSCORE in 2 groups: 
EuroSCORE 6-10 or > 10. The euroSCORE takes into account age, surgical risk and co-
morbidities and is known to predict ICU length of stay (311) and surgical/ peri-operative 
complications (312). This stratification aimed to balance groups according to these risk factors, 
which are suspected to increase the risk of ICUAP. This study design would allow comparison 
to both the patients’ own untreated leg and to sham-NMES (placebo), thus potentially 
identifying systemic and local effects of NMES. Figure 5-1 describes the planned study design 
and inclusion and exclusion criteria are described in Table 5-1.  
Inclusion Criteria 
Elective patients 
 Adult elective cardiothoracic patient, EuroSCORE >6, willing and able to consent 
ICU patients (added later) 
 
High-risk ICU patient, critically unwell, predicted to stay on ICU for a further week, willing and able 
to consent, or next of kin willing and able to assent 
Exclusion Criteria 
All patients  
 
Pre-existing neuromuscular disease, malignancy, only one leg, contraindication to biopsy, 
contraindication to NMES (clarified later), predicted to be anticoagulated 1 week post operatively 
(added later).  
Table 5-1 Inclusion and exclusion criteria for the interventional study of NMES.  
NMES –  neuromuscular electrical stimulation.   
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Figure 5-1 Planned study design for the interventional study of NMES in elective cardiothoracic patients.  
 
The planned protocol is described here. Patients would be identified pre-operatively 
from screening of operating lists and discussion with the surgical teams. Pre-operative/ 
baseline assessment would be carried out prior to surgery and include history, examination 
and ultrasound measurement of the rectus femoris cross sectional area (US RFcsa) as described 
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in the methods chapter of this thesis.  Patients would then be randomised to either NMES or 
sham-NMES and the leg treated also randomised. At the time of surgery, at the start of the 
operation, thus prior to any surgical insult, blood samples and bilateral surgical rectus femoris 
biopsies would be taken (as described in the methods chapter). Starting on the first post-
operative day 2x 1hr sessions of NMES were to be carried out as per the protocol described 
below. In order for the study to remain blinded, the patients would not be told which group 
they were in and the sham-NMES was designed to be felt, but not sufficient to produce muscle 
contraction. Furthermore, the treatment would be carried out by research nurses or other 
colleagues in the ICU team who would not be involved in analysis of the biopsies or 
ultrasounds. This should continue daily for 1 week. At the end of the week US RFcsa would be 
recorded again and repeat blood samples and muscle biopsies taken. Muscle biopsies were to 
be either taken by the Bergstrom technique or, if this was contraindicated, open surgical 
biopsies would be taken (see methods chapter). Patients would then be followed up until 
discharge. An intention-to-treat analysis was envisaged and un-blinding would have happened 
once samples were processed and analysed for the primary outcome.  
The primary outcome for this study was defined as a change in myostatin mRNA 
expression. (At the time of designing this study the group had not yet started to investigate 
GDF-15). Secondary outcomes included change in US RFcsa and change in markers of muscle 
synthesis and breakdown in muscle biopsy and blood samples. As such the study was powered 
to detect a difference in mRNA expression of myostatin.  
The potential change in myostatin mRNA expression level was not known; therefore, 
the sample size calculation was based on data from the group’s patients with COPD (data 
courtesy of Dr Will Man). NMES was considered as an absolute entity (i.e. active muscle with 
NMES or inactive muscle without NMES); the activity of the COPD patients was, however, a 
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spectrum. Therefore, the sample size calculation was based on the difference in myostatin 
mRNA expression in the most active COPD patients versus the least active. 
Myostatin mRNA (qPCR data courtesy of Dr Man)  
 Most active (i.e. the highest quartile of activity >90 mins/ 24 hrs) – to reflect 
the NMES legs – Myostatin 0.0006 (SD 0.0003) Arbitrary units (AU) 
 Least active (i.e. the lowest quartile of activity <40 mins/24hrs) – to reflect the 
sham and untreated legs – Myostatin 0.0021 (SD 0.0029) AU 
The number required in each group to detect a change in myostatin mRNA level in line 
with the COPD study, with power at 80% and a 5% level of significance, was 42. This 
calculation was carried out using Stata software (Stata Corporation, Texas, USA) and 
the help of Dr Jessica Harris (Medical statistician and Lecturer, NHLI, Imperial College 
London).  
5.3.2 Amendments to the protocol 
All amendments set out below were submitted to and approved by the National 
Research Ethics Committee.  
5.3.2.1 Feasibility  
In order to assess the feasibility of recruiting 84 high-risk (EuroSCORE>6) elective 
cardiothoracic patients to the study within the time frame of the PhD, the admission data for 
the main surgeon involved, Mr Mario Petrou, were reviewed. Table 5-2 shows the numbers of, 
and length of stay, for Mr Petrou’s patients for the 6 months prior to starting the PhD (April-
September 2010). A total of 53 potentially suitable patients were admitted in just 6 months 
from 1 surgeon. However, despite their high euroSCORE, length of stay on ICU was very short. 
Consequently it would not be possible to complete the study protocol during the patients’ stay 
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on ICU. This meant that, firstly, the NMES would have to continue onto HDU and the ward; and 
secondly that the second biopsies would have to be done outside of the ICU setting. Bergstrom 
biopsies are routinely carried out in outpatient settings and therefore would not pose a 
problem in the ward environment. However a significant proportion of patients following 
surgery at RBHT require anticoagulation and Bergstrom biopsy is contraindicated in such 
patients. The original protocol plan, approved by the Ethics Committee, had been to carry out 
an open biopsy on anticoagulated patients on the ICU, with the help of the surgical team. In 
view of their high euroSCORE it had been expected that these patients would still be on ICU 
(311) and, therefore, appropriate surgical equipment, conditions and analgesia with sedation 
would be available and safe. However it was not deemed feasible or ethically appropriate to 
carry out an open biopsy once the patient had been discharged from ICU as this would involve 
transfer back to theatre and further anaesthetic. Therefore, as the primary outcome measure 
of the study was dependant on muscle biopsies, patients predicted to be anticoagulated 1 
week after their operation were excluded from the study.  
EuroSCORE 
Number of 
patients 
ICU LOS Hospital LOS 
<6 64 1 (1-2) 6 (5-8) 
6-10 44 2 (1-4) 8 (6-13) 
>10 9 2 (2-3) 9 (7-11) 
Unknown 6   
Total 123   
Table 5-2 Surgical patients admitted under the care on Mr Petrou to the Royal Brompton Hospital between April 
and September 2010.  
LOS –  length of stay. Data presented as median full  days ( interquartile range).  
In summary, this feasibility study resulted in 2 changes to the protocol. Firstly, in order 
to complete the interventional week of the study, NMES would continue after the patient was 
discharged from ICU, on HDU and the wards. Secondly that those patients in whom 
anticoagulation could be predicted would no longer be recruited, as the second set of biopsies 
would now take place on the ward as necessary.  
164 
 
5.3.2.2 Pacemakers 
NMES is contraindicated in patients with permanent pacemakers. This is because of 
the theoretical risk of the NMES electrical current being registered by the pacemaker as 
cardiac electrical activity and therefore either inhibiting or disrupting the pacemaker function 
(381, 382). However, there is no documented occasion of such an interaction happening and 
certainly not any registered patient adverse events. Indeed, NMES in the outpatient setting has 
been tested for safety in patients with pacemakers and no adverse events were recorded (381, 
382).   
Following cardiac surgery a significant number of patients at the Royal Brompton 
hospital have temporary epicardial pacing wires in situ. Many of these are used to optimise 
cardiac function and protect against arrhythmia, some are for back-up pacing should the 
patient become bradycardic, and a small number are required because the patient’s own 
underlying rhythm, following surgery, is asystole or complete heart block. This last group are 
obviously completely dependent on the epicardial pacing and it was felt that putting these 
patients at even theoretical risk of an interaction between their temporary pacing and the 
NMES was unacceptable. Therefore, the protocol was adjusted as follows: Firstly any patient 
with an underlying rhythm of asystole or complete heart block would not receive NMES until 
their rhythm had changed. Secondly any patient receiving NMES with a functioning pacing box, 
even if only for back-up, would be supervised by a doctor (who was qualified and able to turn 
off the NMES if necessary) for the duration of their NMES training session. For safety reasons 
the study was suspended until these changes to the protocol were approved by the Ethics 
Committee (January to April 2011).  
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5.3.2.3 Recruitment of ICU patients.  
Unfortunately, shortly after restarting the study following the above ethical 
amendments, the lead surgeon, Mr Petrou, resigned from the Brompton (Summer 2011). This 
significantly reduced recruitment for the following reasons: inadequate numbers of patients 
with EuroSCORE>6; a high proportion of patients with mitral valve disease and atrial fibrillation 
and therefore requiring anticoagulation; and competition with other surgical consultants’ own 
studies and agenda. Recruitment was on-going in this period, but very slow. However with the 
arrival of a new high-risk aortic surgeon, Mr Rosendahl, recruitment improved (Spring 2012). 
During this time, in order to address the problems of inadequate recruitment (which 
was made even worse by the cancellation of surgical procedures during the swine-flu 
epidemic) the inclusion criteria of the study were extended to include a further group of 
patients. These were ICU patients who remained critically unwell and were predicted to be on 
the ICU for at least a further week but who were stable enough to be enrolled in the trial. It 
was felt that these patients would be likely to have already received a significant insult to their 
muscle and therefore could potentially benefit from the intervention.  
Furthermore, in view of the very slow recruitment it was decided that the sham-NMES 
arm of the trial should be dropped, thus halving the number of patients required. However by 
only using the internal control of the untrained leg the ability to examine systemic effects of 
NMES was lost. Additionally although leg randomisation was still carried out, no stratification 
by euroSCORE or ICU risk was attempted.  
5.3.2.4 Final protocol  
Figure 5-2 shows the final protocol of the study. The principle investigators were to 
remain blinded as to which leg received NMES until after the principle molecular components 
an UFcsa were analysed; however, obviously the patient was no longer blinded. Therefore the 
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final study was a single-blinded, internally-controlled interventional trial of NMES in patients at 
risk of acute muscle wasting.  
Figure 5-2 Final protocol for the interventional study of NMES in elective cardiothoracic patients and critically 
unwell ICU patients. 
 
5.4 Neuromuscular electrical stimulation  
Neuromuscular electrical stimulation (NMES) is the application of an electrical current 
over a muscle or nerve applied via skin surface electrodes. NMES aims to recruit muscle fibres 
and cause muscle contraction. As discussed, there is increasing interest in this technique as the 
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muscle contraction created could potentially have the same benefits as volitional exercise. 
However, the muscle fibre recruitment that results from NMES stimulation is different from 
that which occurs physiologically. When recruited from a motor neurone, small fibres are 
recruited first then sequential recruitment and de-recruitment across the muscle occurs to 
create a coordinated and efficient response. In the case of NMES, the recruitment depends on 
the strength and delivery of the current – thus larger closer fibres are recruited first and there 
is a sustained, but uncoordinated, response (368, 383). This can result muscle fatigue and even 
damage. Furthermore, there is no consensus from the literature as to a particular protocol of 
NMES delivery in the ICU setting and, even in other settings, a wide range of protocols are 
used (368, 369, 383). With this in mind, a study of 2 different devices at different settings was 
conducted, in 8 healthy volunteers from the muscle lab, in order to design a protocol that was 
comfortable for the patient and resulted in a coordinated contraction.  
The conclusions from this study were as follows: 
1) Skin Electrodes:  Larger skin electrodes distribute the current over a wider area 
and, therefore, are more comfortable. In this study 10x5cm reusable long-term 
electrodes were used (VS.10050 Verity Medical Ltd). Electrode position can also 
make a difference to the efficiency and quality of contraction of the stimulated 
muscle. Several positions were tried and, in line with the suggestions from the 
device manufacturers, a horizontal position across the rectus femoris muscle was 
found to be the most efficient. Figure 5-3 shows the positioning of the electrodes. 
2) Frequency: The frequency of the current (measured in Hertz - Hz) describes the 
number of pulses per second delivered. Physiological frequency is variable 
depending on the muscle, nerve and strength/ type of contraction being 
stimulated. However, physiological frequency of motor unit discharge is often 
around 30Hz (384). The frequency also affects the comfort of the sensation of 
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NMES. Lower frequencies were reported as “prickly” and higher ones “smoother”. 
A frequency of <10Hz was not sufficient to be felt, contraction could be stimulated 
at 30Hz, but higher amplitudes (see below) were tolerated at a frequency of 50Hz 
which was reported as more comfortable. This is in line with suggestions from the 
literature (384). 
3) Amplitude: The amplitude (measured in milliAmperes - mA) of the current refers 
to the intensity or strength of the current and will affect the strength of muscle 
contraction produced. Ideally a strong contraction would be produced, which was 
comfortably tolerated by the patient so that NMES could be continued for the 
necessary time (384). Figure 5-4 shows the amplitudes (at 50Hz) at which the 
current was first felt, visible coordinated contraction could be seen and the 
maximum tolerated for the healthy volunteers. In the study of healthy volunteers 
the strength of contraction generated at the maximum tolerated amplitude (at 
50Hz) was found to be only a median of 18% (interquartile range 13-25%) of the 
volitional QMVC (quadriceps maximal voluntary contraction) as measured by the 
quads chair. This is in line with what would be expected without causing pain 
(383). 
4) NMES delivery device: Two different delivery devices were tested; the Microstim 
MS2v2 (Odstock Medical,UK) and the NeuroTrac® Sports XL (Verity Medical, UK). 
The NeuroTrac® device performed better; lower amplitudes were found to give 
better contraction and the delivery of current was found to be more comfortable. 
Furthermore it was easier to programme and cheaper.  
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Figure 5-3 Position of electrodes for NMES.  
 
Figure 5-4 NMES in healthy volunteers.  
Graph shows the first  amplitude at which the current was felt,  produced a vis ible 
contraction and the maximum tolerated (all  at 50Hz).  Data is presented as median, error bars 
represent the interquartile range. N=8  
The protocol for NMES and Sham-NMES (with the aim that stimulation would be felt, 
but would not produce any functional contraction) is described in Table 5-3. A duty cycle of 6 
seconds on and 4 seconds off reflected a gentle, slow, repetitive contraction (with a 0.6 second 
ramp speed). A symmetrical rectangular wave form, with a pulse width of 330µs was chosen as 
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suggested by the manufacturer’s guidelines for the stimulation of large muscles like the 
quadriceps.  
 Frequency (Hz) Amplitude (mA) Comment 
NMES 50 >30 
Starting at 20-30mA and slowly 
increased until a good contraction 
was seen. 
Sham-NMES 10 10 
 
 
Table 5-3 Protocol for NMES and sham-NMES delivery.  
 
5.5 Results 
5.5.1 Effect of cyclic mechanical stretch on myostatin signalling in confluent C2C12 
myoblasts. 
As described in the methods chapter, C2C12 cells transfected with the SMAD driven 
p(CAGA)12–luc plasmid (and control pRL-TK) were cultured on BioFlex® plates to allow cyclic 
mechanical stretch to be applied. Cells were cultured until confluent and then transferred to 
differentiation media. 24 hours of stretch, at 6% elongation and with a duty cycle of 1.5 
seconds on and 1.5 seconds off was then applied. This was based on the literature (319) and 
experience of the group. Cells were stretched either in the presence of myostatin (20ng/ml) or 
BSA control (Bovine Serum Albumin 0.1% with 20mM HCl).  
One-way ANOVA analysis of relative normalised luciferase activity in the different 
conditions confirmed that the conditions are different (p<0.0001) and demonstrated that 
stretch reduced SMAD-dependant signalling both in the presence and absence of myostatin 
(p<0.001 and 0.016 respectively, Bonferroni corrected for multiple testing) (Figure 5-5).  
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Figure 5-5 Effect of cyclic mechanical stretch on myostatin signalling in C2C12 cells.  
p(CAGA)12– luc and pRL-TK transfected C2C12 cells were cultured on BioFlex® plates and 
at confluence were stretched for 24 hours, at 6% elongation with a duty cycle of 1.5:1.5s in the 
presence of myostatin (20ng/ml) or BSA control (Bovine Serum Albumin 0.1%  with 20mM HCl).   
Relative normalised luciferase was measured. Data are presented as mean with error bars 
representing standard deviation. ANOVA analysis confirms that the condit ions are dif ferent 
p<0.0001.  *p<0.05, ***p<0.001 with Bonferroni correction f or multiple testing (n=4 in 
tripl icate).  
5.5.2 Patients studied  
Figure 5-6 shows the consort diagram for the interventional study. After initial 
screening a total of 86 patients were formally screened. The most common reasons for 
exclusion were failure to meet the inclusion criteria; for example, 14 patients in fact did not 
have a euroSCORE of greater than 6 when it was recalculated. 17 patients met exclusion 
criteria when their history was formally reviewed; the most common reason was predicted 
anticoagulation (n=14), but also malignancy and previous neuromuscular disease. Finally a 
total of 12 patients completed the protocol, 7 elective patients and 5 ICU patients.  Their 
demographic data, co-morbidities, surgical procedure or reason for ICU admission, 
interventional and outcome data are described in Table 5-4. The most striking difference 
between the 2 groups of patients was the length of stay both on ICU and in hospital, with the 
ICU patients staying much longer. This was expected as they were already prolonged stay 
patients having been on ICU for a median of 21 days. One patient with cystic fibrosis having 
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eventually recovered from her acute illness was then referred for transplant, which she 
received and was finally discharged from hospital 173 days after admission.  
Figure 5-6 Consort diagram for the interventional study of NMES in patients at risk of acute muscle wasting on 
the cardiothoracic ICU.  
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Elective patients 
(n=7) 
ICU patients 
(n=5) 
All patients 
(n=12) 
Demographic data    
Age (yrs) 69 (64 – 73) 52 (43 – 67) 66 (51 - 71) 
Sex (m/f) 7/0 4/1 11/1 
BMI (kg/m
2
) 24.4 (23.0 – 28.3) 27.0 (26.0 – 27.7) 26 (23.0 – 28.4) 
EuroSCORE 9 (7 – 10)   
SOFA Score  9 (8 – 14)  
Co-morbidities (n)    
IHD 4 1 5 
Cardiac disease 6 1 7 
Respiratory 0 2 2 
Diabetes 1 0 1 
Statin use 4 0 4 
Type of Cardiac surgery(n)    
CABG 1   
Valve surgery 2   
Mixed 4   
Reason for ICU admission (n)    
Post cardiac Surgery  1  
Cardiac  1  
Respiratory  3  
Day on ICU of biopsy  21 (8 – 29)  
Fed at first biopsies (n) 0 2 2 
Fed at second biopsies (n) 3 4 7 
Intervention data     
NMES leg treated (r/l) 4/3 3/1* 7/4* 
Number of sessions 
completed 
10 (5 – 10.5) 11 (10.25 – 11.25) 10 (8.5 – 11) 
mAmps used (mean ± SD) 32.0 ± 10.6 40.8 ± 8.8 36.1 ± 10.7 
Outcome data    
LOS on ICU after starting 
study protocol (d) 
9 (3.5 – 15.5) 48 (32 – 54) 15.5 (8 - 44) 
Total hospital LOS (d) 15 (7 – 31.5) 70 (45.5 – 121.5) 24 (7 – 52)  
Died (n) 1 2 3 
Table 5-4 Demograpic, intervention and outcome data for patients studied in the interventional study of NMES.   
NMES- Neuromusclar electrical  stimulation, BMI –  body mass index, LOS –  length of 
stay, IHD –  ischaemic heart  disease, CABG –  coronary artery bypass graf ting. Data presented as 
median (interquart ile range) or n –  number unless otherwise stated.  * -  please note –  there are 
only 11 treated legs in total  –  please see section 5.5.3 for explanation.   
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5.5.3 Protocol compliance and adverse events.  
One patient was recruited and randomised under the original study protocol. They 
were randomised to receive Sham-NMES. Therefore this leg has been excluded as it does not 
appropriately fit into either treated or untreated groups. Therefore there are only 11 treated 
legs for 12 patients.  
NMES was well tolerated. No patients described pain or discomfort once they had got 
used to the stimulation. Patients received a median of 10 sessions (interquartile range 8.5-11) 
in total (Table 5-4). One patient received no NMES sessions at all and another patient received 
only one session as their underlying cardiac rhythm contraindicated NMES as per the study 
protocol. One patient terminated the study early as they were discharged from hospital at day 
5. Unfortunately some sessions were missed for logistical reasons. During NMES the person 
applying the NMES was asked to record the quality of muscle contraction; all patients achieved 
good contraction except one in whom no visible contractions were seen during the final 2 
sessions. During critical illness, excitability of nerve and motor units is reduced (385, 386) and 
this is reflected in the fact that ICU patients required a higher intensity current to achieve 
contraction than elective surgical patients (Table 5-4).  The results are analysed as per 
intention-to-treat as was decided in the planning of the study. 
Only one serious adverse event was reported. This was the development of a 
haematoma following surgical biopsy and wound infection superficial to the haematoma; 
However, the patient’s clinical management and outcome were not altered and the situation 
was monitored closely by the surgical and research teams. The event was down-graded to an 
adverse event at closure. No adverse events were reported in relation to the NMES itself or 
interaction with temporary pacing boxes.  
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5.5.4 Primary outcome measure: change in myostatin mRNA expression  
Mann-Whitney U tests were used for between group analyses (i.e. control versus 
NMES). Paired analysis was also conducted of the results of each leg at the two time points: 
pre- (baseline) and post- the study protocol (NMES or control) using Wilcoxon matched pairs 
ranked signed tests. This statistical design is comparable to that used by other groups (387, 
388). 
Relative to baseline, myostatin mRNA expression in the untreated control leg at the 
end of the study was median 1.03-fold (IQR 0.43-2.06). In the NMES-treated leg myostatin 
mRNA expression was 1.87-fold higher than baseline (IQR 0.65 – 2.44). This demonstrated a 
statistically significant rise in myostatin mRNA with NMES treatment, but no change over the 
week in the control leg (p=0.032 and 0.569 respectively Wilcoxon matched pairs ranked sign 
test). There was no statistical difference between the two legs at the start or end of the study 
in raw or relative values (Figure 5-7).  
5.5.5 Secondary outcome measures 
5.5.5.1 US 
Due to technical issues with RF UScsa only 7 patients had bilateral pre- and post-paired 
ultrasound (5 elective patients and 2 ICU patients). RF UScsa did not change significantly during 
the study in either control or NMES legs on paired analysis. Three NMES legs and 3 control legs 
would have been defined as “wasting” in the previous study discussed in Chapter 3 (i.e.>9.24% 
muscle loss). Only one patient’s legs behaved differently from each other: the NMES leg 
wasted, whilst the control leg actually increased in size. The median US RFcsa expressed as a 
percentage of baseline at the end of the study was 107% (IQR 63–127) for control legs and 
93% (IQR 64-104) for NMES legs, but there was no statistical difference between the two 
groups of legs (Figure 5-8) 
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Figure 5-7 mRNA expression at baseline (pre) following 1 week (post) of single leg NMES or control.  
N=12, black points represent elective cardiothoracic patients (n=7), blue –ICU patients 
(n=5).Panel A: Data presented relat ive to baseline.  Statist ical comparison to bas el ine with 
Wilcoxon’s test *p<0.05, **<0.01. GDF -15 growth dif ferentiation factor -15, IGF-1 Insul in l ike 
growth factor-1, CYR61 –  cytesine risch protein 61, MuRF-1 mucle ring f inger protein-1. Panel B: 
The same data,  but not presented as relative to base l ine (AU –  arbitrary units) .   
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Figure 5-8 Change in US RFcsa following 1 week of NMES or control. 
Ultrasound rectus femoris cross sectional  area expressed as percentage of baseline  
(upper graphs)  and as raw values ( lower graphs),  pre (baseline)  and fol lowing 1 week of  NMES or 
control.  N=7, black points represent elect ive cardiothoracic patients (n=5), blue –  ICU patients 
n=2).  
5.5.5.2 Effect of NMES on mRNA and microRNA expression 
Relative to baseline, GDF-15 mRNA expression at the end of the study was unchanged 
in the control leg (median 1.18-fold [IQR 0.57-1.94, p=0.339]), but 1.66-fold higher than 
baseline (IQR 0.80-4.71) in the NMES treated leg (p=0.042).  CYR61 mRNA expression was 
significantly elevated in both groups of legs relative to their own baseline (control median 
2.05-fold greater than baseline [IQR 0.81 – 5.49, p=0.043]; NMES 2.19 [IQR 1.2-7.07, p=0.010]), 
but there was no statistical difference between the groups. There was no significant change in 
IGF-1, atrogin or MuRF-1 mRNA expression between baseline and the end of the study and no 
difference between the two legs (Figure 5-7).  
MiRs-1,133a, 181a, 206 and 499 were measured at baseline and at the end of the 
study in both legs. There were no differences between the two legs (control or NMES at either 
time point) and, relative to their own baseline, miR-206 was the only microRNA to change 
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significantly. Relative to baseline, miR-206 was significantly elevated in the NMES legs (median 
2.39-fold [IQR 1.01-3.51] p=0.014), but was unchanged in the control legs (median 1.63-fold 
[0.81-2.14] p =0.084) (Figure 5-9). (Paired analyses – Wilcoxon matched pairs ranked signed 
tests; between group analyses Mann-Whitney U test).  
 
Figure 5-9 microRNA at baseline (pre) following 1 week (post) of single leg NMES or control.  
N=12, black points represent elective cardiothoracic patients (n=7), blue –ICU patients 
(n=5). Panel A: Data presented relative to basel ine.  Statist ical comparison to baseline with 
Wilcoxon’s test *p<0.05.Panel B: The same data, but not presented as relative to basel ine.   
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5.6 Discussion 
5.6.1 Main findings 
The in vitro portion of this study demonstrated that cyclical mechanical stretch, as a 
surrogate for physical activity, down-regulated the activity of the SMAD-2/3 driven luciferase 
reporter both in the presence and absence of myostatin (Figure 5-5). Potentially this might 
imply that activity would protect against TGF-β signalling; however, no mechanistic insight can 
really be drawn from this experiment alone. As discussed, TGF-β signalling is likely to be 
important in the development of ICUAP and from this experiment one could develop a 
hypothesis surrounding the effect of stretch/ activity on TGF-β pathways in ICUAP. However, 
rarely do in vitro experiments translate easily to clinical studies, as is demonstrated by the 
clinical component of this chapter.  
Unfortunately, the current interventional study is significantly underpowered as only 
12 out of a proposed 42 patients were recruited. The consequences of this are as follows. 
Firstly the statistically significant findings that have been detected may reflect a type 1 error 
(falsely rejecting the null hypothesis). As with all small studies the variance of the estimates of 
the parameter being measured is greater than with larger studies and therefore any effect may 
appear larger than it is. Secondly the study is underpowered to detect differences that may 
truly exist, reflecting potential type 2 error. These considerations must be taken into account 
when interpreting the results and their significance.  
The primary outcome measure for the current interventional study was a change in 
myostatin mRNA following NMES treatment in elective cardiothoracic patients. It was 
predicted/expected that the intervention would be beneficial, potentially by preventing 
muscle protein breakdown. Although it was hypothesised that myostatin mRNA expression 
would be reduced by the intervention, on the contrary, a statistically significant rise from 
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baseline was observed in the NMES treated legs, whilst myostatin mRNA remained unchanged 
in the control legs. There was no difference in expression between the two groups of legs 
(NMES treated and control) either at baseline or at the end of the study. GDF-15 is also, our 
group believes, a potential negative regulator of muscle mass and in the current study mRNA 
expression of GDF-15 was also elevated from baseline in NMES treated legs, but not in control 
legs (Figure 5-7). Both these findings would appear to indicate that NMES in the acute phase of 
critical illness, either secondary to the insult of cardiothoracic surgery or whilst critically unwell 
on ICU, may increase the expression of molecular drivers of muscle atrophy. However these 
changes were not associated with any significant change in muscle mass in either treated or 
control legs (Figure 5-8). In addition, contrary to what might be expected based on the in vitro 
study, TGF-β signalling, as measured by CYR61 expression (349), increased relative to baseline 
in the NMES legs; however, it was also increased in the control leg.   
5.6.2 Comment on Recruitment  
Recruitment for this study was disappointing. Despite major protocol amendments in 
order to reduce the number of patients required from 84 to 42 and active screening efforts by 
myself and the ICU team, recruitment targets were still not met. In fact only 19 patients in 
total were recruited and only 12 successfully completed the protocol (7 elective cardiothoracic 
and 5 ICU). The reasons for this were two-fold: firstly logistical and secondly due to the 
requirements of the trial, patients and their relatives were not keen to give consent.  
Considering logistical aspects, the study protocol was relatively intensive and required 
surgical teams to be willing and available to take biopsies and research nurses (or other 
members of the team including physiotherapists, ICU nurses, or other colleagues) to be 
available to carry out the randomised and blinded NMES.  Despite starting as scheduled in the 
PhD plan, the study was immediately suspended whilst amendments were made concerning 
the locations where the NMES would take place and the issues with pacemakers (see above). 
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Furthermore, despite the feasibility study demonstrating that over the 2 year period there 
should have been sufficient suitable patients available this was not the case; due to changes in 
surgical personnel, the number of patients with a euroSCORE greater than 6 fell significantly 
and many more were excluded due to requirements for anticoagulation.  
From a patient perspective the study protocol was also intensive, involving 4 biopsies 
and a week of single-leg NMES. Many patients felt that, in view of the fact that they were 
already undergoing a high-risk surgical procedure, this was too much to ask. Furthermore, 
relatives of critically unwell patients on ICU who were suitable for the study often felt that 
their relation had already “been through enough” and therefore did not want to expose them 
to the perceived risk of 4 biopsies and a week of NMES during their illness (which the patient 
may have felt, although it should not have been painful). This was in contrast to recruitment 
for the observational study discussed in Chapter 4, which involved a single biopsy, where 
relatives of ICUAP patients were generally happy to give assent (only 4 out of 24 who were 
approached refused). One can only speculate on the reasons for this. Perhaps one reason is 
that, because the relatives of patients with ICUAP or the patients themselves have close or 
first-hand experience of the devastating nature of the disease, they therefore understand the 
rationale behind the study. On the contrary, for elective cardiothoracic patients or relatives of 
patients in the acute phase of critical illness the rationale may not have appeared to be as 
relevant or important. Consistent with this suggestion is the fact that all those who were 
recruited to the study from the ICU already had a diagnosis of ICUAP. These patients had 
already been on ICU for a significant time, developed muscle wasting and remained critically 
unwell or had relapsed into acute critical illness; two patients were transferred into our unit 
for cardiothoracic surgery, having been critically unwell on other ICUs and had already 
developed muscle wasting and the other patients had had an acute setback (for example, a 
further bout of sepsis). On the contrary, those approached early in the ICU stay during the first 
acute phase, all declined to participate (n=5). Finally, although muscle biopsies are generally 
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very well tolerated and are often done in the outpatient setting, one can understand why 
consenting to have 4 might be daunting.  
5.6.3 Critique of the method 
As noted the current study was underpowered to detect differences between groups 
and as such no differences were detected between NMES or control legs.  Differences were 
detected between time points of the same legs (i.e. in comparison to baseline) and the pattern 
of these differences in NMES legs compared to control legs were not the same. The findings 
might be more convincing in a true NMES versus control analysis, but the risk of a type 1 error 
in an underpowered study would still exist. 
As discussed above recruitment for this study was very difficult and as a result the 
study was left with only 12 patients. Furthermore, these patients come from 2 separate 
cohorts of patients, those on ICU with established muscle wasting and elective cardiothoracic 
patients. The small numbers of the patients in each cohort do not allow a meaningful separate 
analysis of these groups, but visual inspection of the results suggests that the two groups do 
not separate obviously (Figure 5-8). Also, despite selecting elective patients with high 
euroSCOREs, 3 of the 7 patients were discharged from ICU before the end of the study 
protocol and subsequently from hospital by 1 week. Conceivably such patients might be 
expected to behave differently, in terms of muscle metabolism and effect of NMES, in 
comparison to those elective patients who remained on ICU for longer periods or the ICU 
patients. Gruther et al conducted a randomised controlled trial of NMES in acute (n=17) and 
long-term ICU patients (n=16) and demonstrated a beneficial effect from NMES only in the 
long-term patients (387). These data are consistent with the suggestion that the effect of 
NMES may differ at different time points in the clinical course of ICU and, therefore, it may be 
inappropriate to include the two heterogeneous groups of patients in the current study in the 
same analysis. 
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 A significant potential confounding factor in the current study is the lack of 
standardisation of feeding status of patients at the time of the first and second biopsies. All 
elective patients were fasted for surgery at the time of their first biopsies, but some (but not 
all) were fed at the time of the follow-up biopsy and the feeding status of the ICU patients was 
variable (Table 5-4). Biopsies were taken at a convenient time for the ICU team and this was 
often at the time of another procedure for which the patient was fasted, for example return to 
theatre or tracheostomy; thus only 2 ICU patients were actually fed at the time of biopsy.  
Recently it has become increasingly apparent that fasting status may affect the metabolic 
status of muscle in the acute phase. For example Puthucheary et al demonstrated suppressed 
protein synthesis seen in fasted controls compared to fed controls (40). The degree to which 
feeding regime might affect the development of ICUAP is currently debated, but designing a 
standardised approach to the biopsies would have potentially reduced this confounding factor. 
Other potential confounders include prior exposure to corticosteroids (n=2 in ICU patients) 
and neuromuscular blocking drugs (n=3 in ICU patients). (No patient was on neuromuscular 
blockers during the course of the study).  
A further criticism of the study is the conflicting results of the clinical study and in vitro 
experiments. Several questions arise from the in vitro experiment in terms of both the validity 
of the use of cyclic mechanical stretch as a surrogate for activity and that the SMAD-2/3 
luciferase reporter only reflects one element of a complex molecular system modulating 
muscle mass; downstream markers or drivers of TGF-β-related muscle breakdown (e.g MuRF-
1, atrogin or CYR61) or indeed myostatin itself were not measured.  The reasons for this 
include technical difficulties with the stretch machine and the wide variability in mRNA 
expression between wells and conditions found in the preliminary experiments as discussed in 
the methods chapter.  
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5.6.4 Significance of the results.  
It is of course essential to consider any results of the current study in view of the 
comments and critique above. However the data suggest that NMES may be associated with a 
rise in both myostatin and GDF-15 mRNA expression, whereas no change was seen in these 
markers over the same time period in the control legs. The significance of this is unclear as it 
was not associated with an appreciable difference in muscle size as measured by US RFcsa. 
Again, however, this must be considered in light of the underpowered nature of the study. 
NMES in ICU patients has been shown to be beneficial in terms of muscle size (387-389), 
strength (390-392), potential changes in the muscle microcirculation (393), circulating markers 
of muscle breakdown (394) and even diagnosis of ICUAP and weaning times (390). Studies 
resulting in positive outcomes in terms of muscle bulk or strength have generally been 
conducted with a longer period of NMES intervention (references (390-392)- 2 weeks, (387) – 
28 days), it may be that the intervention in the current study was not long enough to be 
beneficial. A study of similar size (n=8) to the current one also conducted over 1 week also 
failed to show a change in muscle mass as measured by ultrasound (386); the patients were 
suffering from sepsis and in fact there was a trend towards a detrimental effect of NMES with 
greater loss of muscle size in the stimulated leg compared to control (386). The current study 
did not assess muscle strength; this is unfortunate as one study demonstrated changes in 
strength in the absence of changes in bulk (391), and it is possible that NMES may have a more 
profound effect on mechanisms related to strength rather than muscle mass (96).  
The molecular effect of NMES in the ICU setting are not understood as published 
studies to date have not undertaken molecular analysis, although several are awaited (369). 
Extrapolation from other clinical scenarios and diseases may not be appropriate, as ICUAP is a 
complex disease that occurs at a time of systemic stress and therefore the metabolic status of 
the muscle is unlikely to be the same as in, for example, stable COPD or traumatic denervation. 
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Indeed, different molecular environments and stresses may be one of the reasons that in vitro 
results do not directly compare with those seen in the clinical situation. In COPD, NMES has 
been shown to be associated with a reduction in atrogin mRNA expression (395) alongside 
improvements in muscle physiology (muscle cross-sectional area and walking distance); 
however this study was over a 6 week period. Increases in oxidative enzymes, fibre cross-
sectional area and a change in fibre type proportion (although this is reported in both 
directions) have also been shown in healthy volunteers (396). Two studies of similar design to 
the current one have been conducted in patients immediately after surgery, although both 
were in patients following abdominal surgery who were not critically unwell or admitted to 
ICU. Both demonstrated a favourable effect of NMES in terms of molecular markers of muscle 
protein breakdown. Strasser et al demonstrated decreased ubiquitination of sarcolemmal 
proteins and protease activity alongside increased total RNA and sarcoplasmatic protein 
content (397) associated with NMES; however, septic patients were excluded from this study 
and muscle mass was not assessed. In 1996 Vigne et al demonstrated a preservation of 
polyribosomes in response to NMES in patients following abdominal surgery associated with 
reduced loss of muscle bulk as measured by computerised tomography (CT) (398). Both these 
studies would suggest that following the systemic insult of surgery, which may be a model for 
critical illness, NMES has a beneficial effect on muscle by suppressing muscle protein 
breakdown. However muscle damage secondary to NMES has also been documented (399, 
400) and therefore the rise in myostatin and GDF-15 seen here may reflect muscle damage in 
this cohort.  
As far as I am aware, microRNAs have not previously been investigated in either the 
field of ICUAP or in response to NMES. There are, therefore, no other data with which to 
compare the results of the current study. Only miR-206 changed significantly in either control 
or NMES legs, increasing significantly from baseline in the NMES legs, but not the control legs 
(Figure 5-9). MiR-206 is a true myomiR and is expressed only in skeletal muscle; it is involved in 
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the regulation of muscle myogenesis, but is unlikely to function alone (293, 401, 402). Muscle 
biopsies from healthy individuals following acute and short-term endurance training showed 
that many muscle microRNAs are modulated by exercise, but results are often inconsistent. 
MiRs-1, 133a and 181a were increased following one bout of moderate intensity exercise (403-
405), but only miR-1 remained elevated relative to baseline following a 10 day course of 
endurance training (403). Conversely, others have shown down-regulation of myomiRs 
following prolonged exercise (404, 406). MiR-206 was unchanged 1, 3 and 6 hours and 10 days 
post-exercise (403-405), but a reduction was seen following a 12 week course of exercise 
(404). The heterogeneity of these studies, and the current study, makes it difficult to draw 
conclusions. NMES affects molecular signalling in skeletal muscle (396) and, as microRNAs are 
an integral part of this, it is therefore probable that microRNAs will be involved in the 
modulation of the molecular signals, but this does not necessarily mean that this effect is 
independent of their role in healthy muscle homeostasis.  
5.7 Conclusion 
Systematic review of the literature would suggest that NMES is beneficial in terms of 
muscle function in critical illness (96, 369). Furthermore, early rehabilitation is now established 
as a means of preventing and treating ICUAP (80, 366). However, it is also plausible to suggest 
that the ability of muscle to respond favourably to exercise during critical illness will depend 
on at least the nutritional and inflammatory status of the patient. Consistent with this is not 
only the data from the current study, but the trend towards increased wasting seen with NMES 
in Poulsen et al’s study in septic patients (375). The current clinical trial had the potential to 
provide interesting insight into the molecular mechanisms behind ICUAP and the response of 
muscle to NMES in critical illness.  
Ideally the effect of NMES on the ICU would be assessed by a double-blind, 
randomised, placebo-controlled trial, such as was designed for the original study protocol. This 
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would allow an assessment of the effects of NMES on muscle size, strength and molecular 
mechanisms and clinical outcome. Additionally, the design would allow the systemic effects of 
NMES to be measured, for example by assessing changes in circulating markers of muscle 
turnover. Unfortunately, I was unable to recruit the required number of patients even for the 
modified version of the protocol and, as a result, the conclusions are limited. With hindsight 
one important factor that I would change would be to make an alteration in a physiological 
measure (e.g. the US RFcsa) the primary outcome as this would have allowed the biopsies to be 
an optional part of the study. Although this would have potentially limited the ability of the 
study to answer molecular questions, it may have resulted in improved patient acceptability 
and hence recruitment, fewer patients excluded due to anticoagulation and fewer concerns 
from the medical teams. Another factor which would have improved recruitment would have 
been to accept patients with a lower euroSCORE. The study in Chapter 3 demonstrated that, in 
our surgical cohort at least, euroSCORE was not related to risk of developing muscle wasting, 
thus patients with a score lower than 6 were also at risk of developing measurable muscle loss 
that may have been modified by NMES. However, as the study stands the results are difficult 
to interpret in light of the small numbers of very heterogeneous patients. 
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Chapter 6 MiR-181a: a potential biomarker of acute muscle wasting 
following cardiac surgery? 
6.1 Rationale 
As discussed, acute muscle wasting following critical illness is a common clinical 
problem (180) which is associated with significant morbidity and mortality (362). Although 25% 
of patients who are intubated and critically unwell for more than one week develop ICUAP (3) 
it is often difficult to predict which these patients will be and to confidently make the diagnosis 
prior to the patient awakening.  The ability to predict or to diagnose muscle weakness prior to 
awakening would enable clinicians to predict prognosis, direct early rehabilitation and guide 
management. Also, as drugs emerge that modify muscle metabolism (407) a predictive 
biomarker of acute muscle wasting would facilitate selection of high-risk patients and allow 
enrichment of stratified medicine trials. 
Biomarkers are naturally occurring markers of disease, which provide an objective 
measure of the presence or progression of disease. To be clinically useful a biomarker test 
should be reproducible and readily available. The test should have a high specificity and 
sensitivity for the presence of the disease and therefore high positive and negative predictive 
values. Ideally the biomarker would also detect disease development prior to the onset of 
detectable clinical symptoms; biomarkers need not be related to the mechanism of disease, 
although of course they can be.  
The potential of microRNAs as biomarkers in several disease areas is increasingly 
recognised (408). In 2008 circulating microRNAs were first reported to be reliably detectable in 
blood and could be used to distinguish between healthy controls and patients with B-cell 
lymphoma (409). The function of microRNAs in the circulation is not fully understood. They 
circulate in lipid exosomes, micro-vesicles or associated with HDL lipid particles. The secretion 
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of microRNAs from tissues is believed to be regulated and specific, as the microRNA profile 
within cells has been demonstrated to be different from the profile which is secreted by them 
(410). This has led to the hypothesis that specific profiles of circulating microRNAs may reflect 
disease processes and thus the interest in them as biomarkers. Furthermore microRNAs are 
stable in the blood and have been shown to resist multiple freeze-thaw cycles making them 
more attractive as clinically useful biomarkers (411).  Therefore, since 2008 the investigation of 
microRNAs as biomarkers has rapidly developed, covering diseases from multiple organ 
systems (412). Two important fields in this area of research are in the diagnosis and prognosis 
of acute coronary syndromes (413) and in diagnosis of both solid and haematological cancers 
(408). Techniques used to assess and identify the microRNAs in question are also developing, 
from the identification of a few specific and target microRNAs to the use of microRNA array 
screening tools where an expression pattern of several disease-specific microRNAs can be 
identified and the power of the test as a diagnostic tool improved (412). With respect to 
muscle, muscle-specific microRNAs have been postulated as potential biomarkers of 
Duchene’s muscular dystrophy (414), amyotrophic lateral sclerosis (415) and 
rhabdomyosarcoma (416). Additionally our group has shown increased circulating muscle-
specific microRNAs in the blood of COPD patients related to the degree of their muscle atrophy 
(417).  
6.2 Hypothesis 
The above rationale led to the following hypothesis: 
Changes in circulating levels of muscle-specific microRNAs (-1,-133,-206,-499) 
(289) and those involved in the regulation of muscle regeneration and inflammation 
(30b, -181a) (289) may reflect early development of acute muscle wasting in critically 
ill patients and represent potential biomarkers of ICUAP.  
190 
 
6.3 Patients studied 
This study used plasma samples from the study discussed in Chapter 3. The elective 
cardiothoracic patients provide a good model of human acute muscle wasting in the critical 
care setting in which to investigate a potential biomarker as they are a relatively homogeneous 
group. The patients were categorised according to whether they developed muscle wasting or 
not, as defined by the US RFcsa (see chapter 3 for full details).  
6.4 Results 
6.4.1 Patients 
The demographic data and clinical characteristics of this patient cohort have been 
previously published (333) and are described in Chapter 3 (Table 3-1). In brief, 42 patients 
were included in the data analysis, of whom 23 (55%) developed muscle wasting. Those who 
developed muscle wasting and those who did not were well matched in terms of age, sex, 
body mass index, co-morbidities and surgical risk (EuroSCORE)(310) at baseline, indicating that 
these factors cannot be used to predict skeletal muscle loss. The median length of ICU stay was 
1 day for non-wasting patients and 2 for those with muscle wasting (p=0.62 Mann Whitney). 
Total hospital stay was also not different between the groups. 
6.4.2 Circulating microRNAs in acute muscle wasting.  
Samples were analysed for microRNA -1, -499, -181a, -30b and -16 in plasma samples 
from the pre-operative (baseline), first and second post-operative days (D1, D2) and on day 
seven or at discharge if earlier than day seven (D7). MiRs -133a and -206 were not detectable. 
MiR-16 was quantified as a control microRNA (327). Not all time points were available for each 
patient, because samples were excluded if the PCR melt curves suggested multiple products or 
inconsistency between duplicates. Excluded samples were equally distributed between the 
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non-wasting and wasting groups (48/380 and 57/460, respectively; p=0.91, chi-squared test). 
Missing time points were excluded from any repeated measures analysis. Data were non-
parametrically distributed and are described as median values (interquartile range).  
Figure 6-1 Circulating plasma microRNA following cardiothoracic surgery.  
Relative plasma microRNA concentration in non -wasting (n=19) and wasting patients 
(those with >9.24% muscle loss:  n=23)  pre -operatively (PO), on day 1 (D1), day 2 (D2) and on day 
7 (D7).  Data presented as box and whisker plots with median, interquart ile ranges and 5-95% 
percentiles.   *p<0.05, ** p<0.01, *** p<0.001, repeated measures Freidman’s test with Dunn’s 
correction for comparison with pre-operative basel ine. # p=0.03 for comparison between groups 
with Kolmogorov-Smirnov test.   
Raw plasma concentrations of these microRNAs did not differ significantly at baseline 
or any time point between those who developed and those who did not develop muscle 
wasting. Repeated measurements were therefore expressed and analysed as relative to the 
patient’s own baseline (fold-change). 30b and 499 remained statistically unchanged both 
between and within groups over time. No direction of change could be described at any time 
point for these microRNAs (Figure 6-1). 
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6.4.2.1 MiR-181a  
Median plasma miR-181a at D2 was 2.15-fold greater (IQR 0.40-3.15) than baseline in 
those who developed muscle wasting compared to 1.02-fold (IQR 0.50-1.60) in those who did 
not (p=0.03 Kolmogorov-Smirnov test)1. ROC curve analysis for an increase in D2 miR-181a 
gave an area under the curve of 0.6. A rise in miR-181a at D2 of greater than 1.7-times baseline 
gave a specificity of 91% and sensitivity of 56% for acute muscle wasting (Figure 6-2). The 
positive predictive value of a rise in miR-181a >1.7-fold was 91% with a negative predictive 
value of 56%.2  
 
Figure 6-2 ROC curve analysis for change in circulating miR-181a of >1.7-fold following cardiothoracic surgery.  
 
6.4.2.2 MiR-1 
MiR-1 was significantly elevated at D1 compared to baseline in both those who 
developed muscle wasting (median 4.03-fold [IQR 1.65-7.84] higher) and those who did not 
(median 5.14-fold [IQR 1.31 -14.0] higher). The fold-change increase in plasma miR-1 was not 
statistically different between the two groups and MiR-1 returned to baseline by D2 in both 
groups (Figure 6-1). 
                                                          
1
 In this case a Kolmogorov-Smirnov test was used as the distribution of the data in the two 
groups was significantly different making a Mann Whitney test less reliable.  
2
 Of note – in this case the positive predictive value and specificity AND the negative predictive 
value and sensitivity are the same numerically because the number of true positives and true negatives 
are numerically the same – calculated using www.medcalc.org.   
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6.4.2.3 MiR-16  
MiR-16 was significantly reduced at D1 compared to baseline in both groups (wasting 
patients 0.71-fold [IQR 0.21-0.92], non-wasting 0.41 [IQR 0.31-0.87]). However, once again the 
fold-change reduction was not different between the groups and the levels returned to 
baseline in both groups (Figure 6-1).  
6.5 Discussion 
6.5.1 Summary of the findings 
The current study shows that changes in the circulating microRNA profile occur 
following high-risk cardiac surgery in both patients who subsequently develop muscle wasting 
and those who do not. Furthermore, a 1.7-fold increase in miR-181a at D2 was 91% specific for 
a subsequent reduction in RFCSA; however, its sensitivity and negative predictive value was less 
striking.   Obviously, as with all biomarkers, these results should be reproduced in a validation 
cohort. Ideally the validation cohort would be a larger cohort of patients from a wider clinical 
spectrum in order to truly test the hypothesis.  
6.5.2 Clinical perspective 
These data suggest that a rise in miR-181a early in ICU admission has a high specificity 
for muscle wasting at 1 week. Despite the low area under the ROC curve (0.6) of the rise in 
miR-181a (Figure 6-2), the high positive predictive value of this test (91%) would potentially 
allow it to be used to identify at-risk patients. However, due to the relatively low negative 
predictive value (56%), not all patients at risk of muscle wasting would be identified, so this 
test could not be used to exclude the development of acute muscle wasting.   
The low sensitivity might be explained in a number of ways. Firstly it is accepted that 
the pathogenesis of ICUAP is multi-factorial and, therefore, if miR-181a does in fact have a 
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mechanistic role then it may be that this marker will only capture those individuals in whom 
this particular mechanism is the main underlying factor.  Secondly, this study only measured 
microRNAs in the circulation on the first 2 days following surgery and it may be that this time 
point did not capture all individuals in whom muscle wasting would develop; it is possible that 
patients with wasting at D7 but only a small fold-change in miR-181a at D2 would have had a 
greater rise had measurements been taken over a more detailed time-course. Lastly, 
circulating microRNA levels depend on export of the microRNA from cells so other factors 
increasing cell permeability to this microRNA could contribute to the presence of miR-181a in 
the plasma, including potentially release of microRNA into the circulation following cell death.  
As a clinical biomarker of acute muscle wasting, miR-181a would be more useful if an 
absolute cut-off value rather than fold-change from baseline could be applied. As, other than 
elective surgical patients, patients rarely present to critical care prior to becoming unwell and 
therefore their baseline miR-181a level would be unknown. It may be that defining baseline 
normal ranges would be easier in a larger cohort of patients and differences between groups 
in the raw values of microRNA levels in the circulation would be easier to detect. However, the 
data from the current study demonstrated the wide range of microRNA concentrations at 
baseline with raw values varying more than 100-fold between individuals. This is in line with 
most studies in the literature where fold-change differences in relatively small numbers of 
participants are also described (412).  Also, it may be that as our understanding of microRNA 
regulation in the circulation improves, normalisation of these values, for example to body mass 
or circulating lipid levels, may become relevant and may allow a normal range be described.  
Currently there is no effective therapy for muscle atrophy beyond ensuring adequate 
nutrition and facilitating early exercise and mobilisation.  However, there is increasing interest 
in preventing muscle loss, for example, by the application of external neuromuscular electrical 
stimulation (discussed in chapter 5) or with early rehabilitation.  Similarly, new generation 
195 
 
anabolic agents are presently being evaluated in animals, for example, those targeting the 
myostatin signalling pathway (418, 419).  In developing experimental medicine studies which 
bring novel medicines to patients, it will be useful to stratify patients by the likelihood of 
developing subsequent muscle loss and circulating miR-181a could be useful for this purpose 
by reducing the number of participants needed for a proof of concept study.   
The biological role of miR-181a is not fully understood. It is expressed in many 
different tissues and is not muscle-specific. However, in muscle miR-181a is essential for 
regeneration and differentiation after tissue injury (292) and in other tissues has been shown 
to be involved in the regulation of inflammatory pathways (420, 421). Both of these pathways 
may be relevant in the response of muscle to critical illness (109). However, miR-181b is 
reduced in blood from patients on ICU with sepsis (422). Sepsis is certainly a major aetiological 
factor in the development of critical illness-related acute muscle wasting (109), but the 
patients in the current study were not septic. MiR-181 a and b are from the same family of 
microRNAs. Two separate genes hold the sequences for miRs- 181a and b together and as such 
they are almost certainly co-transcribed. However potential differences in their function are 
not fully understood (292), but miR-181a is the major member of the miR-181 family that has 
been shown to be functional in human muscle (292). 
6.5.3 Critique of the method 
In order to provide a fair evaluation of a new test it is important to avoid the scenario 
where there is a high pre-test probability of the condition one is testing for (in this case 
quadriceps loss judged by RFCSA). The current disease model studied patients with brief ICU 
stays and an uncomplicated post-operative course. Nevertheless, approximately 50% of 
patients developed muscle wasting by the seventh postoperative day, suggesting that the 
model is suitable for evaluating the test. While this model of acute muscle wasting following 
cardiac surgery made it possible to control for many of the other factors that occur in the 
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critically ill, and thus investigate a disease marker which is specific to muscle wasting, it 
remains to be seen whether these results are “generalisable” to a wider ICU population. It is 
also important to note that the observed muscle wasting could be classified as “sub-clinical”. 
No patients developed weakness consistent with a diagnosis of ICUAP; in fact, almost all had 
an MRC-SS of 60 at day 7. Therefore, it is possible that larger changes in circulating microRNAs 
may have been seen in a sicker group of patients developing true ICUAP, which might have 
made between group differences easier to detect.  
MiR-16 was measured in this study as a control microRNA. It is widely expressed and in 
plasma has previously been used to demonstrate that findings in other, more specific 
microRNAs do not result from general changes in microRNA levels (327, 417). However miR-16 
has recently been shown to be elevated in the plasma of septic patients and is increasingly 
implicated in disease processes (423). Importantly, significant haemolysis of blood samples 
also increased circulating miR-16 (424). However the data from the current study show a 
reduction in miR-16 in both groups of patients. These patients were not septic, but all did 
experience an inflammatory insult as evidenced by a significant rise in CRP in both groups 
peaking at day 2.  Differences between inflammation secondary to infection (sepsis) and 
inflammation without infection are increasingly being recognised (423) and the current data 
support this.  In the current study, miR-16 levels in plasma changed significantly, implying that 
it is not an appropriate “reference” microRNA in these circumstances. Both groups showed an 
acute increase in miR-1 at D1 recovering to baseline on D2 after surgery; this may have been 
because, as well as being highly expressed in skeletal muscle (which will have been damaged 
by the surgical incisions), miR-1 is also expressed in cardiac muscle and all patients underwent 
cardiac surgery (413). However miR-499 is also present in cardiac muscle and might therefore 
also be expected to increase in the same way. Plasma miR-1 was elevated acutely following 
myocardial damage in acute coronary syndromes in several different clinical studies (413) and 
was predictive of outcome (425).  
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A potential problem of this study is that some patients received fresh frozen plasma 
(FFP) in their peri-operative course (11/23 wasting patients and 8/19 non-wasting on the day 
of surgery or the first post-operative day). The quantified microRNAs have all been measured 
in plasma over this time period and it is difficult to know how the donor plasma may have 
affected the results. FFP is known to be hyperglycaemic and hyperosmotic (426) but, because 
microRNA are a relatively new field of interest, it is not known if they might concentrate in FFP 
or if they are removed during processing and storage. The maximum volume received was 1L 
in a 24 hour period which conceivably could dilute the patient’s own plasma. Clinically, it is 
standard practice to measure factors in a patient’s blood (e.g., creatinine or sodium) without 
considering the diluting volume, or donor content, of any transfusion therapy (except of 
course its therapeutic content) and one could argue that, even if these factors were coming 
from the donor, the patient’s exposure to those factors is still relevant. Additionally, one 
would expect donor levels to be “normal” and therefore dilute any changes detected. 
Importantly, however, equal numbers of patients in both groups received FFP (chi-squared 
p=0.14).  
Lastly, although these microRNAs were chosen because of their roles in muscle 
homeostasis it is not known how the observed changes in plasma level of these microRNAs 
reflect the relative expression or function of these microRNAs in the patients’ muscle and 
caution is therefore required in drawing mechanistic interpretations. MicroRNAs circulate in 
the blood in exosomes or bound to protein and HDL. The regulation, specificity and secretion 
of microRNA into the circulation is not fully understood (413). In COPD, specific microRNAs 
have opposite changes in muscle and plasma; for example, miR-1 was reduced in the muscle of 
patients with COPD and reflected muscle wasting whereas it was increased in plasma of the 
same patients(302, 417). If this were true of the patients in the current study (i.e. the rise in 
miRs-1 and 181a in the plasma reflected a fall in the microRNA level in the muscle) it would be 
consistent with the findings in ICUAP muscle discussed in Chapter 4.  
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6.6 Conclusion 
In conclusion, this study evaluated the potential role of selected microRNAs for the 
prediction of subsequent muscle loss in patients undergoing high-risk cardiac surgery. It 
demonstrated that elevation of miR-181a is a highly specific marker of quadriceps wasting in 
these patients. However, as with all biomarkers, before miR-181a can be accepted as a 
potential biomarker of acute muscle wasting, it needs to be tested in a larger validation cohort 
including a wider range of ICU patients.  
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Chapter 7 General Discussion  
7.1 Summary of main findings 
The principle aim of the work in this thesis was to investigate the molecular 
mechanisms of ICUAP with a view to identifying potential therapeutic targets. GDF-15 was 
identified as a candidate to investigate and results from studies in two clinical models of 
muscle wasting in the critically ill have demonstrated that GDF-15 may at least in part drive the 
pathology of ICUAP. Firstly, in a novel human model of muscle wasting in the critical care 
setting, GDF-15 was elevated in the plasma of patients following cardio-thoracic surgery. This 
elevation was sustained at one week in those who developed muscle wasting, but returned to 
baseline in those who did not (Figure 3-4). These results were in contrast to the pattern of 
change in myostatin concentration, which unexpectedly fell acutely and returned to baseline in 
all patients (Figure 3-2). IGF-1 also fell, however in those who developed muscle wasting, IGF-1 
plasma concentration did not return to baseline, but did in those who did not lose muscle bulk 
(Figure 3-3). Together these data suggest a dynamic imbalance in the circulating drivers of 
muscle homeostasis favouring muscle atrophy in those who develop muscle wasting acutely in 
the critical care setting. Furthermore these data support the current understanding in that 
GDF-15 is elevated by critical illness (279, 363) and support the hypothesis that GDF-15 may be 
important in the pathology of ICUAP.  
In the second clinical model, plasma GDF-15 and muscle GDF-15 mRNA were elevated 
in patients with established ICUAP when compared to controls (Figure 4-6). This observation 
again supports the hypothesis that GDF-15 may be important in the pathogenesis of ICUAP. 
Furthermore, plasma GDF-15 correlated significantly with the patient’s SOFA score, consistent 
with the suggestion that GDF-15 elevation is driven by critical illness. In vitro investigations 
confirmed that GDF-15 treatment could drive an increase in muscle atrophy related genes 
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atrogin and MuRF-1 in cultured myotubes (Figure 4-13)); significantly higher atrogin mRNA was 
also found in the muscle of patients with ICUAP compared to controls (Figure 4-7). 
The mechanism of action of GDF-15 is not yet understood, and activation of the SMAD 
dependant luciferase assay (which was expected as GDF-15 is a member of the TGF-β family 
(427)) was not demonstrated.  Muscle microRNAs are essential for muscle homeostasis and 
regulate many essential molecular pathways (288), dysregulation of microRNAs results in 
disordered growth and differentiation of muscle tissue and it was hypothesised that muscle 
microRNAs in patients with ICUAP would be different from controls. Significantly lower muscle 
microRNAs, miRs-1, -133a, -181a and -499, were found in the muscle of patients with ICUAP 
compared to controls (Figure 4-9). Levels of these muscle microRNAs significantly negatively 
correlated with both plasma GDF-15 concentration and muscle GDF-15 mRNA expression. 
These data suggested that GDF-15 might drive the suppression of essential microRNAs that 
was demonstrated in the muscle of ICUAP patients and consistent with this suggestion GDF-15 
treatment of cultured myotubes in vitro resulted in a reduction in miRs 1, 133a and 181a (but 
not miR-499, which is already at a very low level in these cells and therefore further reduction 
may be difficult to produce) (Figure 4-13). 
One action of the muscle microRNAs analysed that is thought to be important in their 
role as regulators/ coordinators of pathways of homeostasis is protection against TGF-β 
signalling (343). By targeting and down-regulating components of the TGF-β signalling 
pathway, a number of microRNAs have been shown to reduce the response of some cell lines 
to TGF-β (290, 343-346).  Consistent with this mechanism, transfection of miR-181a into 
myoblasts significantly reduced TGF-β activation of the SMAD-dependant luciferase reporter 
(Figure 4-15). In vivo, a suppression of muscle microRNAs would potentially lead to increased 
sensitivity to TGF-β signalling, thus potentially augmenting, for example, myostatin driven 
muscle atrophy. Therefore it was hypothesised that one mechanism by which GDF-15 may 
drive muscle atrophy in ICUAP could be by increasing sensitivity to TGF-β signalling, via 
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suppression of muscle microRNAs. Supporting this hypothesis, higher CYR-61 mRNA expression 
and higher nuclear SMAD positivity was demonstrated in the muscle of patients with ICUAP 
compared to controls (Figure 4-11).  However, attempts to demonstrate elevation of TGF-β 
receptor proteins types 1 and 2 concentration (potential targets of these muscle microRNAs) 
both in response to GDF-15 treatment in vitro and in ICUAP muscle were unsuccessful.  Figure 
7-1 summaries the mechanism of action of GDF-15 in ICUAP proposed as a consequence of the 
work in this thesis.  
 
Figure 7-1 Schematic representation of the possible role of Growth and Differentiation Factor-15 (GDF-15) in the 
development of intensive care unit acquired paresis.   
In normal muscle homeostasis muscle microRNAs (miRs 1, 133a, 181a and 499)  target 
and down-regulate elements of the TGF-β  s ignall ing pathway. However driven by crit ical i l lness 
GDF-15 supresses muscle microRNAs and may result  in a relative increase in elements of the 
TGF-β  signal ling pathway and increased sensit ivity to TGF-β  l igands. This could result in 
increased TGF-β  s ignall ing and TGF-β  dr iven muscle atrophy.  
Unfortunately, it is difficult to draw conclusions from the interventional study of NMES 
in ICU patients that was carried out as part of this thesis. As discussed in Chapter 5, this study 
was significantly underpowered and the results are therefore difficult to interpret and should 
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be taken in light of this limitation. The study demonstrated an increase in muscle expression of 
myostatin and GDF-15 mRNA in NMES treated legs compared to their own baseline, but no 
change in control legs (Figure 5-7). Although it is believed that NMES will have beneficial 
effects in terms of preservation of muscle function in the ICU setting (96) it is also recognised 
to have potential to cause muscle damage. In the setting of sedated patients who cannot 
report pain or those in whom the nutritional and metabolic status of the muscle may be 
expected to be poor, researchers should be aware that NMES may promote muscle 
breakdown.  
Finally, a rise in circulating miR-181a at day 2 post cardiothoracic surgery represented 
a potential biomarker of acute muscle wasting (Figure 6-1). However these data need to be 
reproduced in a larger validation cohort of patients.  
7.2 General limitations  
Although the results of this work support the hypothesis that GDF-15 is important in 
the pathogenesis of ICUAP and provide evidence to suggest a potential mechanism, it is 
important to note that neither the in vitro work nor the clinical study can be interpreted as a 
definitive proof.  The critique of the methods used has been discussed in each chapter, but 
general limitations of this work should be highlighted here to balance the above summary of 
findings. Firstly, the clinical studies (and in particular the interventional study) are limited by 
the relatively small number of participants. Furthermore, these studies were carried out in a 
specialist cardiothoracic ICU, and although this has the advantage of reducing patient 
heterogeneity, it may mean that the results do not represent a mechanism that is relevant to a 
wider, more general, ICU population.  
The results of in vitro studies do not always represent what is seen when the 
hypothesis is tested in the clinical setting; this is a recognised limitation of translational 
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experiments. Although the in vitro results from this thesis have generally supported the 
hypotheses generated from the clinical/ in vivo data, there are some important limitations. 
Particularly, that although it is not possible to directly compare the use of recombinant GDF-15 
protein in the in vitro environment with the true molecular environment within muscle cells or 
tissue, the dose of GDF-15 (50mg/dl) used in the cell culture experiments is significantly higher 
than the range seen in human plasma. As discussed in Chapter 4 attempts to demonstrate the 
effect of GDF-15 on protein targets (TGFBR1 and 2) were unsuccessful. This may be due to 
experimental design (time course etc…) and/or the fact that there are many potentially 
relevant targets within the TGF-β signalling system and an overall effect on the pathway may 
be responsible for the increased sensitivity rather than any particular single protein. 
Alternatively, of course the hypothesis may also be incorrect. In vitro GDF-15 treatment did 
not increase CYR-61 mRNA expression; this could be interpreted as not supporting the 
hypothesis that GDF-15 drives an increase in sensitivity to TGF-β signalling. In addition cyclic 
mechanical stretch of differentiating myoblasts caused a reduction in SMAD signalling, 
whereas (albeit in a significantly underpowered study) increased activity via NMES on ICU 
resulted in a possible increase in the expression of drivers of muscle atrophy. These 
inconsistencies further demonstrate the limitation of the in vitro experiments. The in vitro 
environment used in cell culture was designed to stimulate cell growth and differentiation (as 
is standard).  It therefore contained a number of growth factors and similar regulators at 
concentrations that cells are not normally exposed to in vivo (e.g. Platelet derived growth 
factor). This did not reflect a stressed system reflective of critical illness. The concentration of 
TGF-β ligands in the cell culture media is not known and, if low, may not have been adequate 
to stimulate any TGF-β signalling. Finally the differentiation state of the myotubes is also very 
different from that of the developed myofibre in a mature muscle and therefore may also 
contribute to any differences in the response of the two systems. The response of muscle 
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tissue to stimuli (GDF-15 or stretch/ activity) in different molecular environments is likely to be 
different.  
7.3 Future directions.  
In order to define the mechanism of action of GDF-15-driven muscle atrophy and truly 
support our hypothesis, future in vitro experiments should aim to determine each step in the 
molecular pathway. For example, if GDF-15 drives myotube atrophy (as demonstrated by Dr 
Jen Lee in our group (333)) via suppression of muscle microRNAs, can this effect be blocked or 
even reversed by the transfection of exogenous microRNAs? In addition, future in vitro work 
should include attempts to identify the GDF-15 receptor(s) and the pathways involved in the 
regulation of microRNAs. Furthermore, in order to begin to address the problem of reflecting 
the physiological environment of muscle cells during the development of ICUAP, future 
experiments could combine GDF-15 treatment with the addition of inflammatory mediators 
and TGF-β ligands. Alternatively, a further potential in vitro experiment could include the 
exposure of cultured myotubes to plasma from ICUAP patients with and without the addition 
of neutralising GDF-15 antibodies and those to other components of the TGF-β signalling 
pathway; this could potentially examine the relationship between circulating factors and their 
effect on, for example, microRNA expression within the cells. However these experiments are 
difficult to adequately control as they rely on the use of mixed pools of plasma from several 
subjects and thus are likely to have many unquantifiable confounders (187).  
The definitive experiment to prove the role of GDF-15 in the pathogenesis of ICUAP 
would be a randomised controlled trial of a GDF-15 antagonist in patients at risk of developing 
ICUAP. A first step towards such a trial might be a trial of such an anti-GDF-15 treatment in an 
animal model of ICUAP. Although a perfect animal model of ICUAP does not exist, various 
models have been used that combine critical illness with prolonged immobility and ventilation 
(for example (106, 113)) and might be suitable. GDF-15 blockade would demonstrate if GDF-15 
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is truly important in the aetiology of ICUAP and enable further examination of the potential 
pathways involved.  
Future therapeutic options which should be explored include antibodies against GDF-
15 and microRNA mimics; these options are discussed below.  
7.4 Implications for the treatment of ICUAP 
ICUAP is a potentially devastating consequence of critical illness for which there is 
currently no pharmacological treatment and management relies only on limitation of the 
physiological insult and active rehabilitation (74). The aim of this thesis was to better 
understand the molecular mechanisms of this disease as this is the key to identifying potential 
therapeutic targets and improving outcomes in the long run. Within the limitations discussed 
throughout, this work has been able to identify and mechanistically justify both GDF-15 and 
microRNAs as potential therapeutic targets. Many molecular pathways are described in 
disease. However it is rare to be able to identify a potential target and realistically envisage the 
method/ treatment with which to manipulate it. These targets may have significant 
implications in the future for the treatment of ICUAP and both anti-GDF-15 antibodies and 
means of delivering microRNA mimics already exist. 
 To date, anti-GDF-15 antibodies have not been trialled in humans. However when 
given to mice GDF-15 anti-bodies can reverse cachexia induced by GDF-15 expressing tumours 
(267) and at least one human anti-GDF-15 antibody is underdevelopment. AV-380, developed 
by AVEO oncology, is a new human anti-GDF-15 antibody (www.aveooncology.com). This 
company has developed the drug with a view to treatment of cancer-related cachexia, a 
condition in which plasma GDF-15 is significantly elevated and which is associated with poor 
prognosis (267, 280, 428). Pre-clinical results in mice have suggested that GDF-15 drives 
cancer-related cachexia (280, 429) and that treatment with AV-380 can reverse weight loss 
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and muscle weakness, restoring normal body composition (data presented at the 2nd Cachexia 
Conference, Montreal September 2014 by AVEO oncology). AVEO oncology plan to start first-
in-man studies in the second half of 2015.  
MicroRNA research is a rapidly expanding and developing field. As the understanding 
of the role of microRNA in the pathogenesis of disease increases so does the interest in their 
therapeutic potential. Manipulation of microRNA levels in vivo may involve the suppression of 
an overactive/over-expressed microRNA or the delivery and replacement of a suppressed 
microRNA. An antagomir is the complementary sequence of nucleotides to the target 
microRNA and functions by binding and inactivating the target microRNA (430). In addition, 
over-expression (by transfection into cells) of non-functional genes with multiple binding sites 
for the target microRNA, known as “miR sponges” also act to suppress microRNA activity (431). 
MicroRNA mimics are double-stranded nucleotides, one strand of which represents the 
mature target microRNA. The double-stranded nucleotide is processed in the same way as an 
endogenous hairpin pre-microRNA and thus results in increased concentration of the target 
microRNA (430, 431).  It is important to note that the complementary strand of the miR-
sequence may also be functional and may have divergent effects from the target microRNA. 
MicroRNAs may also be replaced using adenoviral vectors over-expressing the target 
microRNA (430).  
Much of the work so far has been in the field of oncology and the manipulation of both 
oncogenes and tumour suppressor genes using various microRNA targets shows potential for 
the future treatment of cancer (430-432). For example, Let-7 and miR-34 are both tumour 
suppressor genes which are down regulated in lung cancer (432). MicroRNA mimics for both 
have been successfully shown to slow tumour growth and progression in murine models (433-
435).  MRX34, a miR-34 mimic, is the first microRNA mimic based drug to reach human trials 
(Mirna Theraputics, www.mirnarx.com). miR-34 down-regulation is found in several cancers 
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including, lung, liver, haematological malignancy and cervical cancer (432). An ongoing phase 1 
trial in liver and haematological cancer is due to report in 2015. A further example of early 
human studies of microRNA therapy is Miravirsen (Santaris Pharma, www.santaris.com), an 
antagomir to miR-122 which has recently completed phase 2 clinical trials for the treatment of 
Hepatitis C infection (436). The HCV virus uses host miR-122 to enable viral replication and 
therefore, by targeting liver-specific miR-122 Miravirsen inhibits viral replication. Thus far no 
adverse effects have been reported, making microRNA-targeted therapy a viable potential 
therapy for the future (436).  
The potential of microRNA therapy is limited by the complexity of the microRNA 
network and the potential for unwanted side effects due to the multiple targets of any 
individual microRNA. Therefore, the in vivo method of delivery should be carefully developed 
to address this. To date, several methods of microRNA mimic or antagomir delivery have been 
trialled, as alone the oligonucleotides are rapidly degraded and cleared and have poor tissue 
specificity or uptake (430). Mimics may be combined with liposome nanoparticles (437), 
polyethyleneimine (438) or atelocollagen (439) and these may be injected intravenously or 
directly into the specific tissue (for example, work to date has involved intra-tumour injection). 
SMARTPARTICLES® (Marina Biotech, www.marinabio.com) for example are the liposome 
particles used to deliver MRX34. However, these particles may be immunogenic, poorly tissue-
specific and can be cytotoxic (430-432). Adenoviruses can be manipulated to have tissue-
specific promoters (thus improving tissue specificity), they can be delivered intra-nasally or 
systemically and their use was effective in the delivery of miR-26a for the treatment of 
hepatocellular carcinoma in a mouse model (440) and miR-196a in the treatment of spinal and 
bulbar muscular atrophy (441). Importantly, adenoviral vectors have been used for some time 
to deliver other genetic therapies and generally are well tolerated and have a good safety 
profile; however they are expensive and difficult to construct (430, 431). Delivery and function 
of antagomirs may be enhanced by cholesterol conjugation, modification of the phosphate 
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backbone and/or the use of LNA (locked nucleic acids – which are chemically inaccessible 
RNAs) (430, 431). Mivirsen, for example, is composed of a combination of LNA and phosphate 
backbone modified DNA (436). Cellular uptake and distribution are poorly understood.  
In muscle disease, sadly, trials of such treatments have not even reached the pre-
clinical phases, but targeting muscle microRNA expression and activity has demonstrated that 
muscle metabolism and development can be manipulated in vitro and in vivo. For example 
over-expression of the muscle-specific microRNAs can reverse the negative effects seen by 
their knock down in vitro; over expression of miR-1 and 133a can protect against TNFα-induced 
impaired muscle differentiation in vitro (301); forced mir-499 over-expression in knockout 
mice models restore their type 1 fibres and they have better muscle endurance than wild type 
mice (291); and electroporation of miR-486 into the quadriceps of mice with chronic kidney 
disease prevented the development of muscle wasting associated with chronic disease (442).   
Potentially, a combination of muscle microRNAs delivered systemically, but targeting 
muscle tissue, might protect against muscle damage and promote regeneration and recovery 
in critically unwell patients. Many muscle microRNAs are muscle specific (myomiRs) and 
therefore this approach may not be as limited by systemic side effects as other potential 
microRNA targeting therapies.  However it should be remembered that just because the 
microRNA is not expressed in a tissue, targets of that microRNA may well be present and 
therefore systemic delivery of tissue-specific microRNAs may not be side effect free. 
 Despite the rapid recent advances in this field, we are still a long way away from the 
first pharmacological treatment for ICUAP, which therefore remains a potentially devastating 
complication of critical illness. However, the work from this thesis identifies both GDF-15 and 
microRNAs as potential targets that warrant further investigation in the future.  
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Appendix A2 – MicroRNA Array Results 
Differentiating myoblasts - 6 hour microRNA Array results  
Significant hits from the microRNA Array of treatment of differentiating C2C12 
myotblasts with GDF-15 and myostatin for 6 hours. (See Chapter 4 for more details). 
 
GDF-15 (50ng/ml) Myostatin (20ng/ml) 
Gene Ratio p val diff Gene Ratio p val diff 
Arpc1b 1.46357 0.000178 Smarcd3 0.760198 0.004177 
Tsc22d1 1.282381 0.000729 Ch25h 1.383599 0.004441 
Mmp15 0.778498 0.001069 Ctgf * 1.308946 0.022152 
Adamts4 0.804531 0.002023 Fus 1.503563 0.022152 
Eif4ebp2 * 0.782102 0.002023 Yrdc 1.350923 0.028957 
Lig3 0.802163 0.004549 Myh1 0.720727 0.044779 
Bicd2 0.814289 0.005154    
Ch25h 1.312247 0.005405    
Nedd9 0.816245 0.005405    
Osbpl2 0.813058 0.00692    
Pls3 0.819058 0.00692    
Dtx4 0.781917 0.023557    
Id2 * 1.368282 0.026093    
Mcf2l 1.210003 0.027656    
Slc38a2 0.736603 0.027698    
Twist2 1.262217 0.035958    
Tpcn1 0.836711 0.040962    
 
Table A-1 Significant hits from differentiating myoblasts - 6 hour microRNA Array results.  
Ratio compared to control  and p val diff  = p value of the difference between treatment 
and control.  * see below 
* potential genes of interest.  
Eif4ebp2 Negative regulator of translation 
Id2  Inhibitor of differentiation  
CTGF  TGF-β responsive gene 
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Differentiating myoblasts - 24 hour microRNA Array results  
 Significant hits from the microArray of treatment of differentiating C2C12 myotblasts 
with myostatin for 24 hours. (See Chapter 4 for more details). 
Gene Ratio P val diff 
Hes6 * 0.67077 1.93E-09 
Ddx58 0.68241 2.04E-07 
Edg5 1.505408 2.04E-07 
Mtap7d1 1.486597 2.04E-07 
Mcm6 0.694128 6.39E-07 
Cdca8 0.68199 1.13E-06 
Gyg 0.713219 1.13E-06 
Suclg1 0.641688 1.13E-06 
Nol5a 0.653888 1.38E-06 
Cybasc3 1.43205 3.30E-06 
Ywhaq 1.454017 3.30E-06 
Eef2 0.6418 4.63E-06 
Ankrd1 0.67338 6.45E-06 
Nipsnap3a 0.658705 7.98E-06 
1110038F14Rik 1.455819 9.08E-06 
2500002L14Rik 0.725426 1.55E-05 
Ndufs2 0.701354 1.62E-05 
4933426M11Rik 1.451476 2.34E-05 
LOC100044862 1.390789 2.34E-05 
Tsc22d1 0.552042 2.57E-05 
Cct3 0.679166 2.62E-05 
Tmem63a 1.384494 2.93E-05 
BC038286 1.376224 4.73E-05 
Surf2 0.750129 5.76E-05 
Ppp3ca 1.369708 6.35E-05 
Dap3 0.701214 7.69E-05 
2700062C07Rik 0.753319 8.18E-05 
Acaa2 1.467964 0.000157 
Chrnd 0.73235 0.000174 
Mxra8 0.718393 0.000175 
St3gal4 1.361602 0.000205 
Srm 0.730111 0.000237 
Oprs1 0.748927 0.000249 
Polr2d 0.709624 0.000256 
Slc12a3 1.342407 0.000264 
Atp5j 0.76499 0.000281 
Tef 1.733794 0.000281 
Srpx2 0.737354 0.000298 
Gpr108 0.763175 0.000487 
Lrrfip1 1.38352 0.000505 
Phf13 1.34181 0.000548 
Iap 1.332438 0.000609 
Kdelc1 1.328012 0.000609 
1110059P08Rik 1.362805 0.000699 
Gnas 0.708594 0.000799 
Stx8 0.698921 0.000873 
Ddb1 1.509062 0.000906 
Mlf2 0.702553 0.000906 
3000004C01Rik 0.775027 0.000909 
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Birc5 0.599834 0.00102 
Fblim1 1.314092 0.00105 
Rem1 1.33028 0.001129 
Pitpnm1 1.37564 0.001142 
Gmppa 0.73778 0.001253 
Tssc1 0.739146 0.001253 
Dnajb6 1.391504 0.00128 
Atg2a 1.417639 0.001328 
Ppp2r4 1.40567 0.001328 
Eef1e1 0.711894 0.001336 
Wipf2 1.432789 0.001417 
Gtf3a 0.753687 0.001541 
Arl2bp 0.728577 0.001778 
Ccng1 1.407205 0.001912 
Trpc4ap 0.773971 0.001912 
Golga2 1.429314 0.001925 
Ing4 1.461826 0.001925 
Islr 1.50628 0.001925 
P4ha1 1.306324 0.002001 
Tmem85 0.784032 0.00201 
Gpx1 0.780481 0.002145 
BC085271 0.787181 0.002178 
Cacnb1 1.320822 0.002178 
Crebl1 1.304464 0.002178 
Ltbp3 0.697225 0.002178 
Rsn 1.325749 0.002178 
Myg1 0.775934 0.002263 
Nudt5 0.787838 0.002263 
Prnpip1 0.760466 0.002263 
2610019P18Rik 1.301281 0.002315 
2500003M10Rik 1.383181 0.002526 
Nudc 0.784613 0.002526 
Ptrh2 1.330816 0.002526 
B020018G12Rik 1.295865 0.00254 
Polr2d 0.749141 0.002728 
Itgb1 1.522977 0.002835 
Raly 0.769651 0.002835 
Eif4a1 0.790795 0.002858 
Oas2 0.631732 0.002916 
Adh5 0.721364 0.003054 
LOC667609 0.784123 0.003054 
Rnpc2 1.310011 0.003054 
Klhl21 1.361333 0.003054 
Cyb5r3 1.499971 0.003238 
Flii 1.307213 0.003238 
Rpl24 0.790436 0.003238 
Eftud2 1.296555 0.003401 
Fkbp2 0.792577 0.003401 
EG433923 0.716714 0.003401 
Rab24 0.755606 0.003448 
Isca1 0.793662 0.003457 
Nat5 0.780506 0.003457 
Polr2d 0.769001 0.003457 
Actn3 0.787796 0.003517 
Stx12 1.280777 0.003761 
Tpm3 0.663675 0.004766 
Spc25 0.796372 0.00508 
Ankrd1 1.285208 0.005151 
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Egln2 1.35971 0.005798 
Med10 0.753269 0.005864 
Polr2e 0.800055 0.005904 
Hes6 0.754804 0.005946 
Mrpl43 0.753826 0.006039 
Plscr2 1.302347 0.006363 
Ibtk 1.281455 0.006556 
Nt5c3l 0.768689 0.007036 
Sumo3 0.791385 0.007725 
Nsdhl 0.591592 0.008154 
Bcap29 0.771979 0.008941 
Pmp22 0.65942 0.008941 
Pmm2 0.715132 0.009022 
LOC100047856 1.55964 0.009096 
Ric8b 1.396726 0.009096 
Sharpin 1.264366 0.009096 
Tipin 0.754773 0.009096 
Apip 0.77211 0.009343 
Prr3 1.322145 0.009343 
Stat2 0.803049 0.009467 
Calm3 1.268908 0.009971 
Golga7 0.74175 0.009971 
Table 8-2 Significant hits from differentiating myoblasts treated with myostatin - 24 hour microRNA Array results.  
Ratio compared to control  and p val diff  = p value of the difference between treatment 
and control.  There were no significant hits for GDF -15 treatment.* see below.  
*potential genes of interest 
HES6  Transcription factor involved in the regulation of differentiation.  
 
4 day GDF-15 treatment of differentiated myotubes – microRNA Array results. 
Significant hits from the microRNA Array of 4 day treatment of differentiated 
myotubes with GDF-15. (See Chapter 4 for more details). 
Gene Ratio p value diff 
Dhcr24 1.41646 2.96E-06 
Slc2a6 1.277148 2.96E-06 
Cyr61 * 0.774207 1.93E-05 
AI837181 1.45115 0.000221 
Slc30a6 0.794853 0.000221 
Suox 1.237391 0.000372 
Trim54 1.240558 0.000372 
Cav1 0.808125 0.000379 
Glt8d3 1.387861 0.000484 
Gpr176 0.711665 0.000604 
Igf2* 0.792035 0.000779 
Ccl25 1.277468 0.001198 
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Tspan32 1.240218 0.001198 
Itga3 0.77767 0.001777 
Tnni1 1.392912 0.002812 
Myh8 0.825201 0.003422 
Rtkn 1.213962 0.004767 
Uba1* 1.216063 0.004845 
8030451F13Rik 0.80211 0.008073 
Acta2 0.836448 0.010137 
Xist 0.809834 0.010137 
Cbr1 1.203184 0.010552 
Cox7a2 0.78909 0.010552 
Nqo2 1.191264 0.010552 
9130005N14Rik 0.804467 0.010813 
Mxra7 1.338052 0.017653 
Emp3 1.177319 0.018464 
Gcnt2 0.840984 0.019639 
Smpdl3b 0.777131 0.022591 
Tax1bp1* 0.848191 0.028922 
Dstn 0.848682 0.029607 
Myh8 0.754609 0.03196 
Hist1h2bk 1.170608 0.033829 
Shisa4 1.283352 0.034776 
Nrbp2 0.829223 0.036241 
Cmtm6 1.177944 0.046605 
Prpf38b 0.804518 0.046605 
2410129H14Rik 1.170109 0.047856 
Gosr2 0.847394 0.047856 
LOC545013 1.263417 0.049198 
Table 8-3 4 day GDF-15 treatment of differentiated myotubes – microRNA Array results.  
Ratio compared to control  and p val  diff  = p value of the difference between treatment 
and control.  * see below.  
*potential genes of interest  
CYR61  TGF-β responsive gene 
IGF-2  Insulin-like growth factor – 2 
Uba-1  Ubiquitin cycle protein 
Tax1bp1 antiapoptotic  
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Appendix A3 – David analysis of MiRWALK microRNA targets.  
 
Table 8-4 to show results of DAVID analysis. Predicted targets of miRs 1, 133a, 181a and 499 from mirWALK were 
combined to generate significant analysis for significant pathways  
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Molecular Mechanisms of Intensive Care Unit-Acquired Paresis 
Bloch S, Polkey MI, Griffiths M, Kemp P 
European Respiratory Journal  2012 Apr;39(4):1000-11 
 
Sustained elevation of circulating growth and differentiation factor-15 and a 
dynamic imbalance in mediators of muscle homeostasis are associated with the 
development of acute muscle wasting following cardiac surgery. 
Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp PR, Griffiths MJ. 
Critical Care Medicine. 2013 Apr;41(4):982-9.  
 
Increased expression of GDF-15 may mediate ICU-acquired weakness by down-
regulating muscle microRNAs. 
Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. 
Thorax. 2014 Dec 16. pii: thoraxjnl-2014-206225 
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MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk 
cardiothoracic surgery. 
Bloch SA, Donaldson AV, Lewis A, Banya W, Polkey MI, Griffiths MJ, Kemp PR 
Re-submitted to Critical Care January 2015 under review.  
 
Quadriceps wasting and physical inactivity in patients with COPD. 
Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh 
SL, Bloch SA, Sidhu PS, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS. 
Eur Respir J. 2012 Nov;40(5):1115-22.  
 
Presentations 
Circulating regulators of acute muscle wasting in the critically ill: GDF-15 a potential 
novel driver of acute muscle wasting 
Bloch S, Lee J, Wort S, Polkey M, Kemp P, Griffiths M 
British Thoracic Society Winter 2012 
 
Mir-181: a potential biomarker of acute muscle wasting  
Bloch S, Griffiths M, Kemp P, Polkey M  
British Thoracic Society Winter 2013 
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GDF-15 regulation of microRNAs; A Novel Mechanism of Intensive Care Unit 
Acquired Paresis? 
Bloch S, Lee J, Griffiths M, Kemp P, Polkey M,  
American Thoracic Society May 2014 
 
GDF-15 down-regulation of muscle microRNA drives increased sensitivity to TGF-β 
signalling; a novel mechanism in intensive care unit acquired weakness. 
Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. 
British Thoracic Society Winter 2014 
 
A paradoxical rise in rectus femoris myostatin (GDF-8) and GDF-15 in response to 
neuromuscular electrical stimulation in critical care. 
Bloch SA, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. 
British Thoracic Society Winter 2014 
 
GDF-15 driven down-regulation of muscle microRNA drives increased sensitivity to 
TGF-β signalling; a novel mechanism in intensive care unit acquired weakness. 
Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. 
Intensive Care Society State of the Art meeting – Gold medal presentation 2014 
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American Thoracic Society International Travel Scholarship – 2014 
British Lung Foundation Travel Award – 2014 
Intensive Care Society State of the Art Meeting – shortlisted for the Gold Medal Award 
– 2014 
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